The O
effects O
of O
quinine O
and O
4 B
- I
aminopyridine I
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
morphine O
in O
rats O
. O

The O
effects O
of O
two O
unselective O
potassium O
( O
K O
( O
+ O
) O
- O
) O
channel O
blockers O
, O
quinine O
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 B
- I
aminopyridine I
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
biphasic O
changes O
in O
motor O
activity O
induced O
by O
morphine O
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
Wistar O
rats O
. O

Quinine O
is O
known O
to O
block O
voltage O
- O
, O
calcium O
- O
and O
ATP O
- O
sensitive O
K O
( O
+ O
) O
- O
channels O
while O
4 B
- I
aminopyridine I
is O
known O
to O
block O
voltage O
- O
sensitive O
K O
( O
+ O
) O
- O
channels O
. O

In O
the O
counterbalanced O
method O
, O
quinine O
attenuated O
morphine O
- O
induced O
place O
preference O
, O
whereas O
4 B
- I
aminopyridine I
was O
ineffective O
. O

These O
results O
suggest O
the O
involvement O
of O
quinine O
- O
sensitive O
but O
not O
4 B
- I
aminopyridine I
- O
sensitive O
K O
( O
+ O
) O
- O
channels O
in O
morphine O
reward O
. O

It O
is O
also O
suggested O
that O
the O
blockade O
of O
K O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine O
- O
induced O
hypoactivity O
whereas O
morphine O
- O
induced O
hyperactivity O
seems O
to O
be O
connected O
to O
both O
quinine O
- O
and O
4 B
- I
aminopyridine I
- O
sensitive O
K O
( O
+ O
) O
- O
channels O
. O

Nociceptin B
/ O
orphanin B
FQ I
and O
nocistatin B
on O
learning O
and O
memory O
impairment O
induced O
by O
scopolamine O
in O
mice O
. O

Nociceptin B
, O
also O
known O
as O
orphanin B
FQ I
, O
is O
an O
endogenous O
ligand O
for O
the O
orphan O
opioid O
receptor O
- O
like O
receptor O
1 O
( O
ORL1 O
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
CNS O
) O
. O

On O
the O
other O
hand O
, O
nocistatin B
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin B
and O
blocks O
nociceptin B
- O
induced O
allodynia O
and O
hyperalgesia O
. O

The O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin B
/ O
orphanin B
FQ I
and O
nocistatin B
could O
modulate O
impairment O
of O
learning O
and O
memory O
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
Y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

While O
nocistatin B
( O
0 O
. O
5 O
- O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
administered O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
had O
no O
effect O
on O
spontaneous O
alternation O
or O
passive O
avoidance O
behaviours O
, O
a O
lower O
per O
cent O
alternation O
and O
shorter O
median O
step O
- O
down O
latency O
in O
the O
retention O
test O
were O
obtained O
in O
nociceptin B
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal O
mice O
. O

Administration O
of O
nocistatin B
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
attenuated O
the O
scopolamine O
- O
induced O
impairment O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
behaviours O
. O

These O
results O
indicated O
that O
nocistatin B
, O
a O
new O
biologically O
active O
peptide O
, O
ameliorates O
impairments O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
induced O
by O
scopolamine O
, O
and O
suggested O
that O
these O
peptides O
play O
opposite O
roles O
in O
learning O
and O
memory O
. O

Meloxicam B
- O
induced O
liver O
toxicity O
. O

We O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid O
arthritis O
who O
developed O
acute O
cytolytic O
hepatitis O
due O
to O
meloxicam B
. O

Recently O
introduced O
in O
Belgium O
, O
meloxicam B
is O
the O
first O
nonsteroidal O
antiinflammatory O
drug O
with O
selective O
action O
on O
the O
inducible O
form O
of O
cyclooxygenase O
2 O
. O

The O
acute O
cytolytic O
hepatitis O
occurred O
rapidly O
after O
meloxicam B
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity O
mechanism O
. O

This O
first O
case O
of O
meloxicam B
related O
liver O
toxicity O
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic O
damage O
. O

Induction O
of O
apoptosis O
by O
remoxipride B
metabolites O
in O
HL60 O
and O
CD34 O
+ O
/ O
CD19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride B
- O
induced O
aplastic O
anemia O
. O

The O
antipsychotic O
agent O
, O
remoxipride B
[ O
( B
S I
) I
- I
( I
- I
) I
- I
3 I
- I
bromo I
- I
N I
- I
[ I
( I
1 I
- I
ethyl I
- I
2 I
- I
pyrrolidinyl I
) I
methyl I
] I
- I
2 I
, I
6 I
- I
dimethoxybenz I
amide I
] O
has O
been O
associated O
with O
acquired O
aplastic O
anemia O
. O

We O
have O
examined O
the O
ability O
of O
remoxipride B
, O
three O
pyrrolidine B
ring O
metabolites O
and O
five O
aromatic O
ring O
metabolites O
of O
the O
parent O
compound O
to O
induce O
apoptosis O
in O
HL60 O
cells O
and O
human O
bone O
marrow O
progenitor O
( O
HBMP O
) O
cells O
. O

Apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
Hoechst B
33342 I
- O
and O
propidium B
iodide I
stained O
cell O
samples O
. O

The O
catechol B
and O
hydroquinone B
metabolites O
, O
NCQ436 B
and O
NCQ344 B
, O
induced O
apoptosis O
in O
HL60 O
and O
HBMP O
cells O
in O
a O
time O
- O
and O
concentration O
dependent O
manner O
, O
while O
the O
phenols B
, O
NCR181 O
, O
FLA873 O
, O
and O
FLA797 B
, O
and O
the O
derivatives O
formed O
by O
oxidation O
of O
the O
pyrrolidine B
ring O
, O
FLA838 O
, O
NCM001 O
, O
and O
NCL118 O
, O
had O
no O
effect O
. O

No O
necrosis O
was O
observed O
in O
cells O
treated O
with O
NCQ436 B
but O
NCQ344 B
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis O
at O
higher O
concentrations O
. O

These O
data O
show O
that O
the O
catechol B
and O
hydroquinone B
metabolites O
of O
remoxipride B
have O
direct O
toxic O
effects O
in O
HL60 O
and O
HBMP O
cells O
, O
leading O
to O
apoptosis O
, O
while O
the O
phenol B
metabolites O
were O
inactive O
. O

Similarly O
, O
benzene B
- O
derived O
catechol B
and O
hydroquinone B
, O
but O
not O
phenol B
, O
induce O
apoptosis O
in O
HBMP O
cells O
[ O
Moran O
et O
al O
. O
, O
Mol O
. O
Pharmacol O
. O
, O
50 O
( O
1996 O
) O
610 O
- O
615 O
] O
. O

We O
propose O
that O
remoxipride B
and O
benzene B
may O
induce O
aplastic O
anemia O
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
NCQ436 B
and O
NCQ344 B
to O
induce O
apoptosis O
in O
HBMP O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic O
anemia O
that O
has O
been O
associated O
with O
remoxipride B
. O

Synthesis O
and O
preliminary O
pharmacological O
investigations O
of O
1 B
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazine I
derivatives O
as O
potential O
atypical O
antipsychotic O
agents O
in O
mice O
. O

The O
synthesis O
and O
preliminary O
pharmacological O
evaluation O
of O
a O
series O
of O
potential O
atypical O
antipsychotic O
agents O
based O
on O
the O
structure O
of O
1 B
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazine I
( O
7 O
) O
is O
described O
. O

Compound O
7e O
, O
5 B
- I
{ I
2 I
- I
[ I
4 I
- I
( I
1 I
, I
2 I
- I
dihydro I
- I
2 I
- I
acenaphthylenyl I
) I
piperazinyl I
] I
ethyl I
} I
- I
2 I
, I
3 I
- I
dihy I
dro I
- I
1H I
- I
indol I
- I
2 I
- I
one I
, O
from O
this O
series O
showed O
significant O
affinities O
at O
the O
5 O
- O
HT1A O
and O
5 O
- O
HT2A O
receptors O
and O
moderate O
affinity O
at O
the O
D2 O
receptor O
. O

Sub O
- O
chronic O
inhibition O
of O
nitric O
- O
oxide O
synthesis O
modifies O
haloperidol O
- O
induced O
catalepsy O
and O
the O
number O
of O
NADPH B
- O
diaphorase O
neurons O
in O
mice O
. O

RATIONALE O
: O
NG B
- I
nitro I
- I
L I
- I
arginine I
( O
L B
- I
NOARG I
) O
, O
an O
inhibitor O
of O
nitric O
- O
oxide O
synthase O
( O
NOS O
) O
, O
induces O
catalepsy O
in O
mice O
. O

This O
effect O
undergoes O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub O
- O
chronic O
L B
- I
NOARG I
treatment O
. O

OBJECTIVES O
: O
To O
investigate O
the O
effects O
of O
subchronic O
L B
- I
NOARG I
treatment O
in O
haloperidol O
- O
induced O
catalepsy O
and O
the O
number O
of O
NOS O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

METHODS O
: O
Male O
albino O
Swiss O
mice O
were O
treated O
sub O
- O
chronically O
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
L B
- I
NOARG I
( O
40 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
haloperidol O
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

Reduced O
nicotinamide B
adenine I
dinucleotide I
phosphate I
- O
diaphorase O
( O
NADPH B
- O
d O
) O
histochemistry O
was O
also O
employed O
to O
visualize O
NOS O
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O

RESULTS O
: O
L B
- I
NOARG I
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
L B
- I
NOARG I
and O
of O
haloperidol O
- O
induced O
catalepsy O
. O

It O
also O
induced O
an O
increase O
in O
the O
number O
of O
NADPH B
- O
d O
- O
positive O
cells O
in O
the O
dorsal O
part O
of O
the O
caudate O
and O
accumbens O
nuclei O
compared O
with O
haloperidol O
and O
in O
the O
pedunculopontine O
tegmental O
nucleus O
compared O
with O
saline O
. O

In O
contrast O
, O
there O
was O
a O
decrease O
in O
NADPH B
- O
d O
neuron O
number O
in O
the O
substantia O
nigra O
, O
pars O
compacta O
in O
both O
haloperidol O
- O
treated O
and O
L B
- I
NOARG I
- O
treated O
animals O
. O

A O
history O
of O
drug O
exposure O
also O
was O
taken O
with O
special O
attention O
on O
the O
use O
of O
antidepressants O
, O
anorexigens O
, O
and O
amphetamines B
. O

We O
compared O
the O
toxicity O
of O
NS O
- O
718 O
with O
that O
of O
Fungizone O
( O
amphotericin B
B I
- I
sodium I
deoxycholate I
; O
D B
- I
AmB I
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin O
B O
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Incubation O
with O
NS O
- O
718 O
resulted O
in O
significantly O
less O
damage O
of O
cultured O
human O
renal O
proximal O
tubular O
epithelial O
cells O
compared O
with O
D B
- I
AmB I
. O

Serum O
blood O
urea O
and O
creatinine O
concentrations O
increased O
significantly O
in O
rats O
given O
an O
iv O
infusion O
of O
D B
- I
AmB I
3 O
mg O
/ O
kg O
but O
not O
in O
those O
given O
the O
same O
dose O
of O
NS O
- O
718 O
. O

Histopathological O
examination O
of O
the O
kidney O
showed O
tubular O
necrosis O
in O
D B
- I
AmB I
- O
treated O
rats O
but O
no O
change O
in O
NS O
- O
718 O
- O
treated O
rats O
. O

Amphotericin O
B O
concentrations O
in O
the O
kidney O
in O
NS O
- O
718 O
- O
treated O
rats O
were O
higher O
than O
those O
in O
D B
- I
AmB I
- O
treated O
rats O
. O

Patterns O
of O
sulfadiazine B
acute O
nephrotoxicity O
. O

Sulfadiazine B
acute O
nephrotoxicity O
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis O
in O
HIV O
- O
positive O
patients O
. O

Under O
treatment O
with O
sulfadiazine B
they O
developed O
oliguria O
, O
abdominal O
pain O
, O
renal O
failure O
and O
showed O
multiple O
radiolucent O
renal O
calculi O
in O
echography O
. O

Treatment O
with O
sulfadiazine B
requires O
exquisite O
control O
of O
renal O
function O
, O
an O
increase O
in O
water O
ingestion O
and O
possibly O
the O
alcalinization O
of O
the O
urine O
. O

Hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone B
and O
amiodarone O
in O
animals O
with O
a O
healed O
myocardial O
infarction O
. O

The O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone B
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone O
, O
were O
compared O
with O
those O
of O
amiodarone O
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial O
infarction O
. O

All O
dogs O
( O
n O
= O
6 O
) O
randomly O
received O
orally O
dronedarone B
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
amiodarone O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
and O
placebo O
twice O
daily O
for O
7 O
days O
, O
with O
a O
3 O
- O
week O
washout O
between O
consecutive O
treatments O
. O

Resting O
values O
of O
LVEF O
, O
FS O
, O
+ O
LVdP O
/ O
dt O
, O
and O
MBP O
remained O
unchanged O
whatever O
the O
drug O
and O
the O
dosing O
regimen O
, O
whereas O
resting O
HR O
was O
significantly O
and O
dose O
- O
dependently O
lowered O
after O
dronedarone B
and O
to O
a O
lesser O
extent O
after O
amiodarone O
. O

Both O
dronedarone B
and O
amiodarone O
significantly O
reduced O
the O
exercise O
- O
induced O
tachycardia O
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol O
- O
induced O
tachycardia O
. O

Thus O
, O
dronedarone B
and O
amiodarone O
displayed O
a O
similar O
level O
of O
antiadrenergic O
effect O
and O
did O
not O
impair O
the O
resting O
left O
ventricular O
function O
. O

Consequently O
, O
dronedarone B
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias O
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

Phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum B
/ O
paclitaxel O
- O
refractory O
ovarian O
and O
fallopian O
tube O
cancers O
and O
primary O
carcinoma O
of O
the O
peritoneum O
. O

BACKGROUND O
: O
Several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
Doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum B
- O
resistant O
ovarian O
cancer O
, O
with O
dose O
limiting O
toxicity O
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia O
( O
" O
hand O
- O
foot O
syndrome O
" O
) O
and O
stomatitis O
. O

We O
wished O
to O
develop O
a O
more O
tolerable O
liposomal O
doxorubicin O
treatment O
regimen O
and O
document O
its O
level O
of O
activity O
in O
a O
well O
- O
defined O
patient O
population O
with O
platinum B
/ O
paclitaxel O
- O
refractory O
disease O
. O

METHODS O
AND O
MATERIALS O
: O
Patients O
with O
ovarian O
or O
fallopian O
tube O
cancers O
or O
primary O
peritoneal O
carcinoma O
with O
platinum B
/ O
paclitaxel O
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

Definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum B
- O
and O
paclitaxel O
- O
refractory O
ovarian O
cancer O
. O

The O
effect O
of O
pupil O
dilation O
with O
tropicamide B
on O
vision O
and O
driving O
simulator O
performance O
. O

METHODS O
: O
A O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil O
dilation O
using O
guttae O
tropicamide B
1 O
% O
. O

We O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia O
and O
Taussig O
- O
Bing O
malformation O
) O
due O
to O
exposure O
to O
isotretinoin B
within O
the O
first O
trimester O
. O

In O
this O
paper O
we O
aim O
to O
draw O
to O
the O
fact O
that O
caution O
is O
needed O
when O
prescribing O
vitamin B
A I
- O
containing O
drugs O
to O
women O
of O
childbearing O
years O
. O

Effect O
of O
methoxamine B
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress O
incontinence O
: O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
. O

Half O
log O
incremental O
doses O
of O
intravenous O
methoxamine B
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress O
incontinence O
while O
measuring O
maximum O
urethral O
pressure O
( O
MUP O
) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

Methoxamine B
evoked O
non O
- O
significant O
increases O
in O
MUP O
and O
diastolic O
blood O
pressure O
but O
caused O
a O
significant O
rise O
in O
systolic O
blood O
pressure O
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

Hyperglycemic O
effect O
of O
amino B
compounds O
structurally O
related O
to O
caproate B
in O
rats O
. O

The O
chronic O
feeding O
of O
small O
amounts O
( O
0 O
. O
3 O
- O
3 O
% O
of O
diet O
weight O
) O
of O
certain O
amino B
derivatives O
of O
caproate B
resulted O
in O
hyperglycemia O
, O
an O
elevated O
glucose O
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria O
. O

Effective O
compounds O
included O
norleucine B
, O
norvaline B
, O
glutamate O
, O
epsilon B
- I
aminocaproate I
, O
methionine O
, O
and O
leucine B
. O

Cocaine O
, O
ethanol O
, O
and O
cocaethylene B
cardiotoxity O
in O
an O
animal O
model O
of O
cocaine O
and O
ethanol O
abuse O
. O

Their O
combined O
cardiac O
toxicity O
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene B
( O
CE B
) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

The O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
CE B
in O
the O
combined O
cardiotoxicity O
of O
cocaine O
and O
ethanol O
in O
a O
model O
simulating O
their O
abuse O
. O

Peak O
CE B
levels O
were O
associated O
with O
a O
45 O
% O
( O
SD O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
CI O
= O
22 O
% O
to O
69 O
% O
) O
decrease O
in O
cardiac O
output O
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
SD O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
CI O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dP O
/ O
dt O
( O
max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
SD O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
CI O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
SVO O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

Peak O
serum O
cocaethylene B
concentrations O
were O
associated O
with O
prolonged O
myocardial O
depression O
. O

Worsening O
of O
Parkinsonism O
after O
the O
use O
of O
veralipride B
for O
treatment O
of O
menopause O
: O
case O
report O
. O

We O
describe O
a O
female O
patient O
with O
stable O
Parkinson O
' O
s O
disease O
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride B
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

We O
emphasize O
the O
anti O
- O
dopaminergic O
effect O
of O
veralipride B
. O

Viracept B
and O
irregular O
heartbeat O
warning O
. O

A O
group O
of O
doctors O
in O
Boston O
warn O
that O
the O
protease O
inhibitor O
Viracept B
may O
cause O
an O
irregular O
heart O
beat O
, O
known O
as O
bradycardia O
, O
in O
people O
with O
HIV O
. O

Bradycardia O
occurred O
in O
a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
Viracept B
in O
combination O
with O
other O
anti O
- O
HIV O
drugs O
. O

BACKGROUND O
: O
This O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
EAD O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade O
de O
pointes O
( O
TdP O
) O
with O
QT O
prolongation O
induced O
by O
dl O
- O
sotalol B
and O
azimilide B
. O

dl O
- O
Sotalol B
preferentially O
prolonged O
action O
potential O
duration O
( O
APD O
) O
in O
M O
cells O
dose O
- O
dependently O
( O
1 O
to O
100 O
micromol O
/ O
L O
) O
, O
leading O
to O
QT O
prolongation O
and O
an O
increase O
in O
TDR O
. O

Azimilide B
, O
however O
, O
significantly O
prolonged O
APD O
and O
QT O
interval O
at O
concentrations O
from O
0 O
. O
1 O
to O
10 O
micromol O
/ O
L O
but O
shortened O
them O
at O
30 O
micromol O
/ O
L O
. O

Unlike O
dl O
- O
sotalol B
, O
azimilide B
( O
> O
3 O
micromol O
/ O
L O
) O
increased O
epicardial O
APD O
markedly O
, O
causing O
a O
diminished O
TDR O
. O

Although O
both O
dl O
- O
sotalol B
and O
azimilide B
rarely O
induced O
EADs O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
EADs O
in O
rabbits O
, O
in O
which O
more O
pronounced O
QT O
prolongation O
was O
seen O
. O

An O
increase O
in O
TDR O
by O
dl O
- O
sotalol B
facilitated O
transmural O
propagation O
of O
EADs O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
TdP O
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

Of O
note O
, O
although O
azimilide B
( O
3 O
to O
10 O
micromol O
/ O
L O
) O
increased O
APD O
more O
than O
dl O
- O
sotalol B
, O
its O
EADs O
often O
failed O
to O
propagate O
transmurally O
, O
probably O
because O
of O
a O
diminished O
TDR O
. O

Sixty O
- O
seven O
men O
with O
metastatic O
androgen B
- O
independent O
prostate O
cancer O
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
NCS O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

Overexpression O
of O
copper B
/ O
zinc B
- O
superoxide O
dismutase O
protects O
from O
kanamycin O
- O
induced O
hearing O
loss O
. O

We O
therefore O
hypothesized O
that O
overexpression O
of O
Cu B
/ O
Zn B
- O
superoxide O
dismutase O
( O
h O
- O
SOD1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity O
. O

Fatty O
liver O
induced O
by O
tetracycline B
in O
the O
rat O
. O

Dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty O
liver O
induced O
by O
tetracycline B
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

In O
the O
intact O
male O
and O
female O
rat O
, O
no O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline B
and O
hepatic O
accumulation O
of O
triglyceride B
. O

With O
provision O
of O
adequate O
oleic B
acid I
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline B
and O
both O
accumulation O
of O
triglyceride B
in O
the O
liver O
and O
depression O
of O
output O
of O
triglyceride B
by O
livers O
from O
male O
and O
female O
rats O
. O

Marked O
differences O
were O
observed O
between O
female O
and O
male O
rats O
with O
regard O
to O
base O
line O
( O
control O
) O
hepatic O
concentration O
of O
triglyceride B
and O
output O
of O
triglyceride B
. O

Accumulation O
of O
hepatic O
triglyceride B
, O
as O
a O
per O
cent O
of O
control O
values O
, O
in O
response O
to O
graded O
doses O
of O
tetracycline B
, O
did O
not O
differ O
significantly O
between O
male O
, O
female O
and O
pregnant O
rat O
livers O
. O

However O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline B
on O
depression O
of O
output O
of O
triglyceride B
under O
these O
experimental O
conditions O
. O

These O
differences O
between O
the O
sexes O
could O
not O
be O
related O
to O
altered O
disposition O
of O
tetracycline B
or O
altered O
uptake O
of O
oleic B
acid I
. O

Depressed O
hepatic O
secretion O
of O
triglyceride B
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride B
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride B
- O
rich O
fatty O
liver O
in O
response O
to O
tetracycline B
. O

There O
were O
6 O
cases O
implicating O
clarithromycin B
, O
13 O
implicating O
isoniazid O
, O
and O
1 O
case O
each O
implicating O
erythromycin O
and O
amoxicillin O
. O

Of O
these O
, O
clarithromycin B
was O
implicated O
in O
23 O
( O
27 O
. O
6 O
% O
) O
cases O
, O
ciprofloxacin O
in O
12 O
( O
14 O
. O
4 O
% O
) O
cases O
, O
and O
ofloxacin B
in O
10 O
( O
12 O
% O
) O
cases O
. O

Cases O
reported O
by O
the O
FDA O
showed O
clarithromycin B
and O
ciprofloxacin O
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania O
. O

Temocapril B
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular O
injury O
in O
chronic O
puromycin O
aminonucleoside O
nephrosis O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril B
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
, O
reduced O
proteinuria O
, O
inhibited O
glomerular O
hypertrophy O
and O
prevented O
glomerulosclerosis O
in O
chronic O
puromycin O
aminonucleoside O
( O
PAN O
) O
- O
induced O
nephrotic O
rats O
. O

Four O
groups O
were O
used O
, O
i O
) O
the O
PAN O
group O
( O
14 O
) O
, O
ii O
) O
PAN O
/ O
temocapril B
( O
13 O
) O
, O
iii O
) O
temocapril B
( O
14 O
) O
and O
iv O
) O
untreated O
controls O
( O
15 O
) O
. O

Temocapril B
( O
8 O
mg O
/ O
kg O
/ O
day O
) O
was O
administered O
to O
the O
rats O
which O
were O
killed O
at O
weeks O
4 O
, O
14 O
or O
20 O
. O

Systolic O
BP O
in O
the O
PAN O
group O
was O
significantly O
high O
at O
4 O
, O
14 O
and O
20 O
weeks O
, O
but O
was O
normal O
in O
the O
PAN O
/ O
temocapril B
group O
. O

Temocapril B
did O
not O
attenuate O
proteinuria O
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

The O
ratio O
of O
glomerular O
tuft O
area O
to O
the O
area O
of O
Bowman O
' O
s O
capsules O
( O
GT O
/ O
BC O
) O
in O
the O
PAN O
group O
was O
significantly O
increased O
, O
but O
it O
was O
significantly O
lower O
in O
the O
PAN O
/ O
temocapril B
group O
. O

It O
appears O
that O
temocapril B
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
PAN O
neprotic O
rats O
. O

High O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three O
- O
weekly O
mitomycin B
C I
in O
the O
treatment O
of O
advanced O
gastric O
cancer O
. O

In O
a O
previous O
phase O
II O
study O
with O
3 O
- O
weekly O
bolus O
5 O
- O
FU O
, O
FA O
and O
mitomycin B
C I
( O
MMC B
) O
we O
found O
a O
low O
toxicity O
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
ELF O
, O
FAM O
or O
FAMTX O
, O
and O
a O
promising O
median O
overall O
survival O
. O

In O
order O
to O
improve O
this O
MMC B
- O
dependent O
schedule O
we O
initiated O
a O
phase O
II O
study O
with O
high O
- O
dose O
5 O
- O
FU O
/ O
FA O
and O
3 O
- O
weekly O
bolus O
MMC B
. O

Bolus O
MMC B
10 O
mg O
/ O
m O
( O
2 O
) O
was O
added O
in O
3 O
- O
weekly O
intervals O
. O

CONCLUSIONS O
: O
High O
- O
dose O
5 O
- O
FU O
/ O
FA O
/ O
MMC B
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
AGC O
( O
objective O
response O
rate O
54 O
. O
6 O
% O
) O
. O

Acute O
interstitial O
nephritis O
due O
to O
nicergoline B
( O
Sermion B
) O
. O

We O
report O
a O
case O
of O
acute O
interstitial O
nephritis O
( O
AIN O
) O
due O
to O
nicergoline B
( O
Sermion B
) O
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline B
and O
bendazac B
lysine I
due O
to O
retinal O
vein O
occlusion O
at O
ophthalmologic O
department O
. O

A O
lymphocyte O
transformation O
test O
demonstrated O
a O
positive O
result O
against O
nicergoline B
. O

Treatment O
was O
consisted O
of O
withdrawal O
of O
nicergoline B
and O
intravenous O
methylprednisolone O
, O
and O
his O
renal O
function O
was O
completely O
recovered O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline B
- O
associated O
AIN O
. O

A O
patient O
with O
chronic O
renal O
failure O
( O
CRF O
) O
developed O
neuroleptic O
malignant O
syndrome O
( O
NMS O
) O
after O
administration O
of O
risperidone O
and O
levomepromazine B
. O

Adrenaline O
- O
induced O
hypertension O
was O
used O
to O
destroy O
the O
BBB O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium B
( O
TTC B
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline O
for O
30 O
s O
. O

In O
normal O
rats O
, O
the O
whole O
brain O
sections O
exhibited O
complete O
staining O
with O
TTC B
. O

Carvedilol B
protects O
against O
doxorubicin O
- O
induced O
mitochondrial O
cardiomyopathy O
. O

The O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol B
, O
a O
nonselective O
beta O
- O
adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin O
toxicity O
. O

Heart O
and O
liver O
mitochondria O
were O
isolated O
from O
rats O
treated O
for O
7 O
weeks O
with O
doxorubicin O
( O
2 O
mg O
/ O
kg O
sc O
/ O
week O
) O
, O
carvedilol B
( O
1 O
mg O
/ O
kg O
ip O
/ O
week O
) O
, O
or O
the O
combination O
of O
the O
two O
drugs O
. O

Coadministration O
of O
carvedilol B
decreased O
the O
extent O
of O
cellular O
vacuolization O
in O
cardiac O
myocytes O
and O
prevented O
the O
inhibitory O
effect O
of O
doxorubicin O
on O
mitochondrial O
respiration O
in O
both O
heart O
and O
liver O
. O

Carvedilol B
also O
prevented O
the O
decrease O
in O
mitochondrial O
Ca O
( O
2 O
+ O
) O
loading O
capacity O
and O
the O
inhibition O
of O
the O
respiratory O
complexes O
of O
heart O
mitochondria O
caused O
by O
doxorubicin O
. O

Carvedilol B
by O
itself O
did O
not O
affect O
any O
of O
the O
parameters O
measured O
for O
heart O
or O
liver O
mitochondria O
. O

It O
is O
concluded O
that O
this O
protection O
by O
carvedilol B
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial O
dysfunction O
and O
cardiomyopathy O
that O
accompanies O
long O
- O
term O
doxorubicin O
therapy O
in O
cancer O
patients O
. O

Moreover O
, O
all O
adenosine O
receptor O
agonists O
: O
2 B
- I
p I
- I
( I
2 I
- I
carboxyethyl I
) I
phenethylamino I
- I
5 I
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
CGS B
21680 I
) O
, O
A2A O
receptor O
agonist O
, O
N6 O
- O
cyclopentyladenosine O
( O
CPA O
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
NECA B
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine O
- O
induced O
locomotor O
activity O
. O

CPA O
reduced O
cocaine O
action O
at O
the O
doses O
which O
, O
given O
alone O
, O
did O
not O
influence O
motility O
, O
while O
CGS B
21680 I
and O
NECA B
decreased O
the O
action O
of O
cocaine O
at O
the O
doses O
which O
, O
given O
alone O
, O
decreased O
locomotor O
activity O
in O
animals O
. O

The O
selective O
blockade O
of O
A2 O
adenosine O
receptor O
by O
DMPX B
( O
3 B
, I
7 I
- I
dimethyl I
- I
1 I
- I
propargylxanthine I
) O
significantly O
enhanced O
cocaine O
- O
induced O
locomotor O
activity O
of O
animals O
. O

CPT B
( O
8 B
- I
cyclopentyltheophylline I
) O
- O
- O
A1 O
receptor O
antagonist O
, O
did O
not O
show O
any O
influence O
in O
this O
test O
. O

The O
selective O
blockade O
of O
A2 O
adenosine O
receptors O
( O
DMPX B
) O
and O
non O
- O
selective O
blockade O
of O
adenosine O
receptors O
( O
caffeine O
) O
significantly O
increased O
the O
action O
of O
amphetamine O
in O
the O
locomotor O
activity O
test O
. O

Multivariable O
logistic O
regression O
was O
used O
to O
estimate O
the O
odds O
ratio O
( O
OR O
) O
of O
pacemaker O
insertion O
associated O
with O
amiodarone O
use O
, O
controlling O
for O
baseline O
risk O
factors O
and O
exposure O
to O
sotalol B
, O
Class O
I O
antiarrhythmic O
agents O
, O
beta O
- O
blockers O
, O
calcium O
channel O
blockers O
, O
and O
digoxin B
. O

Digoxin B
was O
the O
only O
other O
medication O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
( O
OR O
: O
1 O
. O
78 O
, O
95 O
% O
CI O
: O
1 O
. O
37 O
to O
2 O
. O
31 O
) O
. O

In O
addition O
to O
tiaprofenic B
acid I
, O
indomethacin O
has O
been O
reported O
to O
be O
associated O
with O
this O
condition O
. O

When O
compared O
with O
the O
control O
group O
, O
both O
indomethacin O
groups O
revealed O
statistically O
increased O
numbers O
of O
mast O
cells O
in O
the O
mucosa O
( O
P O
< O
0 O
. O
0001 O
) O
and O
penetration O
of O
lanthanum B
nitrate I
through O
intercellular O
areas O
of O
the O
epithelium O
. O

An O
open O
- O
label O
phase O
II O
study O
of O
low O
- O
dose O
thalidomide O
in O
androgen B
- O
independent O
prostate O
cancer O
. O

We O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen B
- O
independent O
prostate O
cancer O
. O

Central O
nervous O
system O
toxicity O
following O
the O
administration O
of O
levobupivacaine B
for O
lumbar O
plexus O
block O
: O
A O
report O
of O
two O
cases O
. O

Levobupivacaine B
, O
the O
pure O
S O
( O
- O
) O
enantiomer O
of O
bupivacaine O
, O
was O
developed O
to O
improve O
the O
cardiac O
safety O
profile O
of O
bupivacaine O
. O

We O
describe O
2 O
cases O
of O
grand O
mal O
seizures O
following O
accidental O
intravascular O
injection O
of O
levobupivacaine B
. O

Immediately O
after O
the O
administration O
of O
levobupivacaine B
0 O
. O
5 O
% O
with O
epinephrine O
2 O
. O
5 O
microgram O
/ O
mL O
, O
the O
patients O
developed O
grand O
mal O
seizures O
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

Both O
patients O
were O
treated O
preoperatively O
with O
beta O
- O
adrenergic O
antagonist O
medications O
, O
which O
may O
have O
masked O
the O
cardiovascular O
signs O
of O
the O
unintentional O
intravascular O
administration O
of O
levobupivacaine B
with O
epinephrine O
. O

CONCLUSIONS O
: O
Although O
levobupivacaine B
may O
have O
a O
safer O
cardiac O
toxicity O
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine B
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions O
. O

Consistent O
with O
other O
reports O
this O
case O
of O
TdP O
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia O
and O
digoxin B
excess O
. O

Myotonia O
congenita O
( O
MC O
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride B
channel O
function O
, O
which O
may O
cause O
sustained O
membrane O
depolarisation O
. O

After O
determining O
the O
bupivacaine O
AD50 O
( O
the O
concentration O
of O
bupivacaine O
that O
caused O
50 O
% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic O
) O
, O
we O
determined O
the O
effect O
of O
1 O
- O
hour O
progesterone O
HCl B
exposure O
on O
myocyte O
contractile O
rhythm O
. O

Ethambutol B
and O
optic O
neuropathy O
. O

PURPOSE O
: O
To O
demonstrate O
the O
association O
between O
ethambutol B
and O
optic O
neuropathy O
. O

METHOD O
: O
Thirteen O
patients O
who O
developed O
optic O
neuropathy O
after O
being O
treated O
with O
ethambutol B
for O
tuberculosis O
of O
the O
lung O
or O
lymph O
node O
at O
Siriraj O
Hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

RESULTS O
: O
All O
patients O
had O
optic O
neuropathy O
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O
9 O
months O
) O
after O
starting O
ethambutol B
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

CONCLUSION O
: O
Early O
recognition O
of O
optic O
neuropathy O
should O
be O
considered O
in O
patients O
with O
ethambutol B
therapy O
. O

Current O
options O
of O
treatment O
include O
oral O
anticholinergic O
drugs O
, O
the O
topical O
application O
of O
anticholinergics O
or O
aluminum B
chloride I
, O
and O
the O
injection O
of O
botulinum O
toxin O
. O

Neuroleptic B
- O
associated O
hyperprolactinemia O
. O

Six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia O
and O
amenorrhea O
/ O
oligomenorrhea O
associated O
with O
their O
neuroleptic B
medications I
were O
treated O
with O
bromocriptine O
. O

This O
suggests O
that O
bromocriptine O
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic B
- O
associated O
hyperprolactinemia O
and O
amenorrhea O
/ O
galactorrhea O
. O

Ethacrynic B
acid I
- O
induced O
convulsions O
and O
brain O
neurotransmitters O
in O
mice O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B
acid I
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
but O
suppressed O
the O
synthesis O
of O
gamma O
- O
aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

These O
effects O
were O
completely O
antagonized O
by O
pretreatment O
with O
a O
glutamate O
/ O
N O
- O
methyl O
- O
D O
- O
aspartate O
antagonist O
, O
aminophosphonovaleric B
acid I
. O

In O
ethacrynic B
acid I
- O
induced O
convulsions O
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

Pharmacology O
of O
gamma B
- I
aminobutyric I
acidA I
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta O
- O
carboline O
derivative O
abecarnil B
. O

In O
rodents O
, O
the O
effect O
of O
the O
beta O
- O
carboline O
derivative O
isopropyl B
- I
6 I
- I
benzyloxy I
- I
4 I
- I
methoxymethyl I
- I
beta I
- I
carboline I
- I
3 I
- I
carboxylate I
( O
abecarrnil B
) O
, O
a O
new O
ligand O
for O
benzodiazepine O
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma O
- O
aminobutyric O
acid O
( O
GABA O
) O
A O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil B
increased O
[ O
3H O
] O
GABA O
binding O
, O
enhanced O
muscimol B
- O
stimulated O
36Cl O
- O
uptake O
and O
reduced O
the O
binding O
of O
t B
- I
[ I
35S I
] I
butylbicyclophosphorothionate I
( O
[ B
35S I
] I
TBPS I
) O
. O

These O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam O
, O
whereas O
the O
partial O
agonist O
Ro B
16 I
- I
6028 I
( O
tert B
- I
butyl I
- I
( I
S I
) I
- I
8 I
- I
bromo I
- I
11 I
, I
12 I
, I
13 I
, I
13a I
- I
tetrahydro I
- I
9 I
- I
oxo I
- I
9H I
- I
imidazo I
[ I
1 I
, I
5 I
- I
a I
] I
- I
pyrrolo I
- I
[ I
2 I
, I
1 I
- I
c I
] I
[ I
1 I
, I
4 I
] I
benzodiazepine I
- I
1 I
- I
carboxylate I
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

After O
i O
. O
p O
. O
injection O
to O
rats O
, O
abecarnil B
and O
diazepam O
decreased O
in O
a O
time O
- O
dependent O
and O
dose O
- O
related O
( O
0 O
. O
25 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
manner O
[ B
35S I
] I
TBPS I
binding O
measured O
ex O
vivo O
in O
the O
cerebral O
cortex O
. O

Moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
isoniazide O
( O
350 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
as O
well O
as O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
induced O
by O
foot O
- O
shock O
stress O
. O

To O
better O
correlate O
the O
biochemical O
and O
the O
pharmacological O
effects O
, O
we O
studied O
the O
action O
of O
abecarnil B
on O
[ B
35S I
] I
TBPS I
binding O
, O
exploratory O
motility O
and O
on O
isoniazid O
- O
induced O
biochemical O
and O
pharmacological O
effects O
in O
mice O
. O

In O
these O
animals O
, O
abecarnil B
produced O
a O
paralleled O
dose O
- O
dependent O
( O
0 O
. O
05 O
- O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
reduction O
of O
both O
motor O
behavior O
and O
cortical O
[ O
35S O
] O
TBPS O
binding O
. O

Moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta O
- O
carboline O
reduced O
markedly O
the O
increase O
of O
[ B
35S I
] I
TBPS I
binding O
and O
the O
convulsions O
induced O
by O
isoniazid O
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Phenylalanine B
, O
a O
large O
neutral O
amino O
acid O
( O
LNAA O
) O
competing O
with O
levodopa O
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive O
and O
antiparkinsonian O
effects O
of O
levodopa O
. O

Despite O
extensive O
clinical O
experience O
the O
role O
of O
digoxin B
is O
still O
not O
well O
defined O
. O

In O
patients O
with O
atrial O
fibrillation O
digoxin B
is O
beneficial O
for O
ventricular O
rate O
control O
. O

Digoxin B
has O
a O
narrow O
therapeutic O
: O
toxic O
ratio O
and O
concentrations O
are O
affected O
by O
a O
number O
of O
drugs O
. O

Also O
, O
digoxin B
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias O
. O

More O
convincing O
evidence O
is O
required O
showing O
that O
digoxin B
improves O
symptoms O
or O
exercise O
capacity O
. O

Pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin B
may O
increase O
mortality O
after O
myocardial O
infarction O
( O
MI O
) O
. O

Caution O
should O
be O
exercised O
in O
using O
digoxin B
until O
large O
mortality O
trials O
are O
completed O
showing O
either O
benefit O
or O
harm O
. O

Until O
then O
digoxin B
should O
be O
considered O
a O
third O
- O
line O
therapy O
. O

Isradipine B
treatment O
for O
hypertension O
in O
general O
practice O
in O
Hong O
Kong O
. O

A O
6 O
- O
week O
open O
study O
of O
the O
introduction O
of O
isradipine B
treatment O
was O
conducted O
in O
general O
practice O
in O
Hong O
Kong O
. O

The O
main O
side O
- O
effects O
were O
headache O
, O
dizziness O
, O
palpitation O
and O
flushing O
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine B
or O
with O
placebo O
. O

The O
risk O
of O
VNR O
cardiac O
events O
was O
similar O
to O
vindesine B
( O
VDS B
) O
and O
other O
cardiotoxic O
drugs O
[ O
fluorouracil O
, O
anthracyclines O
, O
gemcitabine O
( O
GEM O
) O
em O
leader O
] O
. O

Amiodarone O
induced O
hepatomegaly O
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides B
and O
glucose O
. O

Northern O
blot O
analysis O
of O
hepatic O
RNA O
revealed O
a O
dose O
- O
dependent O
increase O
in O
the O
expression O
of O
a O
number O
of O
genes O
critical O
for O
fatty B
acid I
oxidation O
, O
lipoprotein O
assembly O
, O
and O
lipid O
transport O
. O

Safety O
and O
compliance O
with O
once O
- O
daily O
niacin B
extended I
- I
release I
/ I
lovastatin I
as O
initial O
therapy O
in O
the O
Impact O
of O
Medical O
Subspecialty O
on O
Patient O
Compliance O
to O
Treatment O
( O
IMPACT O
) O
study O
. O

Niacin B
extended I
- I
release I
/ I
lovastatin I
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia O
and O
mixed O
dyslipidemia O
. O

This O
open O
- O
labeled O
, O
multicenter O
study O
evaluated O
the O
safety O
of O
bedtime O
niacin B
extended I
- I
release I
/ I
lovastatin I
when O
dosed O
as O
initial O
therapy O
and O
patient O
compliance O
to O
treatment O
in O
various O
clinical O
practice O
settings O
. O

Patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia O
and O
niacin B
extended I
- I
release I
/ I
lovastatin I
. O

Compliance O
to O
niacin B
extended I
- I
release I
/ I
lovastatin I
was O
77 O
% O
, O
with O
3 O
, O
245 O
patients O
completing O
the O
study O
. O

Niacin B
extended I
- I
release I
/ I
lovastatin I
1 O
, O
000 O
/ O
40 O
mg O
, O
dosed O
as O
initial O
therapy O
, O
was O
associated O
with O
good O
compliance O
and O
safety O
and O
had O
very O
low O
incidences O
of O
increased O
liver O
and O
muscle O
enzymes O
. O

In O
isoproterenol O
administered O
rats O
, O
the O
level O
of O
lipid O
peroxides B
increased O
significantly O
in O
the O
serum O
and O
heart O
. O

T O
. O
chebula O
extract O
pretreatment O
was O
found O
to O
ameliorate O
the O
effect O
of O
isoproterenol O
on O
lipid O
peroxide B
formation O
and O
retained O
the O
activities O
of O
the O
diagnostic O
marker O
enzymes O
. O

A O
case O
of O
postoperative O
anxiety O
due O
to O
low O
dose O
droperidol B
used O
with O
patient O
- O
controlled O
analgesia O
. O

Postoperatively O
, O
she O
was O
given O
a O
patient O
- O
controlled O
analgesia O
device O
delivering O
boluses O
of O
diamorphine O
0 O
. O
5 O
mg O
and O
droperidol B
0 O
. O
025 O
mg O
. O

The O
diagnosis O
of O
droperidol B
- O
induced O
psychological O
disturbance O
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

After O
she O
had O
received O
a O
total O
of O
only O
0 O
. O
9 O
mg O
droperidol B
, O
a O
syringe O
containing O
diamorphine O
only O
was O
substituted O
and O
her O
unease O
resolved O
completely O
. O

BACKGROUND O
AND O
AIM O
: O
Interferon B
and O
ribavirin O
combination O
therapy O
for O
chronic O
hepatitis O
C O
produces O
hemolytic O
anemia O
. O

METHODS O
: O
Eighty O
- O
eight O
patients O
with O
chronic O
hepatitis O
C O
who O
received O
interferon B
- I
alpha I
- I
2b I
at O
a O
dose O
of O
6 O
MU O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen O
( O
ROS O
) O
/ O
nitrogen B
species O
( O
RNS O
) O
reported O
to O
be O
present O
in O
adriamycin O
( O
ADR O
) O
- O
induced O
cardiotoxicity O
actually O
resulted O
in O
cardiomyocyte O
oxidative O
/ O
nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

Ultrastructural O
damage O
and O
levels O
of O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
4HNE B
) O
- O
protein O
adducts O
and O
3 B
- I
nitrotyrosine I
( O
3NT B
) O
were O
analyzed O
. O

Analysis O
of O
4HNE B
protein O
adducts O
by O
immunogold O
electron O
microscopy O
showed O
appearance O
of O
4HNE B
protein O
adducts O
in O
mitochondria O
as O
early O
as O
3 O
hours O
, O
with O
a O
peak O
at O
6 O
hours O
and O
subsequent O
decline O
at O
24 O
hours O
. O

3NT B
levels O
were O
significantly O
increased O
in O
all O
subcellular O
compartments O
at O
6 O
hours O
and O
subsequently O
declined O
at O
24 O
hours O
. O

Our O
data O
showed O
ADR O
induced O
4HNE B
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial O
injury O
initially O
appeared O
. O

Sotalol B
- O
induced O
coronary O
spasm O
in O
a O
patient O
with O
dilated O
cardiomyopathy O
associated O
with O
sustained O
ventricular O
tachycardia O
. O

After O
the O
administration O
of O
nifekalant B
hydrochloride I
, O
sustained O
VT O
was O
terminated O
. O

An O
alternate O
class O
III O
agent O
, O
sotalol B
, O
was O
also O
effective O
for O
the O
prevention O
of O
VT O
. O

However O
, O
one O
month O
after O
switching O
over O
nifekalant B
to O
sotalol B
, O
a O
short O
duration O
of O
ST O
elevation O
was O
documented O
in O
ECG O
monitoring O
at O
almost O
the O
same O
time O
for O
three O
consecutive O
days O
. O

Coronary O
vasospasm O
may O
be O
induced O
by O
the O
non O
- O
selective O
beta O
- O
blocking O
properties O
of O
sotalol B
. O

Effects O
of O
the O
antidepressant O
trazodone B
, O
a O
5 O
- O
HT O
2A O
/ O
2C O
receptor O
antagonist O
, O
on O
dopamine O
- O
dependent O
behaviors O
in O
rats O
. O

The O
antidepressant O
trazodone B
is O
a O
5 O
- O
HT O
2A O
/ O
2C O
receptor O
antagonist O
. O

OBJECTIVES O
: O
To O
evaluate O
the O
effect O
of O
trazodone B
treatment O
on O
behaviors O
dependent O
on O
the O
functional O
status O
of O
the O
nigrostriatal O
DAergic O
system O
. O

METHODS O
: O
The O
effect O
of O
pretreatment O
with O
trazodone B
on O
dexamphetamine O
- O
and O
apomorphine O
- O
induced O
oral O
stereotypies O
, O
on O
catalepsy O
induced O
by O
haloperidol O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
on O
ergometrine B
- O
induced O
wet O
dog O
shake O
( O
WDS O
) O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

We O
also O
investigated O
whether O
trazodone B
induces O
catalepsy O
in O
rats O
. O

RESULTS O
: O
Trazodone B
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
did O
not O
induce O
catalepsy O
, O
and O
did O
not O
antagonize O
apomorphine O
( O
1 O
. O
5 O
and O
3 O
mg O
/ O
kg O
) O
stereotypy O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
) O
- O
induced O
catalepsy O
. O

However O
, O
pretreatment O
with O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
trazodone B
enhanced O
dexamphetamine O
stereotypy O
, O
and O
antagonized O
haloperidol O
catalepsy O
, O
ergometrine B
- O
induced O
WDS O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
. O

Trazodone B
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
i O
. O
p O
. O
induced O
catalepsy O
and O
antagonized O
apomorphine O
and O
dexamphetamine O
stereotypies O
. O

CONCLUSIONS O
: O
Our O
results O
indicate O
that O
trazodone B
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
does O
not O
block O
pre O
- O
and O
postsynaptic O
striatal O
D2 O
DA O
receptors O
, O
while O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
it O
blocks O
postsynaptic O
striatal O
D2 O
DA O
receptors O
. O

Furthermore O
, O
at O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
, O
trazodone B
blocks O
5 O
- O
HT O
2A O
and O
5 O
- O
HT O
2C O
receptors O
. O

We O
suggest O
that O
trazodone B
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 O
- O
HT O
2C O
receptors O
, O
releases O
the O
nigrostriatal O
DAergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 O
- O
HT O
, O
and O
thereby O
potentiates O
dexamphetamine O
stereotypy O
and O
antagonizes O
haloperidol O
catalepsy O
. O

Deglutition O
was O
assessed O
using O
modified O
barium B
swallow O
with O
videofluoroscopy O
. O

Part O
A O
, O
for O
eight O
rats O
in O
each O
group O
brain O
injury O
was O
evaluated O
by O
staining O
tissue O
using O
2 B
, I
3 I
, I
5 I
- I
triphenyltetrazolium I
chloride I
and O
edema O
was O
evaluated O
by O
microgravimetry O
. O

Evans B
Blue I
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
HTN O
group O
( O
24 O
. O
4 O
+ O
/ O
- O
6 O
. O
0 O
) O
versus O
the O
control O
group O
( O
12 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
HTN O
group O
( O
7 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
) O
. O

Safety O
of O
celecoxib B
in O
patients O
with O
adverse O
skin O
reactions O
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide B
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

BACKGROUND O
: O
Acetaminophen O
( O
paracetamol O
- O
- O
P O
) O
and O
Nimesulide B
( O
N B
) O
are O
widely O
used O
analgesic O
- O
antipyretic O
/ O
anti O
- O
inflammatory O
drugs O
. O

Celecoxib B
( O
CE B
) O
is O
a O
novel O
drug O
, O
with O
high O
selectivity O
and O
affinity O
for O
COX O
- O
2 O
enzyme O
. O

OBJECTIVE O
: O
We O
evaluated O
the O
tolerability O
of O
CE B
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous O
reactions O
to O
P O
and O
N B
associated O
or O
not O
to O
classic O
NSAIDs O
. O

METHODS O
: O
We O
studied O
9 O
patients O
with O
hypersensitivity O
to O
P O
and O
N B
with O
or O
without O
associated O
reactions O
to O
classic O
NSAIDs O
. O

The O
diagnosis O
of O
P O
and O
N B
- O
induced O
skin O
reactions O
was O
based O
in O
vivo O
challenge O
. O

After O
three O
days O
, O
a O
cumulative O
dosage O
of O
200 O
mg O
of O
CE B
in O
refracted O
doses O
were O
given O
. O

RESULTS O
: O
No O
reaction O
was O
observed O
with O
placebo O
and O
eight O
patients O
( O
88 O
. O
8 O
% O
) O
tolerated O
CE B
. O

CONCLUSION O
: O
Only O
one O
hypersensitivity O
reaction O
to O
CE B
was O
documented O
among O
9 O
P O
and O
N B
- O
highly O
NSAIDs O
intolerant O
patients O
. O

Thus O
, O
we O
conclude O
that O
CE B
is O
a O
reasonably O
safe O
alternative O
to O
be O
used O
in O
subjects O
who O
do O
not O
tolerate O
P O
and O
N B
. O

For O
specific O
groups O
of O
drugs O
, O
the O
risks O
were O
1 O
. O
56 O
( O
1 O
. O
05 O
- O
2 O
. O
30 O
) O
for O
aspirin O
, O
1 O
. O
03 O
( O
0 O
. O
60 O
- O
1 O
. O
76 O
) O
for O
pyrazolones B
, O
0 O
. O
80 O
( O
0 O
. O
39 O
- O
1 O
. O
63 O
) O
for O
paracetamol O
, O
and O
0 O
. O
94 O
( O
0 O
. O
57 O
- O
1 O
. O
56 O
) O
for O
nonaspirin O
NSAIDs O
. O

Two O
cases O
of O
amisulpride B
overdose O
: O
a O
cause O
for O
prolonged O
QT O
syndrome O
. O

Two O
cases O
of O
deliberate O
self O
- O
poisoning O
with O
5 O
g O
and O
3 O
. O
6 O
g O
of O
amisulpride B
, O
respectively O
, O
are O
reported O
. O

Morphological O
evaluation O
of O
the O
effect O
of O
d B
- I
ribose I
on O
adriamycin O
- O
evoked O
cardiotoxicity O
in O
rats O
. O

The O
influence O
of O
d B
- I
ribose I
on O
adriamycin O
- O
induced O
myocardiopathy O
in O
rats O
was O
studied O
. O

D B
- I
ribose I
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
ADR O
cardiotoxicity O
. O

In O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin O
- O
induced O
nephrotoxicity O
: O
protection O
by O
erdosteine B
. O

The O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
VCM O
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine B
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
VCM O
- O
induced O
renal O
impairment O
in O
rats O
. O

Rats O
were O
divided O
into O
three O
groups O
: O
sham O
, O
VCM O
and O
VCM O
plus O
erdosteine B
. O

Erdosteine B
was O
administered O
orally O
. O

Erdosteine B
administration O
with O
VCM O
injections O
caused O
significantly O
decreased O
renal O
MDA O
and O
urinary O
NAG O
excretion O
, O
and O
increased O
SOD O
activity O
, O
but O
not O
CAT O
activity O
in O
renal O
tissue O
when O
compared O
with O
VCM O
alone O
. O

Erdosteine B
showed O
histopathological O
protection O
against O
VCM O
- O
induced O
nephrotoxicity O
. O

There O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy O
, O
desquamation O
, O
and O
necrosis O
in O
VCM O
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine B
groups O
. O

Erdosteine B
caused O
a O
marked O
reduction O
in O
the O
extent O
of O
tubular O
damage O
. O

It O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
VCM O
- O
induced O
nephrotoxicity O
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine B
reduces O
the O
VCM O
- O
induced O
kidney O
damage O
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

With O
2 O
- O
drug O
therapy O
, O
mean O
total O
cholesterol O
decreased O
22 O
% O
from O
255 O
to O
200 O
mg O
/ O
dl O
, O
triglyceride B
levels O
decreased O
35 O
% O
from O
236 O
to O
154 O
mg O
/ O
dl O
, O
LDL O
cholesterol O
decreased O
26 O
% O
from O
176 O
to O
131 O
mg O
/ O
dl O
, O
and O
the O
total O
cholesterol O
/ O
HDL O
cholesterol O
ratio O
decreased O
24 O
% O
from O
7 O
. O
1 O
to O
5 O
. O
4 O
, O
all O
p O
less O
than O
or O
equal O
to O
0 O
. O
0001 O
. O

Does O
domperidone O
potentiate O
mirtazapine B
- O
associated O
restless O
legs O
syndrome O
? O

Mirtazapine B
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
( O
NaSSA O
) O
, O
has O
been O
associated O
with O
RLS O
in O
several O
recent O
publications O
. O

The O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial O
dyspepsia O
who O
developed O
RLS O
after O
mirtazapine B
had O
been O
added O
to O
his O
domperidone O
therapy O
. O

Our O
patient O
started O
to O
have O
symptoms O
of O
RLS O
only O
after O
he O
had O
been O
treated O
with O
mirtazapine B
, O
and O
his O
RLS O
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine B
. O

Such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine B
and O
the O
symptoms O
of O
RLS O
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione O
on O
mirtazapine B
- O
associated O
RLS O
. O

However O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine B
can O
be O
associated O
with O
RLS O
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine O
D2 O
receptor O
antagonists O
. O

MATERIALS O
AND O
METHODS O
: O
We O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols O
( O
C O
) O
, O
triglycerides B
( O
TG B
) O
, O
lipoproteins O
( O
LP O
) O
, O
and O
apolipoproteins O
( O
Apo O
) O
B O
- O
100 O
, O
A O
- O
I O
, O
and O
A O
- O
II O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate O
cancer O
( O
stage O
: O
T1cN0M0 O
, O
Gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
CPA O
) O
without O

RESULTS O
: O
Significant O
decreases O
of O
HDL O
- O
C O
, O
Apo O
A O
- O
I O
and O
Apo O
A O
- O
II O
and O
an O
increase O
of O
triglyceride B
levels O
in O
VLDL O
were O
induced O
by O
CPA O
. O

5 O
- O
Fluorouracil O
cardiotoxicity O
induced O
by O
alpha B
- I
fluoro I
- I
beta I
- I
alanine I
. O

We O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 O
- O
FU O
- O
induced O
cardiotoxicity O
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha B
- I
fluoro I
- I
beta I
- I
alanine I
( O
FBAL B
) O
was O
observed O
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
FU O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial O
pain O
with O
right O
bundle O
branch O
block O
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL B
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Instead O
, O
oral O
administration O
of O
S O
- O
1 O
( O
a O
derivative O
of O
5 O
- O
FU O
) O
, O
at O
200 O
mg O
/ O
day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
S O
- O
1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine B
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5 O
- O
FU O
into O
FBAL B
. O

The O
serum O
FBAL B
concentration O
subsequently O
decreased O
to O
352 O
ng O
/ O
ml O
, O
the O
same O
as O
the O
value O
measured O
on O
the O
first O
day O
of O
S O
- O
1 O
administration O
. O

The O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
FBAL B
is O
related O
to O
5 O
- O
FU O
- O
induced O
cardiotoxicity O
. O

Hepatocellular O
carcinoma O
in O
Fanconi O
' O
s O
anemia O
treated O
with O
androgen B
and O
corticosteroid O
. O

The O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
Fanconi O
' O
s O
anemia O
for O
3 O
years O
and O
was O
treated O
with O
androgens B
, O
corticosteroids O
and O
transfusions O
. O

This O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic O
neoplasms O
and O
peliosis O
can O
develop O
in O
patients O
with O
androgen B
- O
and O
corticosteroid O
- O
treated O
Fanconi O
' O
s O
anemia O
. O

The O
influence O
of O
the O
time O
interval O
between O
monoHER B
and O
doxorubicin O
administration O
on O
the O
protection O
against O
doxorubicin O
- O
induced O
cardiotoxicity O
in O
mice O
. O

The O
semisynthetic O
flavonoid B
monohydroxyethylrutoside B
( O
monoHER B
) O
showed O
cardioprotection O
against O
DOX O
- O
induced O
cardiotoxicity O
through O
its O
radical O
scavenging O
and O
iron O
chelating O
properties O
. O

Because O
of O
the O
relatively O
short O
final O
half O
- O
life O
of O
monoHER B
( O
about O
30 O
min O
) O
, O
it O
is O
expected O
that O
the O
time O
interval O
between O
monoHER B
and O
DOX O
might O
be O
of O
influence O
on O
the O
cardioprotective O
effect O
of O
monoHER B
. O

METHODS O
: O
Six O
groups O
of O
6 O
BALB O
/ O
c O
mice O
were O
treated O
with O
saline O
, O
DOX O
alone O
or O
DOX O
( O
4 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
preceded O
by O
monoHER B
( O
500 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
with O
an O
interval O
of O
10 O
, O
30 O
, O
60 O
or O
120 O
min O
. O

The O
ratio O
of O
aberrant O
cardiomyocytes O
in O
mice O
treated O
with O
DOX O
preceded O
by O
monoHER B
and O
those O
in O
mice O
treated O
with O
saline O
ranged O
from O
1 O
. O
6 O
to O
2 O
. O
8 O
( O
mean O
2 O
. O
2 O
, O
95 O
% O
CI O
1 O
. O
2 O
- O
4 O
. O
1 O
, O
P O
= O
0 O
. O
019 O
) O
. O

The O
mean O
protective O
effect O
by O
adding O
monoHER B
before O
DOX O
led O
to O
a O
significant O
4 O
. O
4 O
- O
fold O
reduction O
( O
P O
< O
0 O
. O
001 O
, O
95 O
% O
CI O
2 O
. O
3 O
- O
8 O
. O
2 O
) O
of O
abnormal O
cardiomyocytes O
. O

This O
protective O
effect O
did O
not O
depend O
on O
the O
time O
interval O
between O
monoHER B
and O
DOX O
administration O
( O
P O
= O
0 O
. O
345 O
) O
. O

CONCLUSION O
: O
The O
results O
indicate O
that O
in O
an O
outpatient O
clinical O
setting O
monoHER B
may O
be O
administered O
shortly O
before O
DOX O
. O

We O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
Nomega B
- I
nitro I
- I
L I
- I
arginine I
( O
LNNA B
) O
hypertension O
through O
these O
mechanisms O
. O

Rats O
were O
treated O
with O
the O
NO O
synthase O
inhibitor O
LNNA B
( O
0 O
. O
5 O
g O
/ O
L O
in O
drinking O
water O
) O
for O
2 O
weeks O
. O

Mean O
arterial O
pressure O
of O
conscious O
rats O
was O
119 O
+ O
/ O
- O
2 O
mm O
Hg O
in O
control O
and O
194 O
+ O
/ O
- O
5 O
mm O
Hg O
in O
LNNA B
rats O
( O
P O
< O
0 O
. O
05 O
) O
. O

Maximal O
contraction O
to O
norepinephrine O
was O
modestly O
reduced O
in O
arteries O
from O
LNNA B
compared O
with O
control O
rats O
whereas O
the O
maximum O
contraction O
to O
ET O
- O
1 O
was O
significantly O
reduced O
( O
54 O
% O
control O
) O
. O

Mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
LNNA B
hypertension O
at O
1 O
or O
2 O
weeks O
after O
LNNA B
. O

The O
superoxide O
scavenger O
tempol B
( O
30 O
, O
100 O
, O
and O
300 O
micromol O
kg O
( O
- O
1 O
) O
, O
IV O
) O
did O
not O
change O
arterial O
pressure O
in O
control O
rats O
but O
caused O
a O
dose O
- O
dependent O
decrease O
in O
LNNA B
rats O
( O
- O
18 O
+ O
/ O
- O
8 O
, O
- O
26 O
+ O
/ O
- O
15 O
, O
and O
- O
54 O
+ O
/ O
- O
11 O
mm O
Hg O
) O
. O

Similarly O
, O
ganglionic O
blockade O
with O
hexamethonium O
caused O
a O
significantly O
greater O
fall O
in O
LNNA B
hypertensive O
rats O
( O
76 O
+ O
/ O
- O
9 O
mm O
Hg O
) O
compared O
with O
control O
rats O
( O
35 O
+ O
/ O
- O
10 O
mm O
Hg O
) O
. O

Carotid O
arteries O
, O
vena O
cava O
, O
and O
sympathetic O
ganglia O
from O
LNNA B
rats O
had O
higher O
basal O
levels O
of O
superoxide O
compared O
with O
those O
from O
control O
rats O
. O

Minocycline B
- O
induced O
vasculitis O
fulfilling O
the O
criteria O
of O
polyarteritis O
nodosa O
. O

A O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline B
for O
palmoplantar O
pustulosis O
developed O
fever O
, O
myalgias O
, O
polyneuropathy O
, O
and O
testicular O
pain O
, O
with O
elevated O
C O
- O
reactive O
protein O
( O
CRP O
) O
. O

Stopping O
minocycline B
led O
to O
amelioration O
of O
symptoms O
and O
normalization O
of O
CRP O
level O
. O

To O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline B
- O
induced O
vasculitis O
satisfying O
the O
criteria O
. O

Anticonvulsant O
effect O
of O
eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
) O
on O
seizures O
induced O
by O
microperfusion O
of O
picrotoxin O
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

Eslicarbazepine B
acetate I
( O
BIA B
2 I
- I
093 I
, O
S B
- I
( I
- I
) I
- I
10 I
- I
acetoxy I
- I
10 I
, I
11 I
- I
dihydro I
- I
5H I
- I
dibenzo I
/ I
b I
, I
f I
/ I
azepine I
- I
5 I
- I
carboxamide I
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
Phase O
III O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine O
( O
CBZ O
) O
and O
oxcarbazepine O
( O
OXC O
) O
. O

We O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine B
acetate I
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures O
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure O
patterns O
. O

No O
adverse O
effects O
of O
eslicarbazepine B
acetate I
were O
observed O
in O
the O
behavioral O
/ O
EEG O
patterns O
studied O
, O
including O
sleep O
/ O
wakefulness O
cycle O
, O
at O
the O
doses O
studied O
. O

Acute O
renal O
failure O
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones B
. O

Chinese B
herbal I
medicine O
preparations O
are O
widely O
available O
and O
often O
regarded O
by O
the O
public O
as O
natural O
and O
safe O
remedies O
for O
a O
variety O
of O
medical O
conditions O
. O

Nephropathy O
caused O
by O
Chinese B
herbs I
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic B
acids I
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute O
renal O
failure O
following O
prolonged O
use O
of O
a O
proprietary O
Chinese B
herbal I
slimming O
pill O
that O
contained O
anthraquinone B
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

Although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone B
- O
containing O
herbal O
agent O
and O
renal O
injury O
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy O
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal O
failure O
. O

Chloroacetaldehyde O
as O
a O
sulfhydryl B
reagent O
: O
the O
role O
of O
critical O
thiol B
groups O
in O
ifosfamide O
nephropathy O
. O

Depletion O
of O
sulfhydryl B
( O
SH B
) O
groups O
has O
been O
reported O
from O
cell O
culture O
, O
animal O
and O
clinical O
studies O
. O

Toxicity O
of O
CAA O
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
LDH O
release O
, O
trypan B
blue I
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

Free O
thiols B
were O
measured O
by O
the O
method O
of O
Ellman O
. O

CAA O
reduced O
hRPTEC O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols B
and O
an O
increase O
in O
necrosis O
markers O
. O

CAA O
but O
not O
acrolein B
inhibited O
the O
cysteine B
proteases O
caspase O
- O
3 O
, O
caspase O
- O
8 O
and O
cathepsin O
B O
. O

The O
effects O
of O
CAA O
on O
cysteine B
protease O
activities O
and O
thiols B
could O
be O
reproduced O
in O
cell O
lysate O
. O

Acidification O
, O
which O
slowed O
the O
reaction O
of O
CAA O
with O
thiol B
donors O
, O
could O
also O
attenuate O
effects O
of O
CAA O
on O
necrosis O
markers O
, O
thiol B
depletion O
and O
cysteine B
protease O
inhibition O
in O
living O
cells O
. O

Thus O
, O
CAA O
directly O
reacts O
with O
cellular O
protein O
and O
non O
- O
protein O
thiols B
, O
mediating O
its O
toxicity O
on O
hRPTEC O
. O

Early O
paracentral O
visual O
field O
loss O
in O
patients O
taking O
hydroxychloroquine B
. O

OBJECTIVE O
: O
To O
review O
the O
natural O
history O
and O
ocular O
and O
systemic O
adverse O
effects O
of O
patients O
taking O
hydroxychloroquine B
sulfate I
who O
attended O
an O
ophthalmic O
screening O
program O
. O

RESULTS O
: O
Records O
of O
262 O
patients O
who O
were O
taking O
hydroxychloroquine B
and O
screened O
in O
the O
Department O
of O
Ophthalmology O
were O
reviewed O
. O

Thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual O
field O
abnormalities O
, O
which O
were O
attributed O
to O
hydroxychloroquine B
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

Patients O
taking O
hydroxychloroquine B
can O
demonstrate O
a O
toxic O
reaction O
in O
the O
retina O
despite O
the O
absence O
of O
known O
risk O
factors O
. O

Peri O
- O
operative O
atrioventricular O
block O
as O
a O
result O
of O
chemotherapy O
with O
epirubicin B
and O
paclitaxel O
. O

In O
the O
preceding O
months O
she O
had O
received O
neo O
- O
adjuvant O
chemotherapy O
with O
epirubicin B
, O
paclitaxel O
( O
Taxol O
) O
and O
cyclophosphamide O
. O

Risks O
and O
benefits O
of O
COX B
- I
2 I
inhibitors I
vs O
non O
- O
selective O
NSAIDs O
: O
does O
their O
cardiovascular O
risk O
exceed O
their O
gastrointestinal O
benefit O
? O

OBJECTIVES O
: O
The O
risk O
of O
acute O
myocardial O
infarction O
( O
AMI O
) O
with O
COX B
- I
2 I
inhibitors I
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non B
- I
steroidal I
anti I
- I
inflammatory I
drugs I
( O
NSAIDs O
) O
. O

We O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
AMI O
and O
GI O
bleeding O
among O
elderly O
patients O
using O
COX B
- I
2 I
inhibitors I
, O
NS O
- O
NSAIDs O
and O
acetaminophen O
. O

RESULTS O
: O
Person O
- O
years O
of O
exposure O
among O
non O
- O
users O
of O
aspirin O
were O
: O
75 O
, O
761 O
to O
acetaminophen O
, O
42 O
, O
671 O
to O
rofecoxib B
65 O
, O
860 O
to O
celecoxib B
, O
and O
37 O
, O
495 O
to O
NS O
- O
NSAIDs O
. O

Among O
users O
of O
aspirin O
, O
they O
were O
: O
14 O
, O
671 O
to O
rofecoxib B
, O
22 O
, O
875 O
to O
celecoxib B
, O
9 O
, O
832 O
to O
NS O
- O
NSAIDs O
and O
38 O
, O
048 O
to O
acetaminophen O
. O

Among O
non O
- O
users O
of O
aspirin O
, O
the O
adjusted O
hazard O
ratios O
( O
95 O
% O
confidence O
interval O
) O
of O
hospitalization O
for O
AMI O
/ O
GI O
vs O
the O
acetaminophen O
( O
with O
no O
aspirin O
) O
group O
were O
: O
rofecoxib B
1 O
. O
27 O
( O
1 O
. O
13 O
, O
1 O
. O
42 O
) O
, O
celecoxib B
0 O
. O
93 O
( O
0 O
. O
83 O
, O
1 O
. O
03 O
) O
, O
naproxen B
1 O
. O
59 O
( O
1 O
. O
31 O
, O
1 O
. O
93 O
) O
, O
diclofenac O
1 O
. O
17 O
( O
0 O
. O
99 O
, O
1 O
. O
38 O
) O
and O
ibuprofen O
1 O
. O
05 O
( O
0 O
. O

Among O
users O
of O
aspirin O
, O
they O
were O
: O
rofecoxib B
1 O
. O
73 O
( O
1 O
. O
52 O
, O
1 O
. O
98 O
) O
, O
celecoxib B
1 O
. O
34 O
( O
1 O
. O
19 O
, O
1 O
. O
52 O
) O
, O
ibuprofen O
1 O
. O
51 O
( O
0 O
. O
95 O
, O
2 O
. O
41 O
) O
, O
diclofenac O
1 O
. O
69 O
( O
1 O
. O
35 O
, O
2 O
. O
10 O
) O
, O
naproxen B
1 O
. O
35 O
( O
0 O
. O
97 O
, O
1 O
. O
88 O
) O
and O
acetaminophen O
1 O
. O
29 O
( O
1 O
. O
17 O
, O
1 O
. O
42 O
) O
. O

CONCLUSION O
: O
Among O
non O
- O
users O
of O
aspirin O
, O
naproxen B
seemed O
to O
carry O
the O
highest O
risk O
for O
AMI O
/ O
GI O
bleeding O
. O

The O
AMI O
/ O
GI O
toxicity O
of O
celecoxib B
was O
similar O
to O
that O
of O
acetaminophen O
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib B
and O
NS O
- O
NSAIDs O
. O

Among O
users O
of O
aspirin O
, O
both O
celecoxib B
and O
naproxen B
seemed O
to O
be O
the O
least O
toxic O
. O

Quinine O
, O
like O
quinidine B
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti O
- O
arrhythmic O
property O
, O
although O
it O
also O
pro O
- O
arrhythmic O
that O
can O
cause O
various O
arrhythmias O
, O
including O
severe O
arrhythmia O
such O
as O
multiple O
PVC O
. O

Penicillamine O
- O
related O
lichenoid O
dermatitis O
and O
utility O
of O
zinc B
acetate I
in O
a O
Wilson O
disease O
patient O
with O
hepatic O
presentation O
, O
anxiety O
and O
SPECT O
abnormalities O
. O

Wilson O
' O
s O
disease O
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper B
metabolism O
with O
consequent O
copper B
accumulation O
and O
toxicity O
in O
many O
tissues O
and O
consequent O
hepatic O
, O
neurologic O
and O
psychiatric O
disorders O
. O

During O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid O
dermatitis O
, O
and O
zinc B
acetate I
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

In O
our O
case O
the O
therapy O
with O
zinc B
acetate I
represented O
an O
effective O
treatment O
for O
a O
Wilson O
' O
s O
disease O
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc B
acetate I
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson O
' O
s O
disease O
. O

Acute O
encephalopathy O
and O
cerebral O
vasospasm O
after O
multiagent O
chemotherapy O
including O
PEG B
- I
asparaginase I
and O
intrathecal O
cytarabine B
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukemia O
. O

The O
patient O
developed O
acute O
encephalopathy O
evidenced O
by O
behavioral O
changes O
, O
aphasia O
, O
incontinence O
, O
visual O
hallucinations O
, O
and O
right O
- O
sided O
weakness O
with O
diffuse O
cerebral O
vasospasm O
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine B
. O

Vincristine O
, O
dexamethasone O
, O
and O
polyethylene B
glycol I
- I
asparaginase I
were O
also O
administered O
before O
the O
episode O
as O
part O
of O
induction O
therapy O
. O

Comparison O
of O
valsartan B
/ O
hydrochlorothiazide B
combination O
therapy O
at O
doses O
up O
to O
320 O
/ O
25 O
mg O
versus O
monotherapy O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
followed O
by O
long O
- O
term O
combination O
therapy O
in O
hypertensive O
adults O
. O

OBJECTIVE O
: O
This O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan B
( O
VAL B
) O
or O
hydrochlorothiazide B
( O
HCTZ B
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential O
hypertension O
. O

Patients O
with O
essential O
hypertension O
( O
mean O
sitting O
diastolic O
BP O
[ O
MSDBP O
] O
, O
> O
or O
= O
95 O
mm O
Hg O
and O
< O
110 O
mm O
Hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
VAL B
160 O
or O
320 O
mg O
; O
HCTZ B
12 O
. O
5 O
or O
25 O
mg O
; O
VAL B
/ O
HCTZ B
160 O
/ O
12 O
. O
5 O
, O
320 O
/ O
12 O
. O
5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

VAL B
/ O
HCTZ B
320 O
/ O
12 O
. O
5 O
and O
320 O
/ O
25 O
mg O
were O
further O
investigated O
in O
a O
54 O
- O
week O
, O
open O
- O
label O
extension O
. O

All O
active O
treatments O
were O
associated O
with O
significantly O
reduced O
MSSBP O
and O
MSDBP O
during O
the O
core O
8 O
- O
week O
study O
, O
with O
each O
monotherapy O
significantly O
contributing O
to O
the O
overall O
effect O
of O
combination O
therapy O
( O
VAL B
and O
HCTZ B
, O
P O
< O
0 O
. O
001 O
) O
. O

The O
mean O
reduction O
in O
MSSBP O
/ O
MSDBP O
with O
VAL B
/ O
HCTZ B
320 O
/ O
25 O
mg O
was O
24 O
. O
7 O
/ O
16 O
. O
6 O
mm O
Hg O
, O
compared O
with O
5 O
. O
9 O
/ O
7 O
. O
0 O
mm O
Hg O
with O
placebo O
. O

The O
reduction O
in O
MSSBP O
was O
significantly O
greater O
with O
VAL B
/ O
HCTZ B
320 O
/ O
25 O
mg O
compared O
with O
VAL B
/ O
HCTZ B
160 O
/ O
12 O
. O
5 O
mg O
( O
P O
< O
0 O
. O
002 O
) O
. O

The O
incidence O
of O
hypokalemia O
was O
lower O
with O
VAL B
/ O
HCTZ B
combinations O
( O
1 O
. O
8 O
% O
- O
6 O
. O
1 O
% O
) O
than O
with O
HCTZ B
monotherapies O
( O
7 O
. O
1 O
% O
- O
13 O
. O
3 O
% O
) O
. O

The O
efficacy O
and O
tolerability O
of O
VAL B
/ O
HCTZ B
combinations O
were O
maintained O
during O
the O
extension O
( O
797 O
patients O
) O
. O

CONCLUSIONS O
: O
In O
this O
study O
population O
, O
combination O
therapies O
with O
VAL B
/ O
HCTZ B
were O
associated O
with O
significantly O
greater O
BP O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia O
than O
HCTZ B
alone O
. O

Succimer B
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead B
- O
exposed O
rats O
but O
produces O
lasting O
cognitive O
impairment O
in O
the O
absence O
of O
lead B
exposure O
. O

BACKGROUND O
: O
There O
is O
growing O
pressure O
for O
clinicians O
to O
prescribe O
chelation O
therapy O
at O
only O
slightly O
elevated O
blood O
lead B
levels O
. O

OBJECTIVES O
: O
The O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
Pb O
exposure O
and O
treatment O
with O
succimer B
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
Pb O
poisoning O
. O

Succimer B
treatment O
of O
the O
Pb O
- O
exposed O
rats O
significantly O
improved O
learning O
, O
attention O
, O
and O
arousal O
regulation O
, O
although O
the O
efficacy O
of O
the O
treatment O
varied O
as O
a O
function O
of O
the O
Pb O
exposure O
level O
and O
the O
specific O
functional O
deficit O
. O

In O
contrast O
, O
succimer B
treatment O
of O
rats O
not O
previously O
exposed O
to O
Pb O
produced O
lasting O
and O
pervasive O
cognitive O
and O
affective O
dysfunction O
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
Pb O
exposure O
regimen O
. O

These O
findings O
suggest O
that O
it O
may O
be O
possible O
to O
identify O
a O
succimer B
treatment O
protocol O
that O
improves O
cognitive O
outcomes O
in O
Pb O
- O
exposed O
children O
. O

However O
, O
they O
also O
suggest O
that O
succimer B
treatment O
should O
be O
strongly O
discouraged O
for O
children O
who O
do O
not O
have O
elevated O
tissue O
levels O
of O
Pb O
or O
other O
heavy O
metals O
. O

Piperacillin B
/ I
tazobactam I
- O
induced O
seizure O
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

Despite O
popular O
use O
of O
piperacillin B
, O
the O
dire O
neurotoxicity O
associated O
with O
piperacillin B
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end O
- O
stage O
renal O
disease O
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor O
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion O
, O
and O
2 O
episodes O
of O
generalized O
tonic O
- O
clonic O
seizure O
( O
GTCS O
) O
after O
5 O
doses O
of O
piperacillin B
/ I
tazobactam I
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis O
with O
secondary O
infection O
. O

The O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia B
levels O
but O
leukocytosis O
. O

Despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
GTCS O
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin B
/ I
tazobactam I
. O

Piperacillin B
- O
induced O
encephalopathy O
should O
be O
considered O
in O
any O
uremic O
patients O
with O
unexplained O
neurological O
manifestations O
. O

CAPD O
is O
inefficient O
in O
removing O
piperacillin B
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin B
- O
induced O
encephalopathy O
. O

Anesthesia O
was O
performed O
by O
injecting O
20 O
to O
40 O
mL O
of O
a O
mixture O
of O
long O
- O
acting O
( O
ropivacaine B
) O
and O
short O
- O
acting O
( O
prilocaine O
) O
anesthetic O
. O

Neuroprotective O
effects O
of O
melatonin B
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
BCNU O
- O
induced O
cortical O
dysplasia O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine O
- O
[ O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosoure O
] O
( O
BCNU O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin B
upon O
cerebellar O
BCNU O
- O
induced O
cortical O
dysplasia O
, O
using O
histological O
and O
biochemical O
analyses O
. O

Pregnant O
Wistar O
rats O
were O
assigned O
to O
five O
groups O
: O
intact O
- O
control O
, O
saline O
- O
control O
, O
melatonin B
- O
treated O
, O
BCNU O
- O
exposed O
and O
BCNU O
- O
exposed O
plus O
melatonin B
. O

Rats O
were O
exposed O
to O
BCNU O
on O
embryonic O
day O
15 O
and O
melatonin B
was O
given O
until O
delivery O
. O

There O
was O
a O
marked O
increase O
in O
the O
number O
of O
TUNEL O
positive O
cells O
and O
nestin O
positive O
cells O
in O
BCNU O
- O
exposed O
group O
, O
but O
a O
decreased O
immunoreactivity O
to O
glial O
fibrillary O
acidic O
protein O
, O
synaptophysin O
and O
transforming O
growth O
factor O
beta1 O
was O
observed O
, O
indicating O
a O
delayed O
maturation O
, O
and O
melatonin B
significantly O
reversed O
these O
changes O
. O

Malondialdehyde O
level O
in O
BCNU O
- O
exposed O
group O
was O
higher O
than O
those O
in O
control O
groups O
and O
melatonin B
decreased O
malondialdehyde O
levels O
in O
BCNU O
group O
( O
P O
< O
0 O
. O
01 O
) O
, O
while O
there O
were O
no O
significant O
differences O
in O
the O
superoxide O
dismutase O
levels O
between O
these O
groups O
. O

These O
data O
suggest O
that O
exposure O
of O
animals O
to O
BCNU O
during O
pregnancy O
leads O
to O
delayed O
maturation O
of O
offspring O
cerebellum O
and O
melatonin B
protects O
the O
cerebellum O
against O
the O
effects O
of O
BCNU O
. O

Reduced O
cardiotoxicity O
of O
doxorubicin O
given O
in O
the O
form O
of O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

A O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity O
and O
the O
late O
cardiotoxicity O
of O
4 O
mg O
/ O
kg O
doxorubicin O
( O
DOX O
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
conjugates O
. O

In O
these O
HPMA B
copolymers O
, O
DOX O
was O
covalently O
bound O
via O
peptide O
linkages O
that O
were O
either O
non O
- O
biodegradable O
( O
Gly O
- O
Gly O
) O
or O
degradable O
by O
lysosomal O
proteinases O
( O
Gly B
- I
Phe I
- I
Leu I
- I
Gly I
) O
. O

In O
addition O
, O
one O
biodegradable O
conjugate O
containing O
galactosamine B
was O
used O
; O
this O
residue O
was O
targeted O
to O
the O
liver O
. O

However O
, O
the O
maximal O
reduction O
in O
body O
weight O
seen O
in O
animals O
that O
received O
polymer O
- O
bound O
DOX O
( O
4 O
mg O
/ O
kg O
) O
was O
significantly O
lower O
than O
that O
observed O
in O
those O
that O
received O
free O
DOX O
( O
4 O
mg O
/ O
kg O
) O
or O
a O
mixture O
of O
the O
unmodified O
parent O
HPMA B
copolymer O
and O
free O
DOX O
( O
4 O
mg O
/ O
kg O
; O
P O
less O
than O
0 O
. O
01 O
) O
. O

Throughout O
the O
study O
( O
20 O
weeks O
) O
, O
deaths O
related O
to O
cardiotoxicity O
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
DOX O
or O
the O
mixture O
of O
HPMA B
copolymer O
and O
free O
DOX O
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
DOX O
- O
induced O
cardiotoxicity O
. O

Sequential O
measurements O
of O
cardiac O
output O
in O
surviving O
animals O
that O
received O
either O
free O
DOX O
or O
the O
mixture O
of O
HPMA B
copolymer O
and O
free O
DOX O
showed O
a O
reduction O
of O
approximately O
30 O
% O
in O
function O
beginning O
at O
the O
4th O
week O
after O
drug O
administration O
. O

Animals O
that O
were O
given O
the O
HPMA B
copolymer O
conjugates O
containing O
DOX O
exhibited O
no O
significant O
change O
in O
cardiac O
output O
throughout O
the O
study O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
addition O
, O
no O
significant O
histological O
change O
was O
observed O
in O
the O
heart O
of O
animals O
that O
received O
DOX O
in O
the O
form O
of O
HPMA B
copolymer O
conjugates O
and O
were O
killed O
at O
the O
end O
of O
the O
study O
. O

Corneal O
ulcers O
associated O
with O
aerosolized O
crack B
cocaine I
use O
. O

RESULTS O
: O
Four O
patients O
with O
corneal O
ulcers O
associated O
with O
crack B
cocaine I
use O
were O
reviewed O
. O

CONCLUSIONS O
: O
Aerosolized O
crack B
cocaine I
use O
can O
be O
associated O
with O
the O
development O
of O
corneal O
ulcers O
. O

Myo B
- I
inositol I
- I
1 I
- I
phosphate I
( O
MIP B
) O
synthase O
inhibition O
: O
in O
- O
vivo O
study O
in O
rats O
. O

Both O
drugs O
influence O
inositol B
metabolism O
. O

Lithium O
inhibits O
IMPase O
and O
valproate O
inhibits O
MIP B
synthase O
. O

This O
study O
shows O
that O
MIP B
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium O
in O
the O
inositol B
sensitive O
pilocarpine O
- O
induced O
seizures O
model O
. O

This O
lack O
of O
effects O
may O
stem O
from O
the O
low O
contribution O
of O
de O
- O
novo O
synthesis O
to O
cellular O
inositol B
supply O
or O
to O
the O
inhibition O
of O
the O
de O
- O
novo O
synthesis O
by O
lithium O
itself O
. O

The O
differential O
effects O
of O
bupivacaine O
and O
lidocaine O
on O
prostaglandin B
E2 I
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain O
in O
a O
clinical O
pain O
model O
. O

In O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine O
on O
local O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
and O
cyclooxygenase O
( O
COX O
) O
gene O
expression O
that O
increases O
postoperative O
pain O
in O
human O
subjects O
. O

METHODS O
: O
Subjects O
( O
n O
= O
114 O
) O
undergoing O
extraction O
of O
impacted O
third O
molars O
received O
either O
2 O
% O
lidocaine O
or O
0 O
. O
5 O
% O
bupivacaine O
before O
surgery O
and O
either O
rofecoxib B
50 O
mg O
or O
placebo O
orally O
90 O
min O
before O
surgery O
and O
for O
the O
following O
48 O
h O
. O

After O
extraction O
, O
a O
microdialysis O
probe O
was O
placed O
at O
the O
surgical O
site O
for O
PGE2 B
and O
thromboxane B
B2 I
( O
TXB2 B
) O
measurements O
. O

RESULTS O
: O
The O
bupivacaine O
/ O
rofecoxib B
group O
reported O
significantly O
less O
pain O
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h O
. O

However O
, O
the O
bupivacaine O
/ O
placebo O
group O
reported O
significantly O
more O
pain O
at O
24 O
h O
and O
PGE2 B
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

Thromboxane B
levels O
were O
not O
significantly O
affected O
by O
any O
of O
the O
treatments O
, O
indicating O
that O
the O
effects O
seen O
were O
attributable O
to O
inhibition O
of O
COX O
- O
2 O
, O
but O
not O
COX O
- O
1 O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
bupivacaine O
stimulates O
COX O
- O
2 O
gene O
expression O
after O
tissue O
injury O
, O
which O
is O
associated O
with O
higher O
PGE2 B
production O
and O
pain O
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

Alternatively O
, O
anemia O
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine B
( O
PS B
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

According O
to O
annexin O
V O
binding O
, O
erythrocytes O
from O
patients O
indeed O
showed O
a O
significant O
increase O
of O
PS B
exposure O
within O
1 O
week O
of O
treatment O
with O
azathioprine O
. O

In O
a O
second O
series O
, O
cytosolic O
Ca2 B
+ O
activity O
( O
Fluo3 B
fluorescence O
) O
, O
cell O
volume O
( O
forward O
scatter O
) O
, O
and O
PS B
- O
exposure O
( O
annexin O
V O
binding O
) O
were O
determined O
by O
FACS O
analysis O
in O
erythrocytes O
from O
healthy O
volunteers O
. O

RESULTS O
: O
Exposure O
to O
azathioprine O
( O
> O
or O
= O
2 O
microg O
/ O
mL O
) O
for O
48 O
hours O
increased O
cytosolic O
Ca2 B
+ O
activity O
and O
annexin O
V O
binding O
and O
decreased O
forward O
scatter O
. O

The O
effect O
of O
azathioprine O
on O
both O
annexin O
V O
binding O
and O
forward O
scatter O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
Ca2 B
+ O
. O

The O
most O
common O
regimens O
were O
3TC O
+ O
d4T B
+ O
nevirapine B
( O
NVP B
) O
( O
54 O
. O
8 O
% O
) O
, O
zidovudine O
( O
AZT O
) O
+ O
3TC O
+ O
NVP B
( O
14 O
. O
5 O
% O
) O
, O
3TC O
+ O
d4T B
+ O
efavirenz B
( O
EFV B
) O
( O
20 O
. O
1 O
% O
) O
, O
and O
AZT O
+ O
3TC O
+ O
EFV B
( O
5 O
. O
4 O
% O
) O
. O

Among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
NVP B
therapy O
was O
significantly O
associated O
with O
developing O
rash O
and O
d4T B
therapy O
with O
developing O
peripheral O
neuropathy O
( O
p O
< O
0 O
. O
05 O
) O
. O

Five O
cases O
of O
encephalitis O
during O
treatment O
of O
loiasis O
with O
diethylcarbamazine B
. O

Five O
cases O
of O
encephalitis O
following O
treatment O
with O
diethylcarbamazine B
( O
DEC B
) O
were O
observed O
in O
Congolese O
patients O
with O
Loa O
loa O
filariasis O
. O

The O
notable O
fact O
was O
that O
this O
complication O
occurred O
in O
three O
patients O
hospitalized O
before O
treatment O
began O
, O
with O
whom O
particularly O
strict O
therapeutic O
precautions O
were O
taken O
, O
i O
. O
e O
. O
, O
initial O
dose O
less O
than O
10 O
mg O
of O
DEC B
, O
very O
gradual O
dose O
increases O
, O
and O
associated O
anti O
- O
allergic O
treatment O
. O

Risk O
of O
coronary O
artery O
disease O
associated O
with O
initial O
sulphonylurea B
treatment O
of O
patients O
with O
type O
2 O
diabetes O
: O
a O
matched O
case O
- O
control O
study O
. O

AIMS O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary O
artery O
disease O
( O
CAD O
) O
associated O
with O
initial O
treatment O
of O
type O
2 O
diabetes O
with O
different O
sulphonylureas B
. O

The O
hazard O
of O
developing O
CAD O
( O
95 O
% O
CI O
) O
associated O
with O
initial O
treatment O
increased O
by O
2 O
. O
4 O
- O
fold O
( O
1 O
. O
3 O
- O
4 O
. O
3 O
, O
P O
= O
0 O
. O
004 O
) O
with O
glibenclamide O
; O
2 O
- O
fold O
( O
0 O
. O
9 O
- O
4 O
. O
6 O
, O
P O
= O
0 O
. O
099 O
) O
with O
glipizide B
; O
2 O
. O
9 O
- O
fold O
( O
1 O
. O
6 O
- O
5 O
. O
1 O
, O
P O
= O
0 O
. O
000 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin B
. O

The O
hazard O
decreased O
0 O
. O
3 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
7 O
, O
P O
= O
0 O
. O
385 O
) O
with O
glimepiride B
, O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
3 O
, O
P O
= O
0 O
. O
192 O
) O
with O
gliclazide B
, O
and O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
1 O
, O
P O
= O
0 O
. O
09 O
) O
with O
either O
. O

CONCLUSIONS O
: O
Initiating O
treatment O
of O
type O
2 O
diabetes O
with O
glibenclamide O
or O
glipizide B
is O
associated O
with O
increased O
risk O
of O
CAD O
in O
comparison O
to O
gliclazide B
or O
glimepiride B
. O

If O
confirmed O
, O
this O
may O
be O
important O
because O
most O
Indian O
patients O
receive O
the O
cheaper O
older O
sulphonylureas B
, O
and O
present O
guidelines O
do O
not O
distinguish O
between O
individual O
agents O
. O

Delirium O
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol B
. O

Misoprostol B
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache O
. O

We O
present O
a O
case O
in O
which O
an O
89 O
- O
year O
- O
old O
woman O
in O
a O
long O
- O
term O
care O
facility O
became O
confused O
after O
the O
initiation O
of O
misoprostol B
therapy O
. O

Her O
delirium O
significantly O
improved O
after O
misoprostol B
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

Because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium O
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol B
therapy O
. O

The O
metabolic O
responses O
to O
isoprenaline O
in O
dogs O
( O
an O
increase O
in O
circulating O
glucose O
, O
lactate O
and O
free O
fatty B
acids I
) O
were O
all O
blocked O
by O
( O
- O
) O
- O
propranolol O
. O

( O
+ O
) O
- O
Propranolol O
had O
no O
effect O
on O
fatty B
acid I
mobilization O
but O
significantly O
reduced O
the O
increments O
in O
both O
lactate O
and O
glucose O
. O
4 O
. O

The O
isomers O
of O
propranolol O
exhibited O
similar O
local O
anaesthetic O
potencies O
on O
an O
isolated O
frog O
nerve O
preparation O
at O
a O
level O
approximately O
three O
times O
that O
of O
procaine B
. O

Topotecan B
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma O
: O
a O
phase O
2 O
study O
. O

Topotecan B
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma O
as O
well O
as O
brain O
penetration O
. O

The O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
Gy O
/ O
30 O
fractions O
/ O
40 O
days O
) O
and O
topotecan B
( O
0 O
. O
9 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
on O
days O
1 O
- O
5 O
on O
weeks O
1 O
, O
3 O
and O
5 O
) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
GBM O
. O

Topotecan B
in O
combination O
with O
radiotherapy O
was O
well O
tolerated O
. O

BACKGROUND O
: O
The O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding O
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
FESS O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
FRLMA O
) O
versus O
endotracheal O
tube O
( O
ETT O
) O
in O
maintaining O
controlled O
hypotension O
anesthesia O
induced O
by O
propofol O
- O
remifentanil B
total O
i O
. O
v O
. O
anesthesia O
( O
TIVA O
) O
. O

METHODS O
: O
Sixty O
normotensive O
American O
Society O
of O
Anesthesiologists O
I O
- O
II O
adult O
patients O
undergoing O
FESS O
under O
controlled O
hypotension O
anesthesia O
caused O
by O
propofol O
- O
remifentanil B
- O
TIVA O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
I O
, O
FRLMA O
; O
group O
II O
, O
ETT O
. O

RESULTS O
: O
Controlled O
hypotension O
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil B
infusion O
and O
lower O
total O
dose O
of O
remifentanil B
. O

CONCLUSION O
: O
In O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
FRLMA O
during O
controlled O
hypotension O
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension O
with O
low O
doses O
of O
remifentanil B
during O
TIVA O
in O
patients O
undergoing O
FESS O
. O

Anti B
- I
thyroid I
drugs I
, O
like O
carbimazole O
and O
propylthiouracil O
( O
PTU O
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism O
. O

One O
should O
be O
aware O
of O
the O
side O
effects O
of O
antithyroid B
medications I
. O

Antineutrophil O
cytoplasmic O
antibody O
( O
ANCA O
) O
- O
- O
associated O
vasculitis O
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications B
. O

Carbimazole O
and O
methimazole B
have O
a O
lower O
incidence O
of O
reported O
ANCA O
positive O
side O
effects O
than O
PUT O
. O

Motor O
impairment O
, O
dopamine O
( O
DA O
) O
neuronal O
activity O
and O
proenkephalin B
( O
PENK B
) O
gene O
expression O
in O
the O
caudate O
- O
putamen O
( O
CPu O
) O
were O
measured O
in O
6 O
- O
OHDA O
- O
lesioned O
and O
treated O
( O
L B
- I
DOPA I
+ I
benserazide I
) O
CB1 O
KO O
and O
WT O
mice O
. O

A O
lesion O
induced O
by O
6 O
- O
OHDA O
produced O
more O
severe O
motor O
deterioration O
in O
CB1 O
KO O
mice O
accompanied O
by O
more O
loss O
of O
DA O
neurons O
and O
increased O
PENK B
gene O
expression O
in O
the O
CPu O
. O

Treatment O
with O
L B
- I
DOPA I
+ I
benserazide I
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias O
in O
CB1 O
KO O
than O
in O
WT O
mice O
. O

Hepatic O
tissue O
was O
assayed O
for O
lipid O
peroxidation O
products O
and O
oxidized B
and I
reduced I
glutathione I
. O

Oxidized B
glutathione I
( O
GSSG B
) O
increased O
significantly O
following O
30 O
and O
60 O
min O
of O
reperfusion O
. O

An O
increase O
in O
GSSG B
within O
hepatic O
tissue O
during O
intestinal O
reperfusion O
suggests O
exposure O
of O
hepatocytes O
to O
an O
oxidant O
stress O
. O

These O
data O
also O
suggest O
that O
the O
measurement O
of O
tissue O
GSSG B
may O
be O
a O
more O
sensitive O
indicator O
of O
oxidant O
stress O
than O
measurement O
of O
products O
of O
lipid O
peroxidation O
. O

Citrate O
dialysate O
, O
a O
new O
dialysate O
with O
citric B
acid I
can O
be O
used O
for O
anticoagulation O
in O
patients O
who O
cannot O
tolerate O
heparin O
or O
regional O
citrate O
. O

Delirium O
in O
a O
patient O
with O
toxic O
flecainide B
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
flecainide B
- O
induced O
delirium O
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

On O
admission O
the O
patient O
was O
taking O
carvedilol B
12 O
mg O
twice O
daily O
, O
warfarin O
2 O
mg O
/ O
day O
, O
folic O
acid O
1 O
mg O
/ O
day O
, O
levothyroxine O
100 O
microg O
/ O
day O
, O
pantoprazole B
40 O
mg O
/ O
day O
, O
paroxetine O
40 O
mg O
/ O
day O
, O
and O
flecainide B
100 O
mg O
twice O
daily O
. O

Flecainide B
had O
been O
started O
2 O
weeks O
prior O
for O
atrial O
fibrillation O
. O

Laboratory O
test O
findings O
on O
admission O
were O
notable O
only O
for O
a O
flecainide B
plasma O
concentration O
of O
1360 O
microg O
/ O
L O
( O
reference O
range O
200 O
- O
1000 O
) O
. O

A O
metabolic O
drug O
interaction O
between O
flecainide B
and O
paroxetine O
, O
which O
the O
patient O
had O
been O
taking O
for O
more O
than O
5 O
years O
, O
was O
considered O
. O

Paroxetine O
was O
discontinued O
and O
the O
dose O
of O
flecainide B
was O
reduced O
to O
50 O
mg O
twice O
daily O
. O

DISCUSSION O
: O
Flecainide B
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium O
channels O
may O
cause O
delirium O
in O
susceptible O
patients O
. O

A O
MEDLINE O
search O
( O
1966 O
- O
January O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide B
, O
a O
CYP2D6 O
substrate O
, O
and O
paroxetine O
, O
a O
CYP2D6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide B
- O
induced O
delirium O
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
flecainide B
was O
the O
probable O
cause O
of O
the O
patient O
' O
s O
delirium O
; O
the O
Horn O
Drug O
Interaction O
Probability O
Scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide B
and O
paroxetine O
. O

CONCLUSIONS O
: O
Supratherapeutic O
flecainide B
plasma O
concentrations O
may O
cause O
delirium O
. O

Because O
toxicity O
may O
occur O
when O
flecainide B
is O
prescribed O
with O
paroxetine O
and O
other O
potent O
CYP2D6 O
inhibitors O
, O
flecainide B
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
CYP2D6 O
inhibitors O
. O

METHODS O
: O
Stage O
IIIb O
or O
IV O
NSCLC O
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum B
based O
( O
stratum O
1 O
) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitors O
( O
stratum O
2 O
) O
, O
received O
RAD001 O
10 O
mg O
/ O
day O
until O
progression O
or O
unacceptable O
toxicity O
. O

Smoking O
of O
crack B
cocaine I
as O
a O
risk O
factor O
for O
HIV O
infection O
among O
people O
who O
use O
injection O
drugs O
. O

BACKGROUND O
: O
Little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack B
cocaine I
has O
on O
the O
incidence O
of O
HIV O
infection O
. O

Given O
the O
increasing O
use O
of O
crack B
cocaine I
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
HIV O
infection O
. O

To O
determine O
whether O
the O
risk O
of O
HIV O
seroconversion O
among O
daily O
smokers O
of O
crack B
cocaine I
changed O
over O
time O
, O
we O
used O
Cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
May O
1 O
, O
1996 O
- O
Nov O
. O

The O
mean O
proportion O
of O
participants O
who O
reported O
daily O
smoking O
of O
crack B
cocaine I
increased O
from O
11 O
. O
6 O
% O
in O
period O
1 O
to O
39 O
. O
7 O
% O
in O
period O
3 O
. O

After O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
HIV O
seroconversion O
among O
participants O
who O
were O
daily O
smokers O
of O
crack B
cocaine I
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
HR O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
HR O
1 O
. O
68 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
HR O
2 O
. O
74 O
, O
95 O
% O
CI O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

INTERPRETATION O
: O
Smoking O
of O
crack B
cocaine I
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
HIV O
seroconversion O
among O
people O
who O
were O
injection O
drug O
users O
. O

This O
finding O
points O
to O
the O
urgent O
need O
for O
evidence O
- O
based O
public O
health O
initiatives O
targeted O
at O
people O
who O
smoke O
crack B
cocaine I
. O

Metallothionein B
induction O
reduces O
caspase O
- O
3 O
activity O
and O
TNFalpha O
levels O
with O
preservation O
of O
cognitive O
function O
and O
intact O
hippocampal O
neurons O
in O
carmustine O
- O
treated O
rats O
. O

On O
the O
other O
hand O
, O
induction O
of O
metallothionein B
( O
MT B
) O
by O
ZnSO B
( I
4 I
) I
and O
its O
role O
in O
neuroprotection O
has O
been O
documented O
. O

The O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
MT B
induction O
on O
carmustine O
( O
BCNU O
) O
- O
induced O
hippocampal O
cognitive O
dysfunction O
in O
rats O
. O

The O
second O
group O
administered O
ZnSO B
( I
4 I
) I
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
, O
once O
) O
then O
BCNU O
solvent O
( O
i O
. O
v O
) O
after O
24 O
h O
. O

Fourth O
group O
received O
a O
single O
dose O
of O
ZnSO B
( I
4 I
) I
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
) O
then O
BCNU O
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
after O
24 O
h O
. O

Also O
, O
BCNU O
administration O
increased O
serum O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNFalpha O
) O
, O
hippocampal O
MT B
and O
malondialdehyde O
( O
MDA O
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

ZnSO B
( I
4 I
) I
pretreatment O
counteracted O
BCNU O
- O
induced O
inhibition O
of O
GR O
and O
depletion O
of O
GSH O
and O
resulted O
in O
significant O
reduction O
in O
the O
levels O
of O
MDA O
and O
TNFalpha O
as O
well O
as O
the O
activity O
of O
caspase O
- O
3 O
. O

The O
histological O
features O
were O
improved O
in O
hippocampus O
of O
rats O
treated O
with O
ZnSO B
( I
4 I
) I
+ O
BCNU O
compared O
to O
only O
BCNU O
- O
treated O
animals O
. O

In O
conclusion O
, O
MT B
induction O
halts O
BCNU O
- O
induced O
hippocampal O
toxicity O
as O
it O
prevented O
GR O
inhibition O
and O
GSH O
depletion O
and O
counteracted O
the O
increased O
levels O
of O
TNFalpha O
, O
MDA O
and O
caspase O
- O
3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

Levodopa O
( O
15 O
mg O
/ O
kg O
and O
benserazide B
, O
3 O
. O
75 O
mg O
/ O
kg O
) O
p O
. O
o O
. O

Studies O
of O
synergy O
between O
morphine O
and O
a O
novel O
sodium O
channel O
blocker O
, O
CNSB002 B
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic O
pain O
. O

OBJECTIVE O
: O
This O
study O
determined O
the O
antihyperalgesic O
effect O
of O
CNSB002 B
, O
a O
sodium O
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic O
pain O
. O

DESIGN O
: O
Dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
CNSB002 B
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain O
models O
: O
carrageenan B
- O
induced O
paw O
inflammation O
and O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetic O
neuropathy O
. O

RESULTS O
: O
The O
maximum O
nonsedating O
doses O
were O
: O
morphine O
, O
3 O
. O
2 O
mg O
/ O
kg O
; O
CNSB002 B
10 O
. O
0 O
mg O
/ O
kg O
; O
5 O
. O
0 O
mg O
/ O
kg O
CNSB002 B
with O
morphine O
3 O
. O
2 O
mg O
/ O
kg O
in O
combination O
. O

The O
doses O
calculated O
to O
cause O
50 O
% O
reversal O
of O
hyperalgesia O
( O
ED50 O
) O
were O
7 O
. O
54 O
( O
1 O
. O
81 O
) O
and O
4 O
. O
83 O
( O
1 O
. O
54 O
) O
in O
the O
carrageenan B
model O
and O
44 O
. O
18 O
( O
1 O
. O
37 O
) O
and O
9 O
. O
14 O
( O
1 O
. O
24 O
) O
in O
the O
STZ O
- O
induced O
neuropathy O
model O
for O
CNSB002 B
and O
morphine O
, O
respectively O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

The O
ED50 O
values O
for O
morphine O
when O
given O
in O
combination O
with O
CNSB002 B
( O
5 O
mg O
/ O
kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0 O
. O
56 O
( O
1 O
. O
55 O
) O
in O
the O
carrageenan B
model O
and O
1 O
. O
37 O
( O
1 O
. O
23 O
) O
in O
the O
neuropathy O
model O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

The O
antinociception O
after O
morphine O
( O
3 O
. O
2 O
mg O
/ O
kg O
) O
was O
increased O
by O
co O
- O
administration O
with O
CNSB002 B
from O
28 O
. O
0 O
and O
31 O
. O
7 O
% O
to O
114 O
. O
6 O
and O
56 O
. O
9 O
% O
reversal O
of O
hyperalgesia O
in O
the O
inflammatory O
and O
neuropathic O
models O
, O
respectively O
( O
P O
< O
0 O
. O
01 O
; O
one O
- O
way O
analysis O
of O
variance O
- O
significantly O
greater O
than O
either O
drug O
given O
alone O
) O
. O

CONCLUSIONS O
: O
The O
maximum O
antihyperalgesic O
effect O
achievable O
with O
nonsedating O
doses O
of O
morphine O
may O
be O
increased O
significantly O
when O
the O
drug O
is O
used O
in O
combination O
with O
CNSB002 B
. O

The O
treatment O
of O
HIT O
mandates O
an O
immediate O
cessation O
of O
all O
heparin O
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct B
thrombin I
inhibitor I
. O

Direct B
thrombin I
inhibitors I
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin O
in O
patients O
with O
a O
history O
of O
HIT O
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

Abductor O
paralysis O
after O
botox B
injection O
for O
adductor O
spasmodic O
dysphonia O
. O

OBJECTIVES O
/ O
HYPOTHESIS O
: O
Botulinum O
toxin O
( O
Botox B
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor O
spasmodic O
dysphonia O
( O
ADSD O
) O
. O

Here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis O
following O
Botox B
injections O
for O
ADSD O
, O
a O
complication O
previously O
unreported O
. O

METHODS O
: O
Patients O
that O
received O
Botox B
injections O
for O
spasmodic O
dysphonia O
between O
January O
2000 O
and O
October O
2009 O
were O
evaluated O
. O

For O
patients O
with O
bilateral O
abductor O
paralysis O
, O
age O
, O
sex O
, O
paralytic O
Botox B
dose O
, O
prior O
Botox B
dose O
, O
and O
course O
following O
paralysis O
were O
noted O
. O

RESULTS O
: O
From O
a O
database O
of O
452 O
patients O
receiving O
Botox B
, O
352 O
patients O
had O
been O
diagnosed O
with O
ADSD O
. O

The O
incidence O
of O
abductor O
paralysis O
after O
Botox B
injection O
for O
ADSD O
was O
0 O
. O
34 O
% O
. O

CONCLUSIONS O
: O
Bilateral O
abductor O
paralysis O
is O
a O
rare O
complication O
of O
Botox B
injections O
for O
ADSD O
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

The O
likely O
mechanism O
of O
paralysis O
is O
diffusion O
of O
Botox B
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

Mitochondrial O
impairment O
contributes O
to O
cocaine O
- O
induced O
cardiac O
dysfunction O
: O
Prevention O
by O
the O
targeted O
antioxidant O
MitoQ B
. O

MitoQ B
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial O
abnormalities O
as O
well O
as O
cardiac O
dysfunction O
characterized O
here O
by O
a O
diastolic O
dysfunction O
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

Trimethoprim B
- O
induced O
immune O
hemolytic O
anemia O
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

Drug O
studies O
using O
the O
indirect O
antiglobulin O
test O
were O
strongly O
positive O
with O
trimethoprim B
and O
trimethoprim O
- O
sulfamethoxazole O
but O
negative O
with O
sulfamethoxazole B
. O

Cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus B
in O
refractory O
mantle O
cell O
lymphoma O
. O

However O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
MCL O
treated O
with O
temsirolimus B
, O
a O
mTOR O
inhibitor O
. O
Here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
MCL O
who O
had O
tumor O
regression O
two O
months O
after O
temsirolimus B
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

In O
this O
case O
, O
lymph O
node O
biopsies O
were O
performed O
before O
and O
six O
months O
after O
temsirolimus B
therapy O
. O

Comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus B
inhibited O
tumor O
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor O
cells O
. O

Apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus B
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor O
microvessel O
density O
and O
of O
VEGF O
expression O
. O

Moreover O
, O
numerous O
patchy O
, O
well O
- O
limited O
fibrotic O
areas O
, O
compatible O
with O
post O
- O
necrotic O
tissue O
repair O
, O
were O
found O
after O
6 O
- O
month O
temsirolimus B
therapy O
. O

Thus O
, O
temsirolimus B
reduced O
tumor O
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O
This O
dual O
effect O
of O
temsirolimus B
on O
tumor O
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
MCL O
resistant O
to O
conventional O
chemotherapy O
. O

The O
cause O
of O
hyperkalemia O
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone O
, O
an O
aldosterone O
antagonist O
, O
in O
addition O
to O
the O
long O
- O
term O
intake O
of O
ramipril B
, O
an O
ACE O
inhibitor O
. O

Alendronate O
, O
a O
biphosphonate B
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis O
in O
postmenopausal O
women O
. O

Cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin B
in O
suspected O
Staphylococcus O
aureus O
meningitis O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
methicillin B
- O
sensitive O
Staphylococcus O
aureus O
( O
MSSA O
) O
bacteremia O
with O
suspected O
MSSA O
meningitis O
treated O
with O
high O
- O
dose O
daptomycin B
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
. O

Treatment O
was O
empirically O
initiated O
with O
vancomycin O
, O
levofloxacin O
, O
and O
piperacillin B
/ O
tazobactam B
. O

Blood O
cultures O
revealed O
S O
. O
aureus O
susceptible O
to O
oxacillin B
. O

Empiric O
antibiotic O
treatment O
was O
narrowed O
to O
nafcillin B
on O
day O
4 O
. O

Nafcillin B
was O
discontinued O
and O
daptomycin B
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis O
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

Daptomycin B
serum O
and O
CSF O
trough O
concentrations O
were O
11 O
. O
21 O
ug O
/ O
mL O
and O
0 O
. O
52 O
ug O
/ O
mL O
, O
respectively O
, O
prior O
to O
the O
third O
dose O
. O

Creatine O
kinase O
levels O
were O
normal O
prior O
to O
daptomycin B
therapy O
and O
were O
not O
reassessed O
. O

DISCUSSION O
: O
Daptomycin B
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin B
- O
induced O
acute O
interstitial O
nephritis O
and O
relapsing O
bacteremia O
. O

CONCLUSIONS O
: O
High O
- O
dose O
daptomycin B
may O
be O
an O
alternative O
option O
for O
MSSA O
bacteremia O
with O
or O
without O
a O
CNS O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

Neurologic O
toxicities O
have O
been O
described O
with O
IT O
- O
methotrexate O
, O
IT O
- O
cytosine B
arabinoside I
and O
IT O
- O
TSPA O
. O

In O
spite O
of O
the O
fact O
that O
TSPA O
is O
a O
useful O
IT O
agent O
, O
its O
combination O
with O
MTX O
, O
ara B
- I
C I
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity O
. O

Effects O
of O
cromakalim B
and O
pinacidil B
on O
large O
epicardial O
and O
small O
coronary O
arteries O
in O
conscious O
dogs O
. O

The O
effects O
of O
i O
. O
v O
. O
bolus O
administration O
of O
cromakalim B
( O
1 O
- O
10 O
micrograms O
/ O
kg O
) O
and O
pinacidil B
( O
3 O
- O
100 O
micrograms O
/ O
kg O
) O
on O
large O
( O
circumflex O
artery O
) O
and O
small O
coronary O
arteries O
and O
on O
systemic O
hemodynamics O
were O
investigated O
in O
chronically O
instrumented O
conscious O
dogs O
and O
compared O
to O
those O
of O
nitroglycerin O
( O
0 O
. O
03 O
- O
10 O
micrograms O
/ O
kg O
) O
. O

In O
contrast O
, O
cromakalim B
and O
pinacidil B
at O
all O
doses O
and O
nitroglycerin O
at O
doses O
higher O
than O
0 O
. O
3 O
micrograms O
/ O
kg O
simultaneously O
and O
dose O
- O
dependently O
increased O
CxAD O
, O
coronary O
blood O
flow O
and O
heart O
rate O
and O
decreased O
coronary O
vascular O
resistance O
and O
aortic O
pressure O
. O

Cromakalim B
was O
approximately O
8 O
- O
to O
9 O
. O
5 O
- O
fold O
more O
potent O
than O
pinacidil B
in O
increasing O
CxAD O
. O

Vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension O
induced O
by O
cromakalim B
and O
pinacidil B
were O
not O
affected O
by O
prior O
combined O
beta B
adrenergic I
and I
muscarinic I
receptors I
blockade I
but O
drug O
- O
induced O
tachycardia O
was O
abolished O
. O

When O
circumflex O
artery O
blood O
flow O
was O
maintained O
constant O
, O
the O
increases O
in O
CxAD O
induced O
by O
cromakalim B
( O
10 O
micrograms O
/ O
kg O
) O
, O
pinacidil B
( O
30 O
micrograms O
/ O
kg O
) O
and O
nitroglycerin O
( O
10 O
micrograms O
/ O
kg O
) O
were O
reduced O
by O
68 O
+ O
/ O
- O
7 O
, O
54 O
+ O
/ O
- O
9 O
and O
1 O
+ O
/ O
- O
1 O
% O
, O
respectively O
. O

Thus O
, O
whereas O
nitroglycerin O
preferentially O
and O
flow O
- O
independently O
dilates O
large O
coronary O
arteries O
, O
cromakalim B
and O
pinacidil B
dilate O
both O
large O
and O
small O
coronary O
arteries O
and O
this O
effect O
is O
not O
dependent O
upon O
the O
simultaneous O
beta O
adrenoceptors O
- O
mediated O
rise O
in O
myocardial O
metabolic O
demand O
. O

Finally O
, O
two O
mechanisms O
at O
least O
, O
direct O
vasodilation O
and O
flow O
dependency O
, O
are O
involved O
in O
the O
cromakalim B
- O
and O
pinacidil B
- O
induced O
increase O
in O
CxAD O
. O

Mefenamic B
acid I
- O
induced O
neutropenia O
and O
renal O
failure O
in O
elderly O
females O
with O
hypothyroidism O
. O

We O
report O
mefenamic B
acid I
- O
induced O
non O
- O
oliguric O
renal O
failure O
and O
severe O
neutropenia O
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

However O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic B
acid I
in O
hypothyroid O
patients O
until O
the O
hypothyroidism O
has O
been O
corrected O
. O

Etiology O
of O
hypercalcemia O
in O
hemodialysis O
patients O
on O
calcium B
carbonate I
therapy O
. O

Fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic O
after O
switching O
to O
calcium B
carbonate I
as O
their O
principal O
phosphate O
binder O
. O

CaCO3 B
dosage O
, O
calculated O
dietary O
calcium O
intake O
, O
and O
circulating O
levels O
of O
vitamin O
D O
metabolites O
were O
similar O
in O
both O
groups O
. O

Physical O
activity O
index O
and O
predialysis O
serum O
bicarbonate B
levels O
also O
were O
similar O
in O
both O
groups O
. O

The O
rats O
in O
the O
control O
group O
were O
intraperitoneally O
( O
i O
. O
p O
. O
) O
injected O
with O
0 O
. O
9 O
% O
saline O
( O
4 O
ml O
/ O
kg O
) O
; O
the O
rats O
in O
the O
model O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP O
( O
150 O
mg O
/ O
kg O
) O
; O
and O
the O
rats O
in O
the O
intervention O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP O
with O
subsequently O
perfusion O
of O
bladder O
with O
P2X3 O
and O
NK1 O
receptors O
' O
antagonists O
, O
Suramin B
and O
GR B
82334 I
. O

Patient O
tolerance O
study O
of O
topical O
chlorhexidine B
diphosphanilate I
: O
a O
new O
topical O
agent O
for O
burns O
. O

Chlorhexidine B
phosphanilate I
( O
CHP B
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn O
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

This O
study O
compared O
various O
concentrations O
of O
CHP B
to O
determine O
if O
a O
tolerable O
concentration O
could O
be O
identified O
with O
retention O
of O
antimicrobial O
efficacy O
. O

One O
burn O
site O
was O
treated O
with O
each O
of O
four O
different O
CHP B
concentrations O
, O
from O
0 O
. O
25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver B
sulphadiazine I
( O
AgSD B
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn O
wounds O
. O

The O
other O
site O
was O
always O
treated O
with O
AgSD B
cream O
. O

There O
was O
a O
direct O
relationship O
between O
CHP B
concentration O
and O
patients O
' O
ratings O
of O
pain O
on O
an O
analogue O
scale O
. O

The O
0 O
. O
25 O
per O
cent O
CHP B
cream O
was O
closest O
to O
AgSD B
in O
pain O
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
AgSD B
or O
from O
each O
other O
. O

In O
addition O
, O
ease O
of O
application O
of O
CHP B
creams O
was O
less O
satisfactory O
than O
that O
of O
AgSD B
. O

It O
was O
concluded O
that O
formulations O
at O
or O
below O
0 O
. O
5 O
per O
cent O
CHP B
may O
prove O
acceptable O
for O
wound O
care O
, O
but O
the O
vehicle O
system O
needs O
pharmaceutical O
improvement O
to O
render O
it O
more O
tolerable O
and O
easier O
to O
use O
. O

Bortezomib B
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple O
myeloma O
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

Bortezomib B
( O
bort B
) O
- O
dexamethasone O
( O
dex O
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
R O
/ O
R O
) O
multiple O
myeloma O
( O
MM O
) O
. O

This O
retrospective O
study O
investigated O
the O
combination O
of O
bort B
( O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
every O
3 O
weeks O
) O
and O
dex O
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort B
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
R O
/ O
R O
MM O
after O
prior O
autologous O
stem O
cell O
transplantation O
or O
conventional O
chemotherapy O
. O

Eighty O
- O
seven O
percent O
of O
the O
patients O
had O
received O
immunomodulatory O
drugs O
included O
in O
some O
line O
of O
therapy O
before O
bort B
- O
dex O
. O

The O
median O
number O
of O
bort B
- O
dex O
cycles O
was O
6 O
, O
up O
to O
a O
maximum O
of O
12 O
cycles O
. O

Prolonged O
PFS O
and O
OS O
were O
observed O
in O
patients O
achieving O
CR O
and O
receiving O
bort B
- O
dex O
a O
single O
line O
of O
prior O
therapy O
. O

Bort B
- O
dex O
was O
an O
effective O
salvage O
treatment O
for O
MM O
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

Pubertal O
exposure O
to O
Bisphenol B
A I
increases O
anxiety O
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

The O
negative O
effects O
of O
Bisphenol B
A I
( O
BPA B
) O
on O
neurodevelopment O
and O
behaviors O
have O
been O
well O
established O
. O

This O
study O
investigated O
behavioral O
phenotypes O
and O
AChE O
activity O
in O
male O
mice O
following O
BPA B
exposure O
during O
puberty O
. O

On O
postnatal O
day O
( O
PND O
) O
35 O
, O
male O
mice O
were O
exposed O
to O
50mg O
BPA B
/ O
kg O
diet O
per O
day O
for O
a O
period O
of O
35 O
days O
. O

Results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety O
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
BPA B
. O

AChE O
activity O
was O
significantly O
decreased O
in O
the O
hippocampus O
of O
mice O
with O
BPA B
compared O
to O
control O
mice O
, O
whereas O
no O
difference O
was O
found O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
and O
cerebellum O
. O

Our O
findings O
showed O
that O
pubertal O
BPA B
exposure O
increased O
anxiety O
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
AChE O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

The O
subcutaneous O
injection O
of O
isoproterenol O
( O
30 O
mg O
/ O
kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h O
, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate O
dehydrogenase O
, O
creatine O
phosphokinase O
, O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
angiotensin O
- O
converting O
enzyme O
activities O
, O
total O
cholesterol O
, O
triglycerides B
, O
free O
serum O
fatty B
acid I
, O
cardiac O
tissue O
malondialdehyde O
( O
MDA O
) O
, O
and O
nitric O
oxide O
levels O
and O
a O
significant O
decrease O
in O
levels O
of O

Quality O
of O
response O
was O
independent O
of O
previous O
lines O
of O
therapies O
or O
previous O
exposure O
to O
thalidomide O
or O
bortezomib B
. O

Ifosfamide O
( O
IFO O
) O
is O
an O
alkylating O
nitrogen B
mustard O
, O
administrated O
as O
an O
antineoplasmic O
agent O
. O

Twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan O
total O
dose O
with O
continuous O
i O
. O
v O
. O
infusion O
of O
clonazepam B
; O
none O
had O
any O
neurological O
symptoms O
. O

Busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central O
nervous O
system O
disease O
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam B
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

This O
study O
shows O
that O
busulfan O
neurotoxicity O
is O
dose O
- O
dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam B
. O

Long O
- O
term O
oral O
galactose B
treatment O
prevents O
cognitive O
deficits O
in O
male O
Wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

An O
alternative O
source O
of O
energy O
is O
d B
- I
galactose I
( O
the O
C O
- O
4 O
- O
epimer O
of O
d O
- O
glucose O
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin O
- O
independent O
GLUT3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose O
via O
the O
Leloir O
pathway O
. O

Exclusively O
parenteral O
daily O
injections O
of O
galactose B
induce O
memory O
deterioration O
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose B
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

We O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose B
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive O
deficits O
in O
streptozotocin O
- O
induced O
( O
STZ O
- O
icv O
) O
rat O
model O
of O
sAD O
, O
tested O
by O
Morris O
Water O
Maze O
and O
Passive O
Avoidance O
test O
, O
respectively O
. O

One O
month O
of O
oral O
galactose B
treatment O
initiated O
immediately O
after O
the O
STZ O
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
STZ O
- O
icv O
- O
induced O
cognitive O
deficits O
. O

Beneficial O
effect O
of O
oral O
galactose B
was O
independent O
of O
the O
rat O
age O
and O
of O
the O
galactose B
dose O
ranging O
from O
100 O
to O
300 O
mg O
/ O
kg O
/ O
day O
. O

Additionally O
, O
oral O
galactose B
administration O
led O
to O
the O
appearance O
of O
galactose B
in O
the O
blood O
. O

The O
increase O
of O
galactose B
concentration O
in O
the O
cerebrospinal O
fluid O
was O
several O
times O
lower O
after O
oral O
than O
after O
parenteral O
administration O
of O
the O
same O
galactose B
dose O
. O

Oral O
galactose B
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive O
deficits O
associated O
with O
glucose O
hypometabolism O
in O
AD O
. O

An O
investigation O
of O
the O
pattern O
of O
kidney O
injury O
in O
HIV O
- O
positive O
persons O
exposed O
to O
tenofovir B
disoproxil I
fumarate I
: O
an O
examination O
of O
a O
large O
population O
database O
( O
MHRA O
database O
) O
. O

We O
undertook O
a O
descriptive O
analysis O
of O
Yellow O
Card O
records O
of O
407 O
HIV O
- O
positive O
persons O
taking O
tenofovir B
disoproxil I
fumarate I
( O
TDF B
) O
as O
part O
of O
their O
antiretroviral O
therapy O
regimen O
and O
submitted O
to O
the O
Medicines O
and O
Healthcare O
Products O
Regulatory O
Agency O
( O
MHRA O
) O
with O
suspected O
kidney O
adverse O
effects O
. O

Of O
the O
407 O
Yellow O
Card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
TDF B
- O
related O
kidney O
disease O
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney O
tubular O
dysfunction O
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular O
dysfunction O
and O
18 O
( O
17 O
% O
) O
had O
Fanconi O
syndrome O
. O

The O
median O
TDF B
exposure O
was O
316 O
days O
( O
interquartile O
range O
120 O
- O
740 O
) O
. O

The O
incidence O
of O
hospitalisation O
for O
TDF B
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
Fanconi O
syndrome O
. O

Cessation O
of O
TDF B
was O
associated O
with O
complete O
restoration O
of O
kidney O
function O
in O
up O
half O
of O
the O
patients O
in O
this O
report O
. O

Linezolid B
- O
induced O
optic O
neuropathy O
. O

We O
describe O
a O
case O
of O
progressive O
loss O
of O
vision O
associated O
with O
linezolid B
therapy O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid B
and O
ethambutol B
for O
extensively O
drug O
- O
resistant O
tuberculosis O
( O
XDR O
- O
TB O
) O
presented O
to O
us O
with O
painless O
progressive O
loss O
of O
vision O
in O
both O
eyes O
. O

Ethambutol B
- O
induced O
toxic O
optic O
neuropathy O
was O
suspected O
and O
tablet O
ethambutol B
was O
withdrawn O
. O

Deterioration O
of O
vision O
occurred O
despite O
withdrawal O
of O
ethambutol B
. O

Discontinuation O
of O
linezolid B
resulted O
in O
marked O
improvement O
of O
vision O
. O

Our O
report O
emphasizes O
the O
need O
for O
monitoring O
of O
visual O
function O
in O
patients O
on O
long O
- O
term O
linezolid B
treatment O
. O

Resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine B
- O
induced O
cardiac O
toxicity O
in O
newborn O
piglets O
. O

METHODS O
: O
Newborn O
piglets O
received O
levobupivacaine B
until O
cardiovascular O
collapse O
occurred O
. O

Takotsubo O
syndrome O
( O
or O
apical O
ballooning O
syndrome O
) O
secondary O
to O
Zolmitriptan B
. O

Detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan B
sparingly O
only O
when O
she O
had O
migraines O
. O

But O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan B
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine O
headache O
. O

Extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary O
artery O
vasospasm O
secondary O
to O
zolmitriptan B
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
TS O
. O

Crocin B
improves O
lipid O
dysregulation O
in O
subacute O
diazinon B
exposure O
through O
ERK1 O
/ O
2 O
pathway O
in O
rat O
liver O
. O

INTRODUCTION O
: O
Diazinon B
Yis O
one O
of O
the O
most O
broadly O
used O
organophosphorus O
insecticides O
in O
agriculture O
. O

It O
has O
been O
shown O
that O
exposure O
to O
diazinon B
may O
interfere O
with O
lipid O
metabolism O
. O

Moreover O
, O
the O
hypolipidemic O
effect O
of O
crocin B
has O
been O
established O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
changes O
in O
the O
regulation O
of O
lipid O
metabolism O
, O
ERK O
and O
LDLr O
expression O
in O
the O
liver O
of O
rats O
exposed O
to O
subacute O
diazinon B
. O

Furthermore O
ameliorating O
effect O
of O
crocin B
on O
diazinon B
induced O
disturbed O
cholesterol O
homeostasis O
was O
studied O
. O

METHODS O
: O
24 O
Rats O
were O
divided O
into O
4 O
groups O
and O
received O
following O
treatments O
for O
4 O
weeks O
; O
Corn O
oil O
( O
control O
) O
, O
diazinon B
( O
15mg O
/ O
kg O
per O
day O
, O
orally O
) O
and O
crocin B
( O
12 O
. O
5 O
and O
25mg O
/ O
kg O
per O
day O
, O
intraperitoneally O
) O
in O
combination O
with O
diazinon B
( O
15 O
mg O
/ O
kg O
) O
. O

The O
levels O
of O
cholesterol O
, O
triglyceride B
and O
LDL O
in O
blood O
of O
rats O
were O
analyzed O
. O

RESULTS O
: O
Our O
data O
showed O
that O
subacute O
exposure O
to O
diazinon B
significantly O
increased O
concentrations O
of O
cholesterol O
, O
triglyceride B
and O
LDL O
. O

Moreover O
diazinon B
decreased O
ERK1 O
/ O
2 O
protein O
phosphorylation O
and O
LDLr O
transcript O
. O

Crocin B
reduced O
inhibition O
of O
ERK O
activation O
and O
diazinon B
- O
induced O
hyperlipemia O
and O
increased O
levels O
of O
LDLr O
transcript O
. O

CONCLUSIONS O
: O
Crocin B
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon B
- O
induced O
hyperlipemia O
through O
modulating O
of O
ERK O
pathway O
and O
increase O
of O
LDLr O
expression O
. O

CIN O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab B
/ O
irinotecan B
( O
P O
= O
0 O
. O
021 O
) O
and O
in O
patients O
with O
hypertension O
( O
P O
= O
0 O
. O
044 O
) O
. O

Hypertension O
and O
the O
combination O
of O
bevacizumab B
/ O
irinotecan B
may O
be O
additional O
risk O
factors O
for O
CIN O
development O
. O

. O
Hypertension O
and O
treatment O
with O
bevacizumab B
appear O
to O
be O
additional O
risk O
factors O
. O

Syndrome O
of O
inappropriate O
antidiuretic O
hormone O
secretion O
associated O
with O
desvenlafaxine B
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
syndrome O
of O
inappropriate O
anti O
- O
diuretic O
hormone O
( O
SIADH O
) O
secretion O
associated O
with O
desvenlafaxine B
. O

Her O
medications O
included O
desvenlafaxine B
, O
and O
symptoms O
included O
nausea O
, O
anxiety O
and O
confusion O
. O

Desvenlafaxine B
was O
ceased O
and O
fluid O
restriction O
implemented O
. O

During O
her O
further O
3 O
weeks O
inpatient O
admission O
the O
serum O
sodium O
ranged O
from O
134 O
to O
137 O
mmol O
/ O
L O
during O
treatment O
with O
mirtazapine B
. O

This O
case O
report O
suggests O
that O
desvenlafaxine B
might O
cause O
clinically O
significant O
hyponatremia O
. O

The O
flavonoid B
apigenin B
delays O
forgetting O
of O
passive O
avoidance O
conditioning O
in O
rats O
. O

The O
present O
experiments O
were O
performed O
to O
study O
the O
effect O
of O
the O
flavonoid B
apigenin B
( O
20 O
mg O
/ O
kg O
intraperitoneally O
( O
i O
. O
p O
. O
) O
, O
1 O
h O
before O
acquisition O
) O
, O
on O
24 O
h O
retention O
performance O
and O
forgetting O
of O
a O
step O
- O
through O
passive O
avoidance O
task O
, O
in O
young O
male O
Wistar O
rats O
. O

There O
were O
no O
differences O
between O
saline O
- O
and O
apigenin B
- O
treated O
groups O
in O
the O
24 O
h O
retention O
trial O
. O

Furthermore O
, O
apigenin B
did O
not O
prevent O
the O
amnesia O
induced O
by O
scopolamine O
( O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
30 O
min O
before O
the O
acquisition O
) O
. O

The O
saline O
- O
and O
apigenin B
- O
treated O
rats O
that O
did O
not O
step O
through O
into O
the O
dark O
compartment O
during O
the O
cut O
- O
off O
time O
( O
540 O
s O
) O
were O
retested O
weekly O
for O
up O
to O
eight O
weeks O
. O

At O
the O
end O
of O
the O
experimental O
period O
, O
60 O
% O
of O
the O
animals O
treated O
with O
apigenin B
still O
did O
not O
step O
through O
. O

These O
data O
suggest O
that O
1 O
) O
apigenin B
delays O
the O
long O
- O
term O
forgetting O
but O
did O
not O
modulate O
the O
24 O
h O
retention O
of O
fear O
memory O
and O
2 O
) O
the O
obtained O
beneficial O
effect O
of O
apigenin B
on O
the O
passive O
avoidance O
conditioning O
is O
mediated O
by O
mechanisms O
that O
do O
not O
implicate O
its O
action O
on O
the O
muscarinic O
cholinergic O
system O
. O

Histamine O
antagonists O
and O
d B
- I
tubocurarine I
- O
induced O
hypotension O
in O
cardiac O
surgical O
patients O
. O

Hemodynamic O
effects O
and O
histamine O
release O
by O
bolus O
injection O
of O
0 O
. O
35 O
mg O
/ O
kg O
of O
d B
- I
tubocurarine I
were O
studied O
in O
24 O
patients O
. O

H1 O
- O
and O
H2 O
- O
histamine O
antagonists O
or O
placebo O
were O
given O
before O
dosing O
with O
d B
- I
tubocurarine I
in O
a O
randomized O
double O
- O
blind O
fashion O
to O
four O
groups O
: O
group O
1 O
- O
- O
placebo O
; O
group O
2 O
- O
- O
cimetidine O
, O
4 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
group O
3 O
- O
- O
chlorpheniramine B
, O
0 O
. O
1 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
and O
group O
4 O
- O
- O
cimetidine O
plus O
chlorpheniramine B
. O

Histamine O
release O
occurred O
in O
most O
patients O
, O
the O
highest O
level O
2 O
minutes O
after O
d B
- I
tubocurarine I
dosing O
. O

These O
data O
demonstrate O
that O
the O
hemodynamic O
changes O
associated O
with O
d B
- I
tubocurarine I
dosing O
are O
only O
partially O
explained O
by O
histamine O
release O
. O

Cholecystokinin B
- I
octapeptide I
restored O
morphine O
- O
induced O
hippocampal O
long O
- O
term O
potentiation O
impairment O
in O
rats O
. O

Cholecystokinin B
- I
octapeptide I
( O
CCK B
- I
8 I
) O
, O
which O
is O
a O
typical O
brain O
- O
gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

We O
have O
previously O
reported O
that O
CCK B
- I
8 I
significantly O
alleviated O
morphine O
- O
induced O
amnesia O
and O
reversed O
spine O
density O
decreases O
in O
the O
CA1 O
region O
of O
the O
hippocampus O
in O
morphine O
- O
treated O
animals O
. O

Here O
, O
we O
investigated O
the O
effects O
of O
CCK B
- I
8 I
on O
long O
- O
term O
potentiation O
( O
LTP O
) O
in O
the O
lateral O
perforant O
path O
( O
LPP O
) O
- O
granule O
cell O
synapse O
of O
rat O
dentate O
gyrus O
( O
DG O
) O
in O
acute O
saline O
or O
morphine O
- O
treated O
rats O
. O

Acute O
morphine O
( O
30mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
treatment O
significantly O
attenuated O
hippocampal O
LTP O
and O
CCK B
- I
8 I
( O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
restored O
the O
amplitude O
of O
PS O
that O
was O
attenuated O
by O
morphine O
injection O
. O

Furthermore O
, O
microinjection O
of O
CCK B
- I
8 I
( O
0 O
. O
1 O
and O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
also O
significantly O
augmented O
hippocampal O
LTP O
in O
saline O
- O
treated O
( O
1ml O
/ O
kg O
, O
s O
. O
c O
. O
) O
rats O
. O

Pre O
- O
treatment O
of O
the O
CCK2 O
receptor O
antagonist O
L O
- O
365 O
, O
260 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
reversed O
the O
effects O
of O
CCK B
- I
8 I
, O
but O
the O
CCK1 O
receptor O
antagonist O
L O
- O
364 O
, O
718 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
did O
not O
. O

The O
present O
results O
demonstrate O
that O
CCK B
- I
8 I
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK B
- I
8 I
on O
morphine O
- O
induced O
memory O
impairment O
. O

STZ O
also O
significantly O
increased O
the O
level O
of O
ROS O
, O
nitrite B
, O
Ca O
( O
2 O
+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity O
. O

Oral O
treatment O
with O
Memantine B
( O
10mg O
/ O
kg O
) O
and O
Ibuprofen O
( O
50 O
mg O
/ O
kg O
) O
daily O
for O
13 O
days O
attenuated O
STZ O
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity O
in O
rat O
brain O
. O

The O
level O
of O
GFAP O
, O
CD11b O
, O
TNF O
- O
a O
, O
ROS O
and O
nitrite B
levels O
were O
increased O
. O

Fluconazole B
associated O
agranulocytosis O
and O
thrombocytopenia O
. O

CASE O
: O
We O
describe O
a O
second O
case O
of O
fluconazole B
associated O
agranulocytosis O
with O
thrombocytopenia O
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

The O
patient O
began O
to O
have O
changes O
in O
white O
blood O
cells O
and O
platelets O
within O
48 O
h O
of O
administration O
of O
fluconazole B
and O
began O
to O
recover O
with O
48 O
h O
of O
discontinuation O
. O

CONCLUSION O
: O
According O
to O
Naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis O
and O
thrombocytopenia O
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole B
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

In O
particular O
the O
temporal O
relationship O
of O
bone O
marrow O
suppression O
to O
the O
initiation O
of O
fluconazole B
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

Two O
- O
dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high O
- O
sensitive O
cardiac O
troponin O
T O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity O
during O
epirubicine B
- O
based O
chemotherapy O
. O

AIMS O
: O
To O
investigate O
whether O
alterations O
of O
myocardial O
strain O
and O
high O
- O
sensitive O
cardiac O
troponin O
T O
( O
cTnT O
) O
could O
predict O
future O
cardiac O
dysfunction O
in O
patients O
after O
epirubicin B
exposure O
. O

METHODS O
: O
Seventy O
- O
five O
patients O
with O
non O
- O
Hodgkin O
lymphoma O
treated O
with O
epirubicin B
were O
studied O
. O

Prevention O
of O
etomidate B
- O
induced O
myoclonus O
: O
which O
is O
superior O
: O
Fentanyl O
, O
midazolam O
, O
or O
a O
combination O
? O

BACKGROUND O
: O
In O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl O
, O
midazolam O
, O
and O
a O
combination O
of O
fentanyl O
and O
midazolam O
to O
prevent O
etomidate B
- O
induced O
myoclonus O
. O

Depending O
on O
the O
drugs O
that O
would O
be O
given O
before O
the O
induction O
of O
anesthesia O
with O
etomidate B
, O
the O
patients O
were O
separated O
into O
4 O
groups O
: O
no O
pretreatment O
( O
Group O
NP O
) O
, O
fentanyl O
1 O
ug O
. O
kg O
- O
1 O
( O
Group O
F O
) O
, O
midazolam O
0 O
. O
03 O
mg O
. O
kg O
- O
1 O
( O
Group O
M O
) O
, O
and O
midazolam O
0 O
. O
015 O
mg O
. O
kg O
- O
1 O
+ O
fentanyl O
0 O
. O
5 O
ug O
. O
kg O
- O
1 O
( O
Group O
FM O
) O
. O

Patients O
who O
received O
the O
same O
anesthetic O
procedure O
were O
selected O
: O
2 O
minutes O
after O
intravenous O
injections O
of O
the O
pretreatment O
drugs O
, O
anesthesia O
is O
induced O
with O
0 O
. O
3 O
mg O
. O
kg O
- O
1 O
etomidate B
injected O
intravenously O
over O
a O
period O
of O
20 O
- O
30 O
seconds O
. O

Myoclonic O
movements O
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate B
injection O
. O

The O
severity O
of O
pain O
due O
to O
etomidate B
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

CONCLUSIONS O
: O
We O
conclude O
that O
pretreatment O
with O
fentanyl O
or O
combination O
of O
fentanyl O
and O
midazolam O
was O
effective O
in O
preventing O
etomidate B
- O
induced O
myoclonus O
. O

Cholestatic O
presentation O
of O
yellow O
phosphorus B
poisoning O
. O

Yellow O
phosphorus B
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity O
. O

Poisoning O
with O
yellow O
phosphorus B
classically O
manifests O
with O
acute O
hepatitis O
leading O
to O
acute O
liver O
failure O
which O
may O
need O
liver O
transplantation O
. O

We O
present O
a O
case O
of O
yellow O
phosphorus B
poisoning O
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis O
highlighting O
the O
fact O
that O
cholestasis O
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus B
hepatotoxicity O
. O

Vasovagal O
syncope O
and O
severe O
bradycardia O
following O
intranasal O
dexmedetomidine B
for O
pediatric O
procedural O
sedation O
. O

We O
report O
syncope O
and O
bradycardia O
in O
an O
11 O
- O
year O
- O
old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine B
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

Paradoxical O
severe O
agitation O
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine B
in O
schizo O
- O
affective O
disorder O
. O

We O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo O
- O
affective O
disorder O
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol B
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O
85 O
mEq O
/ O
l O
) O
. O

Within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine B
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation O
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness O
or O
personality O
disorder O
. O

The O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine B
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation O
, O
enabled O
us O
to O
attribute O
the O
agitation O
specifically O
to O
quetiapine B
. O

A O
Case O
of O
Sudden O
Cardiac O
Death O
due O
to O
Pilsicainide B
- O
Induced O
Torsades O
de O
Pointes O
. O

An O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide B
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial O
fibrillation O
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden O
cardiac O
death O
two O
days O
later O
. O

Although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide B
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide B
may O
have O
been O
high O
, O
which O
can O
produce O
torsades O
de O
pointes O
in O
the O
octogenarian O
. O

Although O
the O
oral O
administration O
of O
class O
IC O
drugs O
, O
including O
pilsicainide B
, O
is O
effective O
to O
terminate O
atrial O
fibrillation O
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

All B
- I
trans I
retinoic I
acid I
- O
induced O
inflammatory O
myositis O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
. O

All B
- I
trans I
retinoic I
acid I
( O
ATRA B
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

Only O
a O
handful O
of O
cases O
of O
ATRA B
- O
induced O
myositis O
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

Tolerability O
of O
lomustine B
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma O
. O

This O
retrospective O
study O
describes O
toxicity O
associated O
with O
a O
protocol O
of O
lomustine B
( O
CCNU B
) O
and O
cyclophosphamide O
( O
CTX O
) O
in O
dogs O
with O
lymphoma O
. O

CCNU B
was O
administered O
per O
os O
( O
PO O
) O
at O
a O
targeted O
dosage O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
body O
surface O
area O
on O
day O
0 O
, O
CTX O
was O
administered O
PO O
at O
a O
targeted O
dosage O
of O
250 O
mg O
/ O
m O
( O
2 O
) O
divided O
over O
days O
0 O
through O
4 O
, O
and O
all O
dogs O
received O
prophylactic O
antibiotics O
. O

Neutropenia O
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia O
after O
the O
first O
treatment O
of O
CCNU B
/ O
CTX O
was O
30 O
% O
( O
95 O
% O
confidence O
interval O
, O
19 O
- O
43 O
% O
) O
. O

On O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
CCNU B
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
CTX O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor O
- O
bearing O
dogs O
. O

She O
was O
re O
- O
induced O
with O
nelarabine O
1500 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
with O
1 O
dose O
of O
IT O
cytarabine B
100 O
mg O
on O
day O
2 O
as O
central O
nervous O
system O
( O
CNS O
) O
prophylaxis O
. O

Necrotising O
fasciitis O
after O
bortezomib B
and O
dexamethasone O
- O
containing O
regimen O
in O
an O
elderly O
patient O
of O
Waldenstrom O
macroglobulinaemia O
. O

Bortezomib B
and O
high O
- O
dose O
dexamethasone O
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial O
infections O
in O
patients O
with O
B O
- O
cell O
malignancies O
. O

We O
report O
a O
case O
of O
a O
76 O
- O
year O
- O
old O
man O
with O
Waldenstrom O
macroglobulinaemia O
who O
suffered O
necrotising O
fasciitis O
without O
neutropenia O
after O
the O
combination O
treatment O
with O
bortezomib B
, O
high O
- O
dose O
dexamethasone O
and O
rituximab O
. O

Physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial O
infections O
related O
to O
bortezomib B
plus O
high O
- O
dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

Troponin O
I O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium B
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic O
dysfunction O
. O

Furthermore O
, O
reduction O
of O
ER O
stress O
in O
the O
TM O
with O
sodium B
4 I
- I
phenylbutyrate I
prevented O
dexamethasone O
- O
induced O
ocular O
hypertension O
in O
WT O
mice O
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
Re B
, I
Rg1 I
, I
and I
Rb1 I
ginsenosides I
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
OIH O
. O

During O
withdrawal O
( O
days O
8 O
and O
9 O
) O
, O
these O
mice O
were O
administered O
Re B
, O
Rg1 O
, O
or O
Rb1 B
intragastrically O
two O
times O
per O
day O
. O

On O
the O
test O
day O
( O
day O
10 O
) O
, O
mice O
were O
subjected O
to O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

Re B
( O
300 O
mg O
/ O
kg O
) O
inhibited O
OIH O
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

However O
, O
the O
Rg1 B
and I
Rb1 I
ginsenosides I
failed O
to O
prevent O
OIH O
in O
either O
test O
. O

Furthermore O
, O
Rg1 O
showed O
a O
tendency O
to O
aggravate O
OIH O
in O
the O
acetic B
acid I
- O
induced O
writhing O
test O
. O

Our O
data O
suggested O
that O
the O
ginsenoside B
Re I
, O
but O
not O
Rg1 O
or O
Rb1 B
, O
may O
contribute O
toward O
reversal O
of O
OIH O
. O

A O
comparison O
of O
severe O
hemodynamic O
disturbances O
between O
dexmedetomidine B
and O
propofol O
for O
sedation O
in O
neurocritical O
care O
patients O
. O

OBJECTIVE O
: O
Dexmedetomidine B
and O
propofol O
are O
commonly O
used O
sedatives O
in O
neurocritical O
care O
as O
they O
allow O
for O
frequent O
neurologic O
examinations O
. O

The O
primary O
objective O
of O
this O
study O
is O
to O
compare O
the O
prevalence O
of O
severe O
hemodynamic O
effects O
in O
neurocritical O
care O
patients O
receiving O
dexmedetomidine B
and O
propofol O
. O

INTERVENTIONS O
: O
Continuous O
sedation O
with O
dexmedetomidine B
or O
propofol O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
A O
total O
of O
342 O
patients O
( O
105 O
dexmedetomidine B
and O
237 O
propofol O
) O
were O
included O
in O
the O
analysis O
, O
with O
190 O
matched O
( O
95 O
in O
each O
group O
) O
by O
propensity O
score O
. O

CONCLUSIONS O
: O
Severe O
hypotension O
and O
bradycardia O
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine B
or O
propofol O
. O

Hydroxytyrosol B
ameliorates O
oxidative O
stress O
and O
mitochondrial O
dysfunction O
in O
doxorubicin O
- O
induced O
cardiotoxicity O
in O
rats O
with O
breast O
cancer O
. O

Herein O
, O
we O
investigate O
whether O
doxorubicin O
- O
associated O
chronic O
cardiac O
toxicity O
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol B
in O
rats O
with O
breast O
cancer O
. O

Thirty O
- O
six O
rats O
bearing O
breast O
tumors O
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol B
( O
0 O
. O
5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin O
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol B
. O

Hydroxytyrosol B
improved O
the O
cardiac O
disturbances O
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

These O
results O
suggest O
that O
hydroxytyrosol B
improve O
the O
mitochondrial O
electron O
transport O
chain O
. O

This O
study O
demonstrates O
that O
hydroxytyrosol B
protect O
rat O
heart O
damage O
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

The O
24 O
hour O
excretion O
of O
iodine B
was O
3657 O
( O
mcg O
( O
25 O
- O
756 O
( O
mcg O
) O
. O

Effects O
of O
dehydroepiandrosterone B
in O
amphetamine O
- O
induced O
schizophrenia O
models O
in O
mice O
. O

OBJECTIVE O
: O
To O
examine O
the O
effects O
of O
dehydroepiandrosterone B
( O
DHEA B
) O
on O
animal O
models O
of O
schizophrenia O
. O

METHODS O
: O
Seventy O
Swiss O
albino O
female O
mice O
( O
25 O
- O
35 O
g O
) O
were O
divided O
into O
4 O
groups O
: O
amphetamine O
- O
free O
( O
control O
) O
, O
amphetamine O
, O
50 O
, O
and O
100 O
mg O
/ O
kg O
DHEA B
. O

The O
DHEA B
was O
administered O
intraperitoneally O
( O
ip O
) O
for O
5 O
days O
. O

Both O
DHEA B
50 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
100 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
01 O
) O
significantly O
decreased O
all O
movements O
compared O
with O
the O
amphetamine O
- O
induced O
locomotion O
group O
. O

CONCLUSION O
: O
We O
observed O
that O
DHEA B
reduced O
locomotor O
activity O
and O
increased O
catalepsy O
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

We O
suggest O
that O
DHEA B
displays O
typical O
neuroleptic O
- O
like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia O
. O

BACKGROUND O
: O
S B
- I
53482 I
and O
S B
- I
23121 I
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality O
, O
teratogenicity O
( O
mainly O
ventricular O
septal O
defects O
and O
wavy O
ribs O
) O
, O
and O
growth O
retardation O
in O
rats O
in O
conventional O
oral O
developmental O
toxicity O
studies O
. O

METHODS O
: O
S B
- I
53482 I
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg O
/ O
kg O
during O
organogenesis O
, O
and O
S B
- I
23121 I
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg O
/ O
kg O
( O
the O
maximum O
applicable O
dose O
level O
) O
. O

RESULTS O
: O
Dermal O
exposure O
of O
rats O
to O
S B
- I
53482 I
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity O
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

Dermal O
administration O
of O
S B
- I
23121 I
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic O
death O
and O
ventricular O
septal O
defect O
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S B
- I
23121 I
. O

CONCLUSIONS O
: O
Based O
on O
the O
results O
, O
S B
- I
53482 I
and O
S B
- I
23121 I
were O
teratogenic O
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

Metformin B
protects O
against O
seizures O
, O
learning O
and O
memory O
impairments O
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

Metformin B
, O
the O
most O
commonly O
prescribed O
antidiabetic O
oral O
drug O
, O
has O
antioxidant O
properties O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin B
on O
seizures O
, O
cognitive O
impairment O
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole O
- O
induced O
kindling O
animals O
. O

Metformin B
was O
injected O
intraperitoneally O
in O
dose O
of O
200mg O
/ O
kg O
along O
with O
alternate O
- O
day O
PTZ O
. O

We O
found O
that O
metformin B
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive O
impairment O
and O
decreased O
brain O
oxidative O
stress O
. O

Thus O
the O
present O
study O
concluded O
that O
metformin B
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy O
as O
well O
as O
a O
protective O
medicine O
against O
cognitive O
impairment O
induced O
by O
seizures O
. O

Aconitine B
- O
induced O
Ca2 B
+ O
overload O
causes O
arrhythmia O
and O
triggers O
apoptosis O
through O
p38 O
MAPK O
signaling O
pathway O
in O
rats O
. O

Aconitine B
is O
a O
major O
bioactive O
diterpenoid O
alkaloid O
with O
high O
content O
derived O
from O
herbal O
aconitum O
plants O
. O

Emerging O
evidence O
indicates O
that O
voltage O
- O
dependent O
Na O
( O
+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity O
of O
aconitine B
. O

However O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
Ca O
( O
2 O
+ O
) O
in O
aconitine B
poisoning O
. O

In O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
Ca O
( O
2 O
+ O
) O
signaling O
in O
aconitine B
poisoning O
in O
vitro O
and O
in O
vivo O
. O

To O
investigate O
effects O
of O
aconitine B
on O
myocardial O
injury O
, O
we O
performed O
cytotoxicity O
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
NRVMs O
) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
NRVMs O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

The O
results O
showed O
that O
aconitine B
resulted O
in O
myocardial O
injury O
and O
reduced O
NRVMs O
viability O
dose O
- O
dependently O
. O

To O
confirm O
the O
pro O
- O
apoptotic O
effects O
, O
we O
performed O
flow O
cytometric O
detection O
, O
cardiac O
histology O
, O
transmission O
electron O
microscopy O
and O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP B
- O
biotin B
nick O
end O
labeling O
assay O
. O

The O
results O
showed O
that O
aconitine B
stimulated O
apoptosis O
time O
- O
dependently O
. O

The O
expression O
analysis O
of O
Ca O
( O
2 O
+ O
) O
handling O
proteins O
demonstrated O
that O
aconitine B
promoted O
Ca O
( O
2 O
+ O
) O
overload O
through O
the O
expression O
regulation O
of O
Ca O
( O
2 O
+ O
) O
handling O
proteins O
. O

Hence O
, O
our O
results O
suggest O
that O
aconitine B
significantly O
aggravates O
Ca O
( O
2 O
+ O
) O
overload O
and O
causes O
arrhythmia O
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
P38 O
mitogen O
- O
activated O
protein O
kinase O
. O

Chronic O
treatment O
with O
metformin B
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left O
ventricular O
dysfunction O
following O
myocardial O
infarction O
. O

Acute O
treatment O
with O
metformin B
has O
a O
protective O
effect O
in O
myocardial O
infarction O
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
AMP O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin B
on O
cardiac O
dysfunction O
and O
toll O
- O
like O
receptor O
4 O
( O
TLR4 O
) O
activities O
following O
myocardial O
infarction O
and O
their O
relation O
with O
AMPK O
were O
assessed O
. O

Male O
Wistar O
rats O
were O
randomly O
assigned O
to O
one O
of O
5 O
groups O
( O
n O
= O
6 O
) O
: O
normal O
control O
and O
groups O
were O
injected O
isoproterenol O
after O
chronic O
pre O
- O
treatment O
with O
0 O
, O
25 O
, O
50 O
, O
or O
100mg O
/ O
kg O
of O
metformin B
twice O
daily O
for O
14 O
days O
. O

The O
left O
ventricular O
dysfunction O
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin B
. O

Phosphorylated O
AMPKa O
( O
p O
- O
AMPK O
) O
in O
the O
myocardium O
was O
significantly O
elevated O
by O
25mg O
/ O
kg O
of O
metformin B
, O
slightly O
by O
50mg O
/ O
kg O
, O
but O
not O
by O
100mg O
/ O
kg O
. O

Chronic O
pre O
- O
treatment O
with O
metformin B
reduces O
post O
- O
myocardial O
infarction O
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
TLR4 O
activities O
. O

Two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis O
, O
one O
case O
of O
fatal O
methimazole B
- O
associated O
hepatocellular O
necrosis O
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus O
- O
like O
syndrome O
are O
described O
. O

Neuroleptic O
malignant O
syndrome O
induced O
by O
combination O
therapy O
with O
tetrabenazine B
and O
tiapride B
in O
a O
Japanese O
patient O
with O
Huntington O
' O
s O
disease O
at O
the O
terminal O
stage O
of O
recurrent O
breast O
cancer O
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic O
malignant O
syndrome O
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride B
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine B
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington O
' O
s O
disease O
. O

The O
patient O
had O
been O
treated O
with O
tiapride B
or O
tetrabenazine B
alone O
without O
any O
adverse O
effects O
before O
the O
administration O
of O
the O
combination O
therapy O
. O

To O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic O
malignant O
syndrome O
due O
to O
combination O
therapy O
with O
tetrabenazine B
and O
tiapride B
has O
not O
been O
previously O
reported O
. O

Tetrabenazine B
should O
be O
administered O
very O
carefully O
in O
combination O
with O
other O
neuroleptic B
drugs I
, O
particularly O
in O
patients O
with O
a O
worsening O
general O
condition O
. O

A O
metoprolol O
- O
terbinafine B
combination O
induced O
bradycardia O
. O

To O
report O
a O
sinus O
bradycardia O
induced O
by O
metoprolol O
and O
terbinafine B
drug O
- O
drug O
interaction O
and O
its O
management O
. O

A O
63 O
year O
- O
old O
Caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary O
artery O
disease O
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine B
250 O
mg O
/ O
day O
for O
onychomycosis O
. O

On O
the O
49th O
day O
of O
terbinafine B
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion O
and O
falls O
. O

A O
score O
of O
7 O
on O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus O
bradycardia O
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine B
. O

It O
was O
subsequently O
changed O
to O
bisoprolol B
and O
the O
heart O
rate O
remained O
normal O
. O

By O
inhibiting O
the O
cytochrome O
P450 O
2D6 O
, O
terbinafine B
had O
decreased O
metoprolol O
' O
s O
clearance O
, O
leading O
in O
metoprolol O
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus O
bradycardia O
. O

Optochiasmatic O
and O
peripheral O
neuropathy O
due O
to O
ethambutol B
overtreatment O
. O

Ethambutol B
is O
known O
to O
cause O
optic O
neuropathy O
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy O
. O

We O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual O
loss O
and O
paresthesias O
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol B
. O

This O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol B
toxicity O
. O

Testosterone O
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
sc O
) O
, O
the O
androgen B
receptor O
antagonist O
flutamide O
( O
10 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
, O
the O
estrogen O
receptor O
antagonist O
tamoxifen O
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
or O
the O
aromatase O
inhibitor O
letrozole B
( O
4 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
ip O
) O
were O
administered O
for O
6 O
d O
after O
the O
first O
injection O
of O
STZ O
. O

Administration O
of O
flutamide O
, O
letrozole B
or O
tamoxifen O
significantly O
impaired O
the O
memory O
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
STZ O
- O
and O
castration O
- O
induced O
memory O
impairment O
. O

Behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone B
FC I
in O
pilocarpine O
- O
induced O
seizures O
. O

Garcinielliptone B
FC I
( O
GFC B
) O
isolated O
from O
hexanic O
fraction O
seed O
extract O
of O
species O
Platonia O
insignis O
Mart O
. O

However O
, O
there O
is O
no O
research O
on O
GFC B
effects O
in O
the O
central O
nervous O
system O
of O
rodents O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC B
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure O
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r O
- O
aminobutyric O
acid O
( O
GABA O
) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
AChE O
) O
activity O
in O
mice O
hippocampus O
after O
seizures O
. O

GFC B
produced O
an O
increased O
latency O
to O
first O
seizure O
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O
12 O
+ O
2 O
. O
20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O
95 O
+ O
2 O
. O
21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O
43 O
+ O
1 O
. O
99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

The O
results O
indicate O
that O
GFC B
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine O
- O
induced O
status O
epilepticus O
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure O
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

In O
conclusion O
, O
our O
data O
suggest O
that O
GFC B
may O
influence O
in O
epileptogenesis O
and O
promote O
anticonvulsant O
actions O
in O
pilocarpine O
model O
by O
modulating O
the O
GABA O
and O
glutamate O
contents O
and O
of O
AChE O
activity O
in O
seized O
mice O
hippocampus O
. O

Rhabdomyolysis O
in O
a O
hepatitis O
C O
virus O
infected O
patient O
treated O
with O
telaprevir B
and O
simvastatin O
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis O
C O
virus O
infection O
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir B
. O

Telaprevir B
was O
considered O
the O
probable O
causative O
agent O
of O
an O
interaction O
with O
simvastatin O
according O
to O
the O
Drug O
Interaction O
Probability O
Scale O
. O

In O
conclusion O
, O
with O
this O
case O
we O
illustrate O
that O
telaprevir B
as O
well O
as O
statins O
are O
susceptible O
to O
clinical O
relevant O
drug O
- O
drug O
interactions O
. O

Combination O
of O
bortezomib B
, O
thalidomide O
, O
and O
dexamethasone O
( O
VTD O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple O
myeloma O
in O
Japanese O
patients O
. O

In O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib B
, O
thalidomide O
, O
and O
dexamethasone O
( O
VTD O
) O
as O
consolidation O
therapy O
in O
24 O
Japanese O
patients O
with O
newly O
diagnosed O
MM O
. O

VTD O
consisted O
of O
bortezomib B
at O
a O
dose O
of O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone O
at O
a O
dose O
of O
40 O
mg O
/ O
day O
on O
days O
1 O
, O
8 O
, O
15 O
, O
and O
22 O
of O
a O
35 O
- O
day O
cycle O
, O
with O
daily O
oral O
thalidomide O
at O
a O
dose O
of O
100 O
mg O
/ O
day O
. O

Renal O
lesions O
were O
analyzed O
in O
hematoxylin B
and O
eosin B
, O
periodic O
acid O
- O
Schiff O
, O
and O
Masson O
' O
s O
trichrome O
stains O
. O

Safety O
and O
efficacy O
of O
fluocinolone B
acetonide I
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
birdshot O
retinochoroidopathy O
. O

PURPOSE O
: O
To O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone B
acetonide I
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
patients O
with O
birdshot O
retinochoroidopathy O
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

Eleven O
patients O
( O
11 O
eyes O
) O
underwent O
surgery O
for O
fluocinolone B
acetonide I
implant O
( O
0 O
. O
59 O
mg O
) O
. O

Treatment O
outcomes O
of O
interest O
were O
noted O
at O
baseline O
, O
before O
fluocinolone B
acetonide I
implant O
, O
and O
then O
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
. O

CONCLUSION O
: O
The O
data O
suggest O
that O
fluocinolone B
acetonide I
implant O
( O
0 O
. O
59 O
mg O
) O
helps O
to O
control O
inflammation O
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot O
retinochoroidopathy O
. O

Optimal O
precurarizing O
dose O
of O
rocuronium B
to O
decrease O
fasciculation O
and O
myalgia O
following O
succinylcholine O
administration O
. O

The O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium B
to O
prevent O
succinylcholine O
- O
induced O
fasciculation O
and O
myalgia O
and O
evaluated O
the O
influence O
of O
rocuronium B
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

Patients O
were O
randomized O
to O
receive O
0 O
. O
02 O
, O
0 O
. O
03 O
, O
0 O
. O
04 O
, O
0 O
. O
05 O
and O
0 O
. O
06 O
mg O
/ O
kg O
rocuronium B
as O
a O
precurarizing O
dose O
. O

RESULTS O
: O
The O
incidence O
and O
severity O
of O
visible O
muscle O
fasciculation O
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B
( O
P O
< O
0 O
. O
001 O
) O
. O

Those O
of O
myalgia O
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B
, O
but O
there O
was O
no O
significance O
( O
P O
= O
0 O
. O
072 O
) O
. O

The O
onset O
time O
of O
succinylcholine O
was O
significantly O
longer O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B
( O
P O
< O
0 O
. O
001 O
) O
. O

CONCLUSIONS O
: O
Precurarization O
with O
0 O
. O
04 O
mg O
/ O
kg O
rocuronium B
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation O
and O
myalgia O
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

The O
decreased O
capacity O
to O
concentrate O
urine O
is O
likely O
due O
to O
lithium O
acutely O
disrupting O
the O
cAMP B
pathway O
and O
chronically O
reducing O
urea O
transporter O
( O
UT O
- O
A1 O
) O
and O
water O
channel O
( O
AQP2 O
) O
expression O
in O
the O
inner O
medulla O
. O

Is O
Dysguesia O
Going O
to O
be O
a O
Rare O
or O
a O
Common O
Side O
- O
effect O
of O
Amlodipine B
? O

A O
very O
rare O
side O
- O
effect O
of O
amlodipine B
is O
dysguesia O
. O

We O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension O
on O
drug O
treatment O
with O
amlodipine B
developed O
loss O
of O
taste O
sensation O
. O

We O
conclude O
that O
amlodipine B
can O
cause O
dysguesia O
. O

Here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine B
and O
dysguesia O
. O

Rhabdomyolysis O
in O
association O
with O
simvastatin O
and O
dosage O
increment O
in O
clarithromycin B
. O

Clarithromycin B
is O
the O
most O
documented O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
inhibitor O
to O
cause O
an O
adverse O
interaction O
with O
simvastatin O
. O

This O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis O
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin B
. O

Butyrylcholinesterase O
deficiency O
is O
characterized O
by O
prolonged O
apnea O
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium B
) O
in O
patients O
who O
have O
mutations O
in O
the O
BCHE O
gene O
. O

Low O
activity O
of O
patient O
plasma O
butyrylcholinesterase O
with O
butyrylthiocholine B
( O
BTC B
) O
and O
benzoylcholine B
, O
and O
values O
of O
dibucaine B
and O
fluoride B
numbers O
fit O
with O
heterozygous O
atypical O
silent O
genotype O
. O

Kinetic O
analysis O
showed O
that O
the O
p O
. O
Val204Asp O
/ O
p O
. O
Asp70Gly O
- O
p O
. O
Ala539Thr O
BChE O
displays O
a O
pure O
Michaelian O
behavior O
with O
BTC B
as O
the O
substrate O
. O

Both O
catalytic O
parameters O
Km O
= O
265 O
uM O
for O
BTC B
, O
two O
times O
higher O
than O
that O
of O
the O
atypical O
enzyme O
, O
and O
a O
low O
Vmax O
are O
consistent O
with O
the O
absence O
of O
activity O
against O
suxamethonium O
. O

Delayed O
anemia O
after O
treatment O
with O
injectable O
artesunate B
in O
the O
Democratic O
Republic O
of O
the O
Congo O
: O
a O
manageable O
issue O
. O

Cases O
of O
delayed O
hemolytic O
anemia O
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate B
, O
the O
current O
World O
Health O
Organization O
( O
WHO O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria O
. O

A O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O
4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O
6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate B
for O
severe O
malaria O
in O
hospitals O
and O
health O
centers O
of O
the O
Democratic O
Republic O
of O
the O
Congo O
. O

Regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine B
attenuates O
isoproterenol O
- O
induced O
acute O
myocardial O
injury O
in O
rats O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine B
on O
acute O
myocardial O
ischemia O
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
STAT3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

Male O
Sprague O
Dawley O
rats O
were O
treated O
with O
betaine B
( O
100 O
, O
200 O
, O
and O
400 O
mg O
/ O
kg O
) O
orally O
for O
40 O
days O
. O

Oral O
administration O
of O
betaine B
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular O
remodeling O
. O

Western O
blot O
analysis O
showed O
that O
isoproterenol O
- O
induced O
phosphorylation O
of O
STAT3 O
was O
maintained O
or O
further O
enhanced O
by O
betaine B
treatment O
in O
myocardium O
. O

Furthermore O
, O
betaine B
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
treatment O
increased O
the O
ventricular O
expression O
of O
Bcl O
- O
2 O
and O
reduced O
the O
level O
of O
Bax O
, O
therefore O
causing O
a O
significant O
increase O
in O
the O
ratio O
of O
Bcl O
- O
2 O
/ O
Bax O
. O

The O
protective O
role O
of O
betaine B
on O
myocardial O
damage O
was O
further O
confirmed O
by O
histopathological O
examination O
. O

In O
summary O
, O
our O
results O
showed O
that O
betaine B
pretreatment O
attenuated O
isoproterenol O
- O
induced O
acute O
myocardial O
ischemia O
via O
the O
regulation O
of O
STAT3 O
and O
apoptotic O
pathways O
. O

Quetiapine B
- O
induced O
neutropenia O
in O
a O
bipolar O
patient O
with O
hepatocellular O
carcinoma O
. O

OBJECTIVE O
: O
Quetiapine B
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine O
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood O
dyscrasias O
, O
especially O
neutropenia O
. O

There O
are O
some O
case O
reports O
about O
this O
side O
effect O
of O
quetiapine B
, O
but O
possible O
risk O
factors O
are O
seldom O
discussed O
and O
identified O
. O

A O
case O
of O
a O
patient O
with O
hepatocellular O
carcinoma O
that O
developed O
neutropenia O
after O
treatment O
with O
quetiapine B
is O
described O
here O
. O

She O
developed O
leucopenia O
after O
being O
treated O
with O
quetiapine B
. O

After O
quetiapine B
was O
discontinued O
, O
her O
white O
blood O
cell O
count O
returned O
to O
normal O
. O

CONCLUSIONS O
: O
Although O
neutropenia O
is O
not O
a O
common O
side O
effect O
of O
quetiapine B
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O

Hepatic O
dysfunction O
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever O
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine B
. O

Curcumin O
prevents O
maleate B
- O
induced O
nephrotoxicity O
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
I O
. O

The O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg O
/ O
Kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal O
injury O
induced O
by O
maleate B
was O
evaluated O
. O

Tubular O
proteinuria O
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate B
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

Maleate B
- O
induced O
renal O
injury O
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
NGAL O
) O
and O
N O
- O
acetyl O
b O
- O
D O
- O
glucosaminidase O
( O
NAG O
) O
, O
upregulation O
of O
kidney O
injury O
molecule O
( O
KIM O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis O
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

Maleate B
induced O
cell O
damage O
and O
reactive O
oxygen O
species O
( O
ROS O
) O
production O
in O
LLC O
- O
PK1 O
cells O
in O
culture O
. O

In O
addition O
, O
maleate B
treatment O
reduced O
oxygen O
consumption O
in O
ADP O
- O
stimulated O
mitochondria O
and O
diminished O
respiratory O
control O
index O
when O
using O
malate B
/ O
glutamate O
as O
substrate O
. O

It O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate B
- O
induced O
nephropathy O
and O
in O
vitro O
cell O
damage O
. O

Continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin B
for O
infections O
in O
cancer O
patients O
. O

To O
overcome O
the O
adverse O
effects O
of O
neutropenia O
, O
tobramycin O
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin B
. O

Tobramycin O
was O
given O
to O
a O
total O
daily O
dose O
of O
300 O
mg O
/ O
m2 O
and O
carbenicillin B
was O
given O
at O
a O
dose O
of O
5 O
gm O
every O
four O
hours O
. O

Incidence O
of O
solid O
tumours O
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon B
in O
the O
Agricultural O
Health O
Study O
: O
an O
updated O
analysis O
. O

OBJECTIVE O
: O
Diazinon B
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung O
cancer O
in O
the O
Agricultural O
Health O
Study O
( O
AHS O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon B
- O
associated O
cancer O
risk O
. O

We O
used O
updated O
diazinon B
exposure O
and O
cancer O
incidence O
information O
to O
evaluate O
solid O
tumour O
risk O
in O
the O
AHS O
. O

METHODS O
: O
Male O
pesticide O
applicators O
in O
Iowa O
and O
North O
Carolina O
reported O
lifetime O
diazinon B
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer O
incidence O
was O
assessed O
through O
2010 O
( O
North O
Carolina O
) O
/ O
2011 O
( O
Iowa O
) O
. O

RESULTS O
: O
We O
observed O
elevated O
lung O
cancer O
risks O
( O
N O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
LT O
( O
RR O
= O
1 O
. O
60 O
; O
95 O
% O
CI O
1 O
. O
11 O
to O
2 O
. O
31 O
; O
Ptrend O
= O
0 O
. O
02 O
) O
and O
IW O
days O
of O
diazinon B
use O
( O
RR O
= O
1 O
. O
41 O
; O
95 O
% O
CI O
0 O
. O
98 O
to O
2 O
. O
04 O
; O
Ptrend O
= O
0 O
. O
08 O
) O
. O

CONCLUSIONS O
: O
Our O
updated O
evaluation O
of O
diazinon B
provides O
additional O
evidence O
of O
an O
association O
with O
lung O
cancer O
risk O
. O

OBJECTIVE O
: O
This O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate B
matter I
with O
Parkinson O
' O
s O
disease O
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

RESULTS O
: O
We O
observed O
positive O
associations O
of O
Parkinson O
' O
s O
disease O
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate B
matter I
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

1 B
, I
3 I
- I
Butadiene I
, O
CML O
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
A O
reality O
check O
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 B
, I
3 I
- I
butadiene I
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

We O
have O
proposed O
that O
1 B
, I
3 I
- I
butadiene I
metabolites O
be O
so O
tested O
as O
a O
reality O
check O
on O
the O
epidemiological O
reports O
. O

Conditions O
that O
will O
be O
required O
for O
studies O
of O
1 B
, I
3 I
- I
butadiene I
are O
discussed O
. O

Cancer O
incidence O
and O
metolachlor B
use O
in O
the O
Agricultural O
Health O
Study O
: O
An O
update O
. O

UNASSIGNED O
: O
Metolachlor B
, O
a O
widely O
used O
herbicide O
, O
is O
classified O
as O
a O
Group O
C O
carcinogen O
by O
the O
U O
. O
S O
. O

Epidemiologic O
studies O
of O
the O
health O
effects O
of O
metolachlor B
have O
been O
limited O
. O

We O
evaluated O
cancer O
incidence O
through O
2010 O
/ O
2011 O
( O
NC O
/ O
IA O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor B
. O

We O
used O
Poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor B
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer O
incidence O
. O

We O
saw O
no O
association O
between O
metolachlor B
use O
and O
incidence O
of O
all O
cancers O
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers O
. O

However O
, O
trends O
for O
both O
lifetime O
and O
intensity O
- O
weighted O
lifetime O
days O
of O
metolachor B
use O
were O
positive O
and O
statistically O
significant O
with O
an O
unexposed O
reference O
group O
. O

An O
earlier O
suggestion O
of O
increased O
lung O
cancer O
risk O
at O
high O
levels O
of O
metolachlor B
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

This O
suggestion O
of O
an O
association O
between O
metolachlor B
and O
liver O
cancer O
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver O
neoplasms O
in O
some O
animal O
studies O
. O

However O
, O
our O
findings O
for O
both O
liver O
cancer O
and O
follicular O
cell O
lymphoma O
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor B
use O
from O
other O
factors O
. O

Mechanisms O
Underlying O
Latent O
Disease O
Risk O
Associated O
with O
Early O
- O
Life O
Arsenic B
Exposure O
: O
Current O
Research O
Trends O
and O
Scientific O
Gaps O
. O

BACKGROUND O
: O
Millions O
of O
individuals O
worldwide O
, O
particularly O
those O
living O
in O
rural O
and O
developing O
areas O
, O
are O
exposed O
to O
harmful O
levels O
of O
inorganic B
arsenic I
( O
iAs B
) O
in O
their O
drinking O
water O
. O

Inorganic B
As I
exposure O
during O
key O
developmental O
periods O
is O
associated O
with O
a O
variety O
of O
adverse O
health O
effects O
including O
those O
that O
are O
evident O
in O
adulthood O
. O

There O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
iAs B
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer O
. O

OBJECTIVES O
: O
This O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer O
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
iAs B
exposure O
. O

DISCUSSION O
: O
Epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer O
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
iAs B
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

CONCLUSIONS O
: O
Evidence O
is O
mounting O
that O
relates O
early O
- O
life O
iAs B
exposure O
and O
cancer O
development O
later O
in O
life O
. O

Bradycardia O
due O
to O
biperiden B
. O

In O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric O
trigeminal O
neuralgia O
, O
intravenous O
application O
of O
10 O
mg O
biperiden B
lactate I
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia O
, O
dysarthria O
, O
and O
dysphagia O
. O

The O
heart O
rate O
was O
back O
to O
normal O
within O
12 O
hours O
upon O
administration O
of O
orciprenaline B
under O
cardiac O
monitoring O
in O
an O
intensive O
care O
unit O
. O

Bradycardia O
induced O
by O
biperiden B
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose O
- O
related O
dual O
effect O
of O
atropine O
- O
like O
drugs O
on O
muscarine B
receptors O
. O

In O
addition O
, O
the O
patients O
received O
fentanyl O
and O
d B
- I
tubocurarine I
. O

Pharmacology O
of O
ACC B
- I
9653 I
( O
phenytoin O
prodrug O
) O
. O

ACC B
- I
9653 I
, O
the O
disodium B
phosphate I
ester I
of O
3 B
- I
hydroxymethyl I
- I
5 I
, I
5 I
- I
diphenylhydantoin I
, O
is O
a O
prodrug O
of O
phenytoin O
with O
advantageous O
physicochemical O
properties O
. O

ACC B
- I
9653 I
is O
rapidly O
converted O
enzymatically O
to O
phenytoin O
in O
vivo O
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
equivalent O
anticonvulsant O
activity O
against O
seizures O
induced O
by O
maximal O
electroshock O
( O
MES O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

The O
ED50 O
doses O
were O
16 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
ACC B
- I
9653 I
and O
8 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
phenytoin B
sodium I
. O

ACC B
- I
9653 I
and O
phenytoin B
sodium I
have O
similar O
antiarrhythmic O
activity O
against O
ouabain O
- O
induced O
ventricular O
tachycardia O
in O
anesthetized O
dogs O
. O

The O
total O
doses O
of O
ACC B
- I
9653 I
or O
phenytoin B
sodium I
necessary O
to O
convert O
the O
arrhythmia O
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

Only O
phenytoin B
sodium I
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin B
- O
induced O
arrhythmias O
in O
guinea O
pig O
right O
atria O
. O

In O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
ACC B
- I
9653 I
( O
31 O
mg O
/ O
kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin B
sodium I
( O
21 O
mg O
/ O
kg O
) O
. O

The O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
( O
LVdP O
/ O
dt O
) O
. O

The O
maximum O
effects O
of O
each O
treatment O
occurred O
at O
the O
time O
of O
maximum O
phenytoin B
sodium I
levels O
. O

Acute O
toxicity O
studies O
of O
ACC B
- I
9653 I
and O
phenytoin B
sodium I
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

Importantly O
, O
the O
local O
irritation O
of O
ACC B
- I
9653 I
was O
markedly O
less O
than O
phenytoin B
sodium I
following O
i O
. O
m O
. O
administration O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Treatment O
of O
lethal O
pertussis B
vaccine I
reaction O
with O
histamine O
H1 O
antagonists O
. O

After O
pretreatment O
with O
3 O
mg O
of O
cyproheptadine B
, O
2 O
mg O
mianserin B
, O
or O
2 O
mg O
chlorpheniramine B
, O
only O
5 O
of O
105 O
animals O
( O
5 O
% O
) O
died O
after O
receiving O
BSA O
on O
day O
+ O
7 O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

Effect O
of O
alkylxanthines B
on O
gentamicin O
- O
induced O
acute O
renal O
failure O
in O
the O
rat O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines B
with O
different O
potencies O
as O
adenosine O
antagonists O
8 B
- I
phenyltheophylline I
, O
theophylline O
and O
enprofylline B
, O
were O
examined O
in O
rats O
developing O
acute O
renal O
failure O
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea O
and O
creatinine O
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3H O
] O
inulin O
and O
[ O
14C O
] O
p B
- I
aminohippuric I
acid I
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis O
) O
indices O
. O

However O
, O
any O
improvement O
produced O
by O
drug O
treatment O
was O
largely O
a O
result O
of O
a O
beneficial O
effect O
exerted O
by O
its O
vehicle O
( O
polyethylene O
glycol O
and O
NaOH B
) O
. O

The O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines B
tested O
in O
the O
present O
study O
indicates O
that O
adenosine O
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin O
- O
induced O
ARF O
. O

Adverse O
ocular O
reactions O
possibly O
associated O
with O
isotretinoin B
. O

A O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin B
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne O
. O

Isotretinoin B
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital O
abnormalities O
after O
maternal O
use O
( O
including O
microphthalmos O
, O
orbital O
hypertelorism O
, O
and O
optic O
nerve O
hypoplasia O
) O
. O

Procaterol B
and O
terbutaline O
in O
bronchial O
asthma O
. O

Procaterol B
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial O
asthma O
. O

Oral O
procaterol B
50 O
micrograms O
b O
. O
d O
. O
, O
procaterol B
100 O
micrograms O
b O
. O
d O
. O
, O
and O
terbutaline O
5 O
mg O
t O
. O
i O
. O
d O
. O
, O
were O
compared O
when O
given O
randomly O
in O
1 O
- O
week O
treatment O
periods O
. O

Both O
anti O
- O
asthmatic O
and O
tremorgenic O
effects O
of O
procaterol B
were O
dose O
- O
related O
. O

Procaterol B
appeared O
effective O
in O
the O
doses O
tested O
, O
and O
a O
twice O
daily O
regimen O
would O
appear O
to O
be O
suitable O
with O
this O
drug O
. O

It O
was O
possible O
to O
suppress O
the O
increased O
ornithine B
decarboxylase O
activity O
with O
both O
beta O
- O
blockers O
in O
hypertrophied O
hearts O
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

The O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 B
- I
methoxy I
- I
4 I
- I
hydroxyphenethyleneglycol I
( O
MHPG B
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
DSM O
- O
III O
criteria O
for O
agoraphobia O
with O
panic O
attacks O
or O
panic O
disorder O
. O

Caffeine O
did O
not O
alter O
plasma O
MHPG B
levels O
in O
either O
the O
healthy O
subjects O
or O
patients O
. O

Comparison O
of O
the O
effect O
of O
oxitropium B
bromide I
and O
of O
slow O
- O
release O
theophylline O
on O
nocturnal O
asthma O
. O

The O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium B
bromide I
, O
and O
of O
a O
slow O
- O
release O
theophylline O
preparation O
upon O
nocturnal O
asthma O
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

Two O
samples O
were O
studied O
: O
12 O
patients O
received O
oxitropium B
at O
600 O
micrograms O
( O
6 O
subjects O
) O
or O
at O
400 O
micrograms O
t O
. O
i O
. O
d O
. O

No O
significant O
difference O
was O
noticed O
between O
results O
obtained O
with O
either O
active O
drug O
, O
as O
well O
as O
with O
either O
dosage O
of O
oxitropium B
. O

No O
subject O
reported O
side O
effects O
of O
oxitropium B
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea O
, O
vomiting O
and O
tremors O
after O
theophylline O
. O

Oxitropium B
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline O
in O
nocturnal O
asthma O
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium B
salicylate I
, O
phenylbutazone B
, O
indomethacin O
, O
ibuprofen O
and O
mefenamic B
acid I
, O
on O
seizures O
produced O
by O
pilocarpine O
. O

Pretreatment O
of O
rats O
with O
sodium B
salicylate I
, O
ED50 O
103 O
mg O
/ O
kg O
( O
60 O
- O
174 O
) O
, O
and O
phenylbutazone B
, O
59 O
mg O
/ O
kg O
( O
50 O
- O
70 O
) O
converted O
the O
non O
- O
convulsant O
dose O
of O
pilocarpine O
, O
200 O
mg O
/ O
kg O
, O
to O
a O
convulsant O
one O
. O

Mefenamic B
acid I
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures O
and O
protected O
rats O
from O
seizure O
- O
related O
brain O
damage O
induced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

Progressive O
bile O
duct O
injury O
after O
thiabendazole B
administration O
. O

A O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice O
2 O
wk O
after O
exposure O
to O
thiabendazole B
. O

Differential O
effects O
of O
1 B
, I
4 I
- I
dihydropyridine I
calcium B
channel I
blockers I
: O
therapeutic O
implications O
. O

Increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular O
disease O
has O
stimulated O
research O
into O
the O
use O
of O
calcium B
channel I
blocking I
agents I
for O
treatment O
of O
a O
variety O
of O
cardiovascular O
diseases O
. O

Clinical O
applications O
of O
calcium B
channel I
blockers I
parallel O
their O
tissue O
selectivity O
. O

In O
contrast O
to O
verapamil O
and O
diltiazem O
, O
which O
are O
roughly O
equipotent O
in O
their O
actions O
on O
the O
heart O
and O
vascular O
smooth O
muscle O
, O
the O
dihydropyridine B
calcium B
channel I
blockers I
are O
a O
group O
of O
potent O
peripheral O
vasodilator O
agents O
that O
exert O
minimal O
electrophysiologic O
effects O
on O
cardiac O
nodal O
or O
conduction O
tissue O
. O

As O
the O
first O
dihydropyridine B
available O
for O
use O
in O
the O
United O
States O
, O
nifedipine O
controls O
angina O
and O
hypertension O
with O
minimal O
depression O
of O
cardiac O
function O
. O

Additional O
members O
of O
this O
group O
of O
calcium B
channel I
blockers I
have O
been O
studied O
for O
a O
variety O
of O
indications O
for O
which O
they O
may O
offer O
advantages O
over O
current O
therapy O
. O

Once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine O
and O
nisoldipine B
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long O
- O
term O
therapy O
of O
hypertension O
. O

The O
coronary O
vasodilating O
properties O
of O
nisoldipine B
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina O
. O

In O
general O
, O
the O
dihydropyridine B
calcium B
channel I
blockers I
are O
usually O
well O
tolerated O
, O
with O
headache O
, O
facial O
flushing O
, O
palpitations O
, O
edema O
, O
nausea O
, O
anorexia O
, O
and O
dizziness O
being O
the O
more O
common O
adverse O
effects O
. O

An O
experimental O
model O
of O
focal O
segmental O
glomerular O
sclerosis O
( O
FSGS O
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
AMNS O
) O
and O
protamine B
sulfate I
( O
PS B
) O
. O

Male O
Sprague O
- O
Dawley O
rats O
, O
uninephrectomized O
three O
weeks O
before O
, O
received O
daily O
injections O
of O
subcutaneous O
AMNS O
( O
1 O
mg O
/ O
100 O
g O
body O
wt O
) O
and O
intravenous O
PS B
( O
2 O
separated O
doses O
of O
2 O
. O
5 O
mg O
/ O
100 O
g O
body O
wt O
) O
for O
four O
days O
. O

The O
time O
- O
course O
curve O
of O
creatinine O
clearance O
dropped O
and O
showed O
significant O
difference O
( O
P O
less O
than O
0 O
. O
01 O
) O
from O
that O
of O
each O
control O
group O
, O
such O
as O
, O
AMNS O
alone O
, O
PS B
alone O
or O
saline O
injected O
. O

The O
ultrastructural O
studies O
in O
the O
initial O
stage O
revealed O
significant O
lack O
of O
particles O
of O
perfused O
ruthenium B
red O
on O
the O
lamina O
rara O
externa O
and O
marked O
changes O
in O
epithelial O
cell O
cytoplasm O
. O

Therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
PS B
enhances O
the O
toxicity O
of O
AMNS O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
FSGS O
in O
rats O
resulting O
in O
the O
end O
- O
stage O
renal O
disease O
. O

Hyperkalemia O
induced O
by O
indomethacin O
and O
naproxen B
and O
reversed O
by O
fludrocortisone B
. O

We O
have O
described O
a O
patient O
with O
severe O
rheumatoid O
arthritis O
and O
a O
history O
of O
mefenamic B
acid I
nephropathy O
in O
whom O
hyperkalemia O
and O
inappropriate O
hypoaldosteronism O
were O
caused O
by O
both O
indomethacin O
and O
naproxen B
, O
without O
major O
decline O
in O
renal O
function O
. O

Because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti O
- O
inflammatory O
drug O
therapy O
, O
fludrocortisone B
was O
added O
, O
correcting O
the O
hyperkalemia O
and O
allowing O
indomethacin O
therapy O
to O
be O
continued O
safely O
. O

Furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 O
- O
HT O
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 B
, I
7 I
- I
dihydroxytryptamine I
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac O
responses O
to O
clonidine O
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

Rechallenge O
of O
patients O
who O
developed O
oral O
candidiasis O
or O
hoarseness O
with O
beclomethasone B
dipropionate I
. O

Of O
158 O
asthmatic O
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone B
, O
15 O
( O
9 O
. O
5 O
% O
) O
developed O
either O
hoarseness O
( O
8 O
) O
, O
oral O
thrush O
( O
6 O
) O
, O
or O
both O
( O
1 O
) O
. O

When O
their O
adverse O
reactions O
subsided O
, O
seven O
of O
these O
15 O
patients O
were O
rechallenged O
with O
inhaled O
beclomethasone B
. O

We O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone B
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness O
should O
not O
be O
re O
- O
challenged O
. O

Concomitant O
use O
of O
oral O
prednisone O
and O
topical O
beclomethasone B
may O
increase O
the O
risk O
of O
developing O
hoarseness O
or O
candidiasis O
. O

The O
effect O
of O
clonidine O
, O
naphazoline B
and O
xylometazoline B
on O
analgesia O
induced O
by O
morphine O
, O
codeine B
, O
fentanyl O
and O
pentazocine O
, O
and O
on O
cataleptic O
effect O
of O
morphine O
, O
codine B
and O
fentanyl O
was O
studied O
in O
rats O
. O

Codeine B
catalepsy O
was O
increased O
by O
clonidine O
and O
decreased O
by O
naphazoline B
and O
xylometazoline B
. O

The O
brain O
concentration O
of O
NA O
was O
not O
changed O
by O
morphine O
and O
fentanyl O
, O
but O
one O
of O
the O
doses O
of O
codeine B
( O
45 O
mg O
/ O
kg O
) O
slightly O
enhanced O
it O
. O

It O
is O
suggested O
that O
in O
rats O
the O
brain O
NA O
plays O
a O
less O
important O
function O
than O
the O
other O
monoamines B
in O
the O
behavioural O
activity O
of O
potent O
analgesics O
. O

Flurothyl O
seizure O
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium B
glutamate I
( O
MSG B
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure O
testing O
. O

Monosodium B
glutamate I
( O
MSG B
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions O
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

These O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
MSG B
produced O
permanent O
alterations O
in O
seizure O
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

A O
flurothyl O
ether B
seizure O
screening O
technique O
was O
used O
to O
evaluate O
seizure O
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
MSG B
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

MSG B
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure O
threshold O
. O

A O
naloxone O
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure O
thresholds O
of O
either O
control O
of O
MSG B
- O
treated O
mice O
. O

Flurothyl O
ether B
produced O
hypothermia O
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia O
to O
seizure O
induction O
was O
unclear O
. O

In O
the O
first O
, O
cobalt B
cardiomyopathy O
was O
induced O
in O
eight O
dogs O
; O
VIP O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
SD O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Improvement O
by O
denopamine B
( O
TA B
- I
064 I
) O
of O
pentobarbital O
- O
induced O
cardiac O
failure O
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

The O
efficacy O
of O
denopamine B
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac O
failure O
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

Cardiac O
functions O
depressed O
by O
pentobarbital O
( O
118 O
+ O
/ O
- O
28 O
mg O
; O
mean O
value O
+ O
/ O
- O
SD O
) O
such O
that O
cardiac O
output O
and O
maximum O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
LV O
dP O
/ O
dt O
max O
) O
had O
been O
reduced O
by O
about O
35 O
% O
and O
26 O
% O
of O
the O
respective O
controls O
were O
improved O
by O
denopamine B
( O
10 O
- O
300 O
micrograms O
) O
in O
a O
dose O
- O
dependent O
manner O
. O

With O
100 O
micrograms O
denopamine B
, O
almost O
complete O
restoration O
of O
cardiac O
performance O
was O
attained O
, O
associated O
with O
a O
slight O
increase O
in O
heart O
rate O
. O

No O
arrhythmias O
were O
induced O
by O
these O
doses O
of O
denopamine B
. O

The O
results O
warrant O
clinical O
trials O
of O
denopamine B
in O
the O
treatment O
of O
cardiac O
failure O
. O

Clonazepam B
monotherapy O
for O
epilepsy O
in O
childhood O
. O

Sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy O
than O
infantile O
spasms O
were O
treated O
with O
clonazepam B
. O

Postmarketing O
study O
of O
timolol O
- O
hydrochlorothiazide B
antihypertensive O
therapy O
. O

A O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol O
maleate O
and O
25 O
mg O
of O
hydrochlorothiazide B
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive O
patients O
. O

Mean O
systolic O
blood O
pressure O
decreased O
25 O
mmHg O
and O
mean O
diastolic O
blood O
pressure O
declined O
15 O
mmHg O
after O
one O
month O
of O
timolol O
- O
hydrochlorothiazide B
therapy O
( O
P O
less O
than O
0 O
. O
01 O
, O
both O
comparisons O
) O
. O

Salicylate B
nephropathy O
in O
the O
Gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

The O
homozygous O
Gunn O
rats O
have O
unconjugated O
hyperbilirubinemia O
due O
to O
the O
absence O
of O
glucuronyl B
transferase O
, O
leading O
to O
marked O
bilirubin O
deposition O
in O
renal O
medulla O
and O
papilla O
. O

PGE2 B
synthesis O
was O
significantly O
higher O
in O
outer O
medulla O
, O
but O
not O
cortex O
or O
inner O
medulla O
, O
of O
jj O
( O
38 O
+ O
/ O
- O
6 O
ng O
/ O
mg O
prot O
) O
than O
jJ O
rats O
( O
15 O
+ O
/ O
- O
3 O
) O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

Aspirin O
treatment O
reduced O
PGE2 B
synthesis O
in O
all O
regions O
, O
but O
outer O
medullary O
PGE2 B
remained O
higher O
in O
jj O
( O
18 O
+ O
/ O
- O
3 O
) O
than O
jJ O
rats O
( O
9 O
+ O
/ O
- O
2 O
) O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

Experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy O
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic B
- O
induced O
catalepsy O
. O

These O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy O
that O
is O
produced O
by O
neuroleptics B
such O
as O
haloperidol O
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

Cardiovascular O
dysfunction O
and O
hypersensitivity O
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium B
chloride I
ingestion O
. O

Barium B
- O
supplemented O
Long O
- O
Evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension O
that O
was O
evident O
after O
1 O
month O
of O
barium B
( O
100 O
micrograms O
/ O
ml O
mineral O
fortified O
water O
) O
treatment O
. O

Analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium B
- O
induced O
disturbances O
within O
the O
cardiovascular O
system O
. O

The O
most O
distinctive O
aspect O
of O
the O
barium B
effect O
was O
a O
demonstrated O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

Under O
barbiturate B
anesthesia O
, O
virtually O
all O
of O
the O
myocardial O
contractile O
indices O
were O
depressed O
significantly O
in O
barium B
- O
exposed O
rats O
relative O
to O
the O
corresponding O
control O
- O
fed O
rats O
. O

The O
lack O
of O
a O
similar O
response O
to O
ketamine O
and O
xylazine B
anesthesia O
revealed O
that O
the O
cardiovascular O
actions O
of O
sodium O
pentobarbital O
in O
barium B
- O
treated O
rats O
were O
linked O
specifically O
to O
this O
anesthetic O
, O
and O
were O
not O
representative O
of O
a O
generalized O
anesthetic O
response O
. O

Other O
myocardial O
pathophysiologic O
and O
metabolic O
changes O
induced O
by O
barium B
were O
manifest O
, O
irrespective O
of O
the O
anesthetic O
employed O
. O

The O
contractile O
element O
shortening O
velocity O
of O
the O
cardiac O
muscle O
fibers O
was O
significantly O
slower O
in O
both O
groups O
of O
barium B
- O
treated O
rats O
relative O
to O
the O
control O
groups O
, O
irrespective O
of O
the O
anesthetic O
regimen O
. O

Similarly O
, O
significant O
disturbances O
in O
myocardial O
energy O
metabolism O
were O
detected O
in O
the O
barium B
- O
exposed O
rats O
which O
were O
consistent O
with O
the O
reduced O
contractile O
element O
shortening O
velocity O
. O

In O
addition O
, O
the O
excitability O
of O
the O
cardiac O
conduction O
system O
was O
depressed O
preferentially O
in O
the O
atrioventricular O
nodal O
region O
of O
hearts O
from O
barium B
- O
exposed O
rats O
. O

Overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic O
disturbances O
, O
and O
the O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic O
disorder O
induced O
by O
chronic O
barium B
exposure O
. O

These O
experimental O
findings O
represent O
the O
first O
indication O
that O
life O
- O
long O
barium B
ingestion O
may O
have O
significant O
adverse O
effects O
on O
the O
mammalian O
cardiovascular O
system O
. O

After O
4 O
weeks O
the O
PAN O
rats O
were O
severely O
proteinuric O
( O
190 O
+ O
/ O
- O
80 O
mg O
/ O
24 O
hr O
) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon B
( O
CC O
) O
intravenously O
. O

The O
binding O
sites O
from O
seizure O
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol B
, O
trypsin O
or O
heat O
. O

The O
role O
of O
p B
- I
aminophenol I
in O
acetaminophen O
- O
induced O
nephrotoxicity O
: O
effect O
of O
bis B
( I
p I
- I
nitrophenyl I
) I
phosphate I
on O
acetaminophen O
and O
p B
- I
aminophenol I
nephrotoxicity O
and O
metabolism O
in O
Fischer O
344 O
rats O
. O

Recently O
, O
p B
- I
aminophenol I
( O
PAP B
) O
, O
a O
known O
potent O
nephrotoxicant O
, O
was O
identified O
as O
a O
metabolite O
of O
APAP O
in O
F344 O
rats O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PAP B
formation O
is O
a O
requisite O
step O
in O
APAP O
- O
induced O
nephrotoxicity O
. O

Therefore O
, O
the O
effect O
of O
bis B
( I
p I
- I
nitrophenyl I
) I
phosphate I
( O
BNPP B
) O
, O
an O
acylamidase O
inhibitor O
, O
on O
APAP O
and O
PAP B
nephrotoxicity O
and O
metabolism O
was O
determined O
. O

BNPP B
( O
1 O
to O
8 O
mM O
) O
reduced O
APAP O
deacetylation O
and O
covalent O
binding O
in O
F344 O
renal O
cortical O
homogenates O
in O
a O
concentration O
- O
dependent O
manner O
. O

Pretreatment O
of O
animals O
with O
BNPP B
prior O
to O
APAP O
or O
PAP B
administration O
resulted O
in O
marked O
reduction O
of O
APAP O
( O
900 O
mg O
/ O
kg O
) O
nephrotoxicity O
but O
not O
PAP B
nephrotoxicity O
. O

Rather O
, O
BNPP B
pretreatment O
reduced O
the O
fraction O
of O
APAP O
excreted O
as O
PAP B
by O
64 O
and O
75 O
% O
after O
APAP O
doses O
of O
750 O
and O
900 O
mg O
/ O
kg O
. O

BNPP B
did O
not O
alter O
the O
excretion O
of O
APAP O
or O
any O
of O
its O
non O
- O
deacetylated O
metabolites O
nor O
did O
BNPP B
alter O
excretion O
of O
PAP B
or O
its O
metabolites O
after O
PAP B
doses O
of O
150 O
and O
300 O
mg O
/ O
kg O
. O

Therefore O
, O
the O
BNPP B
- O
induced O
reduction O
in O
APAP O
- O
induced O
nephrotoxicity O
appears O
to O
be O
due O
to O
inhibition O
of O
APAP O
deacetylation O
. O

It O
is O
concluded O
that O
PAP B
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
APAP O
- O
induced O
renal O
tubular O
necrosis O
. O

On O
the O
antiarrhythmic O
activity O
of O
one O
N O
- O
substituted O
piperazine B
derivative O
of O
trans B
- I
2 I
- I
amino I
- I
3 I
- I
hydroxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroanaphthalene I
. O

The O
antiarrhythmic O
activity O
of O
the O
compound O
N B
- I
( I
trans I
- I
3 I
- I
hydroxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
- I
2 I
- I
naphthyl I
) I
- I
N I
- I
( I
3 I
- I
oxo I
- I
3 I
- I
phenyl I
- I
2 I
- I
methylpropyl I
) I
- I
piperazine I
hydrochloride I
, O
referred O
to O
as O
P11 B
, O
is O
studied O
on O
anaesthesized O
cats O
and O
Wistar O
albino O
rats O
, O
as O
well O
as O
on O
non O
- O
anaesthesized O
rabbits O
. O

Four O
types O
of O
experimental O
arrhythmia O
are O
used O
- O
- O
with O
BaCl2 B
, O
with O
chloroform B
- O
adrenaline O
, O
with O
strophantine O
G O
and O
with O
aconitine B
. O

The O
compound O
P11 B
is O
introduced O
in O
doses O
of O
0 O
. O
25 O
and O
0 O
. O
50 O
mg O
/ O
kg O
intravenously O
and O
10 O
mg O
/ O
kg O
orally O
. O

The O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia O
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia O
induced O
by O
chloroform B
- O
adrenaline O
( O
in O
90 O
per O
cent O
) O
and O
with O
BaCl2 B
( O
in O
84 O
per O
cent O
) O
. O

Recurrent O
subarachnoid O
hemorrhage O
associated O
with O
aminocaproic B
acid I
therapy O
and O
acute O
renal O
artery O
thrombosis O
. O

Epsilon B
aminocaproic I
acid I
( O
EACA B
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid O
hemorrhage O
( O
SAH O
) O
. O

Although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic O
complications O
of O
EACA B
therapy O
. O

These O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial O
vascular O
thrombosis O
in O
patients O
with O
SAH O
, O
arteriolar O
and O
capillary O
fibrin O
thrombi O
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
EACA B
, O
or O
other O
thromboembolic O
phenomena O
. O

Since O
intravascular O
fibrin O
thrombi O
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
EACA B
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi O
in O
patients O
with O
disseminated O
intravascular O
coagulation O
or O
other O
" O
consumption O
coagulopathies O
. O
" O
This O
report O
describes O
subtotal O
infarction O
of O
the O
kidney O
due O
to O
thrombosis O
of O
a O
normal O
renal O
artery O
. O

This O
occlusion O
occurred O
after O
EACA B
therapy O
in O
a O
patient O
with O
SAH O
and O
histopathological O
documentation O
of O
recurrent O
SAH O
. O

Central O
excitatory O
actions O
of O
flurazepam B
. O

Toxic O
actions O
of O
flurazepam B
( O
FZP B
) O
were O
studied O
in O
cats O
, O
mice O
and O
rats O
. O

Signs O
of O
FZP B
toxocity O
in O
cats O
included O
excessive O
salivation O
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle O
tremors O
and O
convulsions O
. O

An O
interaction O
between O
FZP B
and O
pentylenetetrazol O
( O
PTZ O
) O
was O
shown O
by O
pretreating O
mice O
with O
FZP B
before O
PTZ O
challenge O
. O

As O
a O
function O
of O
dose O
, O
FZP B
first O
protected O
against O
convulsions O
and O
death O
. O

These O
doses O
of O
FZP B
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions O
. O

These O
results O
may O
be O
relevant O
to O
the O
use O
of O
FZP B
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy O
or O
sedative O
- O
hypnotic O
drug O
withdrawal O
. O

Total O
intravenous O
anesthesia O
with O
etomidate B
. O

An O
investigation O
was O
undertaken O
to O
determine O
the O
dosage O
of O
etomidate B
required O
to O
maintain O
sleep O
in O
adults O
undergoing O
surgery O
under O
regional O
local O
anesthesia O
. O

Premedication O
of O
diazepam O
10 O
mg O
and O
atropine O
0 O
. O
5 O
mg O
was O
given O
, O
and O
sleep O
was O
induced O
and O
maintained O
by O
intermittent O
intravenous O
injections O
of O
etomidate B
0 O
. O
1 O
/ O
mg O
/ O
kg O
, O
given O
whenever O
the O
patient O
would O
open O
his O
eyes O
on O
request O
. O

A O
mean O
overall O
dose O
of O
etomidate B
17 O
. O
4 O
microgram O
/ O
kg O
/ O
min O
. O
was O
required O
to O
maintain O
sleep O
, O
but O
great O
individual O
variation O
occurred O
, O
with O
older O
patients O
requiring O
less O
drug O
. O

It O
is O
considered O
unlikely O
that O
etomidate B
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia O
after O
prolonged O
administration O
. O

We O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol B
( O
cardioselective O
) O
, O
40 O
mg O
propranolol O
( O
nonselective O
) O
, O
and O
placebo O
on O
both O
exercise O
- O
and O
isoproterenol O
- O
induced O
tachycardia O
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

Maximal O
exercise O
heart O
rate O
was O
reduced O
from O
187 O
+ O
/ O
- O
4 O
( O
SEM O
) O
after O
placebo O
to O
146 O
+ O
/ O
- O
7 O
bpm O
after O
atenolol B
and O
138 O
+ O
/ O
- O
6 O
bpm O
after O
propranolol O
, O
but O
there O
were O
no O
differences O
between O
the O
drugs O
. O

Isoproterenol O
sensitivity O
was O
determined O
as O
the O
intravenous O
dose O
that O
increased O
heart O
rate O
by O
25 O
bpm O
( O
CD25 O
) O
and O
this O
was O
increased O
from O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
after O
placebo O
to O
38 O
. O
9 O
+ O
/ O
- O
8 O
. O
3 O
micrograms O
after O
propranolol O
and O
8 O
. O
3 O
+ O
/ O
- O
1 O
. O
7 O
micrograms O
after O
atenolol B
. O

After O
atropine O
the O
CD25 O
was O
unchanged O
after O
placebo O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
) O
and O
atenolol B
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
3 O
micrograms O
) O
; O
it O
was O
reduced O
after O
propranolol O
( O
24 O
. O
8 O
+ O
/ O
- O
5 O
. O
0 O
micrograms O
) O
, O
but O
remained O
different O
from O
atenolol B
. O

The O
treatment O
schedule O
consisted O
of O
conjugated B
estrogens I
( O
Premarin B
) O
1 O
. O
25 O
mg O
/ O
day O
for O
21 O
days O
and O
Medroxyprogesterone B
acetate I
10 O
mg O
/ O
day O
for O
10 O
days O
in O
each O
month O
. O

Structure O
- O
activity O
and O
dose O
- O
effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin O
- O
induced O
seizures O
by O
cholecystokinin B
, O
fragments O
and O
analogues O
of O
cholecystokinin B
in O
mice O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B
octapeptide I
sulphate O
ester O
( O
CCK B
- I
8 I
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B
octapeptide I
( O
CCK B
- I
8 I
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin O
in O
mice O
. O

The O
analogues O
CCK B
- I
8 I
- O
SE O
and O
CCK B
- I
8 I
- O
NS O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein B
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
CCK B
- I
8 I
- O
NS O
. O

Experiments O
with O
analogues O
and O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
demonstrated O
that O
the O
effectiveness O
of O
the O
beta O
- O
alanyl O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
were O
enhanced O
and O
that O
they O
were O
equipotent O
with O
CCK B
- I
8 I
- O
SE O
. O

Of O
the O
CCK O
- O
2 O
- O
8 O
analogues O
, O
Ser O
( O
SO3H O
) O
7 O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Thr O
( O
SO3H O
) O
7 O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Hyp O
( O
SO3H O
) O
- O
Ac O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
were O
slightly O
more O
active O
than O
CCK B
- I
8 I
- O
SE O
. O

Administration O
of O
DDAVP B
which O
has O
antidiuretic O
action O
but O
minimal O
vasopressor O
effect O
failed O
to O
increase O
blood O
pressure O
to O
the O
levels O
observed O
after O
administration O
of O
AVP O
. O

Atrial O
thrombosis O
involving O
the O
heart O
of O
F O
- O
344 O
rats O
ingesting O
quinacrine B
hydrochloride I
. O

Quinacrine B
hydrochloride I
is O
toxic O
for O
the O
heart O
of O
F O
- O
344 O
rats O
. O

Rats O
treated O
with O
500 O
ppm O
quinacrine B
hydrochloride I
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial O
thrombosis O
. O

Seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine B
hydrochloride I
and O
1 O
, O
000 O
ppm O
sodium B
nitrite I
simultaneously O
in O
the O
diet O
had O
thrombosis O
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial O
thrombosis O
. O

Sodium B
nitrite I
in O
combination O
with O
quinacrine B
hydrochloride I
appeared O
to O
have O
no O
additional O
effect O
. O

Edrophonium B
10 O
mg O
, O
given O
74 O
min O
after O
succinylcholine O
, O
when O
train O
- O
of O
- O
four O
stimulation O
was O
characteristic O
of O
phase O
II O
block O
, O
produced O
partial O
antagonism O
which O
was O
not O
sustained O
. O

Repeated O
doses O
of O
edrophonium B
to O
70 O
mg O
and O
neostigmine O
to O
2 O
. O
5 O
mg O
did O
not O
antagonize O
or O
augment O
the O
block O
. O

Effect O
of O
doxorubicin O
on O
[ B
omega I
- I
I I
- I
131 I
] I
heptadecanoic I
acid I
myocardial O
scintigraphy O
and O
echocardiography O
in O
dogs O
. O

The O
effects O
of O
serial O
treatment O
with O
doxorubicin O
on O
dynamic O
myocardial O
scintigraphy O
with O
[ B
omega I
- I
I I
- I
131 I
] I
heptadecanoic I
acid I
( O
I B
- I
131 I
HA I
) O
, O
and O
on O
global O
left O
- O
ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

A O
significant O
increase O
in O
the O
myocardial O
t1 O
/ O
2 O
of O
the O
I B
- I
131 I
HA I
was O
observed O
only O
at O
a O
higher O
cumulative O
dose O
, O
10 O
mg O
/ O
kg O
. O

Our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
I B
- I
131 I
HA I
are O
not O
the O
initiating O
factor O
in O
doxorubicin O
cardiotoxicity O
. O

Male O
rats O
received O
the O
noradrenaline O
neurotoxin O
DSP4 B
( O
50 O
mg O
/ O
kg O
) O
7 O
days O
prior O
to O
injection O
of O
D O
- O
amphetamine O
( O
10 O
or O
40 O
mumol O
/ O
kg O
i O
. O
p O
. O
) O
. O

The O
hyperactivity O
induced O
by O
D O
- O
amphetamine O
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
DSP4 B
pretreatment O
. O

However O
, O
the O
increased O
rearings O
and O
the O
amphetamine O
- O
induced O
stereotypies O
were O
not O
blocked O
by O
pretreatment O
with O
DSP4 B
. O

The O
reduction O
of O
amphetamine O
hyperactivity O
induced O
by O
DSP4 B
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline O
- O
uptake O
blocking O
agent O
, O
desipramine O
, O
which O
prevents O
the O
neurotoxic O
action O
of O
DSP4 B
. O

These O
results O
indicate O
that O
behavioral O
toxicity O
testing O
of O
alkylxanthines B
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

Treatment O
of O
ovarian O
cancer O
with O
a O
combination O
of O
cis O
- O
platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine B
. O

During O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian O
cancer O
were O
treated O
with O
a O
combination O
of O
cisplatinum O
( O
CPDD B
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin O
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide O
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine B
( O
HMM B
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

14 O
of O
the O
38 O
patients O
were O
previously O
treated O
with O
chemotherapy O
, O
1 O
with O
radiation O
, O
6 O
with O
both O
chemotherapy O
and O
radiation O
, O
and O
17 O
did O
not O
have O
any O
treatment O
before O
CPDD B
combination O
. O

Gastrointestinal O
side O
effects O
from O
CPDD B
were O
universal O
. O

HMM B
gastrointestinal O
toxicity O
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

The O
actions O
of O
fenoterol B
- I
hydrobromide I
, O
ritodrin O
- O
HCl O
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double O
- O
blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

After O
the O
end O
of O
fenoterol B
- I
hydrobromide I
infusion O
, O
tremor O
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin O
- O
HCl O
infusion O
. O

Hepatitis O
and O
renal O
tubular O
acidosis O
after O
anesthesia O
with O
methoxyflurane B
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute O
cholecystitis O
under O
methoxyflurane B
anesthesia O
developed O
postoperatively O
a O
hepatic O
insufficiency O
syndrome O
and O
renal O
tubular O
acidosis O
. O

Comparative O
study O
: O
Endografine B
( O
diatrizoate B
) O
, O
Vasurix B
polyvidone I
( O
acetrizoate B
) O
, O
Dimer B
- I
X I
( O
iocarmate B
) O
and O
Hexabrix B
( O
ioxaglate B
) O
in O
hysterosalpingography O
. O

Side O
effects O
of O
hysterosalpingography O
with O
Dimer B
- I
X I
, O
Hexabrix B
, O
Vasurix B
polyvidone I
and O
Endografine B
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

The O
Dimer B
- I
X I
group O
had O
a O
higher O
incidence O
of O
nausea O
and O
dizziness O
. O

The O
Endografine B
group O
had O
a O
higher O
incidence O
of O
abdominal O
pain O
. O

Hexabrix B
and O
Vasurix B
polyvidone I
are O
considered O
the O
best O
contrast O
media O
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity O
Hexabrix B
should O
be O
preferred O
. O

The O
abolition O
of O
muscle O
fasciculations O
( O
by O
0 O
. O
075mg O
/ O
kg O
dose O
of O
Fazadinium B
) O
did O
not O
influence O
the O
occurrence O
of O
scoline O
pain O
. O

Neither O
the O
type O
of O
induction O
agent O
( O
Althesin B
or O
Thiopentone O
) O
nor O
the O
salt O
preparation O
of O
suxamethonium O
used O
( O
chloride B
or O
bromide B
) O
, O
affected O
the O
incidence O
of O
scoline O
pain O
. O

Two O
well O
- O
documented O
cases O
of O
bilateral O
retinal O
artery O
and O
choriocapillaris O
occlusions O
with O
blindness O
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone B
acetate I
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

An O
11 O
- O
year O
- O
old O
boy O
was O
given O
halothane O
, O
nitrous O
oxide O
and O
oxygen O
, O
pancuronium B
0 O
. O
4 O
mg O
and O
suxamethonium O
100 O
mg O
for O
induction O
of O
anaesthesia O
. O

He O
was O
found O
to O
have O
atypical O
plasma O
cholinesterase O
with O
a O
dibucaine B
number O
of O
12 O
, O
indicating O
homozygocity O
. O

The O
case O
shows O
that O
prolonged O
jaw O
rigidity O
and O
myalgia O
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium B
. O

Etomidate B
: O
a O
foreshortened O
clinical O
trial O
. O

A O
clinical O
evaluation O
of O
etomidate B
for O
outpatient O
cystoscopy O
was O
embarked O
upon O
. O

Unpremedicated O
patients O
were O
given O
fentanyl O
1 O
microgram O
/ O
kg O
followed O
by O
etomidate B
0 O
. O
3 O
mg O
/ O
kg O
. O

Anaesthesia O
was O
maintained O
with O
intermittent O
etomidate B
in O
2 O
- O
4 O
mg O
doses O
. O

A O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim O
- O
sulfamethoxazole O
, O
trimethoprim B
, O
and O
cephalexin B
for O
uncommon O
serious O
drug O
toxicity O
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim O
- O
sulfamethoxazole O
( O
TMP O
- O
SMZ O
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim B
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin B
, O
to O
estimate O
the O
risk O
of O
serious O
liver O
, O
blood O
, O
skin O
, O
and O
renal O
disorders O
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

The O
risk O
of O
clinically O
important O
idiopathic O
liver O
disease O
was O
similar O
for O
persons O
prescribed O
TMP O
- O
SMZ O
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim B
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

The O
risk O
for O
those O
prescribed O
cephalexin B
was O
somewhat O
lower O
( O
2 O
. O
0 O
/ O
100 O
, O
000 O
) O
. O

The O
one O
case O
of O
toxic O
epidermal O
necrolysis O
occurred O
in O
a O
patient O
who O
took O
cephalexin B
. O

The O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic O
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
Dianabol B
, O
CIBA B
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic O
by O
a O
diet O
deficient O
in O
vitamin O
E O
. O

The O
dose O
- O
dependent O
effect O
of O
misoprostol B
on O
indomethacin O
- O
induced O
renal O
dysfunction O
in O
well O
compensated O
cirrhosis O
. O

Misoprostol B
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin O
- O
induced O
renal O
dysfunction O
in O
well O
compensated O
cirrhotic O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
if O
the O
prophylactic O
value O
of O
misoprostol B
was O
dose O
- O
dependent O
. O

Parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic O
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol B
. O

These O
results O
suggest O
that O
the O
renal O
protective O
effects O
of O
misoprostol B
is O
dose O
- O
dependent O
. O

However O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol B
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis O
. O

Myoclonus O
associated O
with O
lorazepam B
therapy O
in O
very O
- O
low O
- O
birth O
- O
weight O
infants O
. O

Lorazepam B
is O
being O
used O
with O
increasing O
frequency O
as O
a O
sedative O
in O
the O
newborn O
and O
the O
young O
infant O
. O

Concern O
has O
been O
raised O
with O
regard O
to O
the O
safety O
of O
lorazepam B
in O
this O
age O
group O
, O
especially O
in O
very O
- O
low O
- O
birth O
- O
weight O
( O
VLBW O
; O
< O
1 O
, O
500 O
g O
) O
infants O
. O

Three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1 O
, O
500 O
g O
, O
experienced O
myoclonus O
following O
the O
intravenous O
administration O
of O
lorazepam B
. O

Injectable O
lorazepam B
should O
be O
used O
with O
caution O
in O
VLBW O
infants O
. O

Efficacy O
and O
safety O
of O
granisetron B
, O
a O
selective O
5 O
- O
hydroxytryptamine O
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea O
and O
vomiting O
induced O
by O
high O
- O
dose O
cisplatin O
. O

PURPOSE O
: O
To O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron B
( O
Kytril B
; O
SmithKline O
Beecham O
Pharmaceuticals O
, O
Philadelphia O
, O
PA O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
IV O
) O
dose O
for O
prophylaxis O
of O
cisplatin O
- O
induced O
nausea O
and O
vomiting O
. O

PATIENTS O
AND O
METHODS O
: O
One O
hundred O
eighty O
- O
four O
chemotherapy O
- O
naive O
patients O
receiving O
high O
- O
dose O
cisplatin O
( O
81 O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron B
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

RESULTS O
: O
After O
granisetron B
doses O
of O
5 O
, O
10 O
, O
20 O
, O
and O
40 O
micrograms O
/ O
kg O
, O
a O
major O
response O
( O
< O
or O
= O
two O
vomiting O
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23 O
% O
, O
57 O
% O
, O
58 O
% O
, O
and O
60 O
% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting O
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18 O
% O
, O
41 O
% O
, O
40 O
% O
, O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

As O
granisetron B
dose O
increased O
, O
appetite O
return O
increased O
( O
P O
= O
. O
040 O
) O
. O

CONCLUSION O
: O
A O
single O
10 O
- O
, O
20 O
- O
, O
or O
40 O
- O
micrograms O
/ O
kg O
dose O
of O
granisetron B
was O
effective O
in O
controlling O
vomiting O
in O
57 O
% O
to O
60 O
% O
of O
patients O
who O
received O
cisplatin O
at O
doses O
greater O
than O
81 O
mg O
/ O
m2 O
and O
totally O
prevented O
vomiting O
in O
40 O
% O
to O
47 O
% O
of O
patients O
. O

Granisetron B
was O
well O
tolerated O
at O
all O
doses O
. O

Pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine B
calcium I
antagonist O
, O
S B
- I
312 I
- I
d I
. O

S B
- I
312 I
, O
S B
- I
312 I
- I
d I
, O
but O
not O
S B
- I
312 I
- I
l I
, O
L O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic O
tonic O
convulsions O
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine B
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

Although O
moderate O
anticonvulsant O
effects O
of O
S B
- I
312 I
- I
d I
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions O
induced O
by O
pentylenetetrazole O
( O
85 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
or O
bemegride B
( O
40 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
no O
effects O
were O
observed O
in O
convulsions O
induced O
by O
N O
- O
methyl O
- O
D O
- O
aspartate O
, O
picrotoxin O
, O
or O
electroshock O
in O
Slc O
: O
ddY O
mice O
. O

S B
- I
312 I
- I
d I
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy O
. O

A O
significant O
reduction O
in O
urinary O
guanosine B
3 I
' I
, I
5 I
' I
- I
cyclic I
monophosphate I
( O
cGMP B
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
GM O
- O
mediated O
nephropathy O
. O

Superoxide O
dismutase O
( O
SOD O
) O
or O
dimethylthiourea B
( O
DMTU B
) O
significantly O
lessened O
the O
GM O
- O
induced O
decrement O
in O
CIn O
. O

The O
SOD O
- O
induced O
increase O
in O
glomerular O
filtration O
rate O
was O
associated O
with O
a O
marked O
improvement O
in O
RBF O
, O
an O
increase O
in O
urinary O
cGMP B
excretion O
, O
and O
a O
decrease O
in O
renal O
renin O
and O
endothelin O
- O
1 O
content O
. O

In O
contrast O
, O
DMTU B
significantly O
reduced O
the O
tubular O
damage O
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

Neither O
SOD O
nor O
DMTU B
affected O
the O
renal O
cortical O
GM O
content O
in O
GM O
- O
treated O
rats O
. O

These O
results O
suggest O
that O
1 O
) O
both O
SOD O
and O
DMTU B
have O
protective O
effects O
on O
GM O
- O
mediated O
nephropathy O
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
SOD O
and O
DMTU B
, O
and O
3 O
) O
superoxide O
anions O
play O
a O
critical O
role O
in O
GM O
- O
induced O
renal O
vasoconstriction O
. O

Cytomegalovirus O
infections O
were O
treated O
successfully O
with O
ganciclovir B
in O
11 O
patients O
. O

In O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic O
delirium O
connected O
with O
a O
high O
serum O
total O
fluoxetine O
( O
fluoxetine O
plus O
desmethylfluoxetine B
) O
concentration O
. O

Pulmonary O
edema O
and O
shock O
after O
high O
- O
dose O
aracytine B
- I
C I
for O
lymphoma O
; O
possible O
role O
of O
TNF O
- O
alpha O
and O
PAF O
. O

Four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
Ara B
- I
C I
for O
lymphomas O
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

Sequential O
biological O
assays O
of O
IL O
- O
1 O
, O
IL O
- O
2 O
, O
TNF O
and O
PAF O
were O
performed O
during O
Ara B
- I
C I
infusion O
to O
ten O
patients O
, O
including O
the O
four O
who O
developed O
the O
syndrome O
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock O
and O
adult O
respiratory O
distress O
syndrome O
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara B
- I
C I
may O
be O
associated O
with O
cytokine O
release O
. O

Protective O
effect O
of O
clentiazem B
against O
epinephrine O
- O
induced O
cardiac O
injury O
in O
rats O
. O

We O
investigated O
the O
effects O
of O
clentiazem B
, O
a O
1 B
, I
5 I
- I
benzothiazepine I
calcium O
antagonist O
, O
on O
epinephrine O
- O
induced O
cardiomyopathy O
in O
rats O
. O

Treatment O
with O
clentiazem B
prevented O
epinephrine O
- O
induced O
death O
( O
P O
< O
. O
05 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic O
lesions O
and O
fibrosis O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

Left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol O
were O
reduced O
compared O
to O
controls O
in O
groups O
treated O
with O
clentiazem B
alone O
, O
but O
combined O
with O
epinephrine O
, O
clentiazem B
restored O
left O
atrial O
responses O
and O
enhanced O
left O
ventricular O
papillary O
responses O
to O
isoproterenol O
. O

On O
the O
other O
hand O
clentiazem B
did O
not O
prevent O
epinephrine O
- O
induced O
down O
- O
regulation O
of O
alpha O
and O
beta O
adrenoceptors O
. O

Interestingly O
, O
clentiazem B
, O
infused O
alone O
, O
resulted O
in O
decreased O
adrenergic O
receptor O
densities O
in O
the O
left O
ventricle O
. O

Clentiazem B
also O
did O
not O
prevent O
the O
enhanced O
responses O
to O
calcium O
seen O
in O
the O
epinephrine O
- O
treated O
animals O
, O
although O
the O
high O
dose O
of O
clentiazem B
partially O
attenuated O
the O
maximal O
response O
to O
calcium O
compared O
to O
epinephrine O
- O
treated O
animals O
. O

In O
conclusion O
, O
clentiazem B
attenuated O
epinephrine O
- O
induced O
cardiac O
injury O
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

With O
this O
model O
we O
investigated O
the O
effect O
of O
chronic O
doxorubicin O
administration O
on O
the O
ECG O
of O
freely O
moving O
BALB O
/ O
c O
mice O
and O
the O
efficacy O
of O
ICRF B
- I
187 I
as O
a O
protective O
agent O
. O

As O
this O
schedule O
exerted O
more O
toxicity O
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
ICRF B
- I
187 I
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity O
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin O
given O
i O
. O
v O
. O
plus O
2 O
weeks O
of O
observation O
) O
. O

On O
this O
schedule O
, O
the O
animals O
' O
hearts O
appeared O
normal O
after O
sacrifice O
and O
ICRF B
- I
187 I
( O
50 O
mg O
/ O
kg O
given O
i O
. O
p O
. O
1 O
h O
before O
doxorubicin O
) O
provided O
almost O
full O
protection O
. O

These O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin O
- O
induced O
cardiotoxicity O
as O
demonstrated O
by O
the O
protection O
provided O
by O
ICRF B
- I
187 I
. O

Milk O
- O
alkali O
syndrome O
induced O
by O
1 B
, I
25 I
( I
OH I
) I
2D I
in O
a O
patient O
with O
hypoparathyroidism O
. O

Milk O
- O
alkali O
syndrome O
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic O
ulcer O
disease O
with O
large O
amounts O
of O
calcium O
and O
alkali B
. O

Although O
with O
current O
ulcer O
therapy O
( O
H O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate B
) O
, O
the O
frequency O
of O
milk O
- O
alkali O
syndrome O
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia O
, O
alkalosis O
, O
and O
renal O
impairment O
remains O
the O
hallmark O
of O
the O
syndrome O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium B
carbonate I
and O
calcitriol B
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk O
- O
alkali O
syndrome O
. O

The O
patient O
was O
successfully O
treated O
with O
intravenous O
pamidronate B
on O
his O
first O
admission O
and O
with O
hydrocortisone O
on O
the O
second O
. O

This O
illustrates O
intravenous O
pamidronate B
as O
a O
valuable O
therapeutic O
tool O
when O
milk O
- O
alkali O
syndrome O
presents O
as O
hypercalcemic O
emergency O
. O

Famotidine B
- O
associated O
delirium O
. O

Famotidine B
is O
a O
histamine O
H2 O
- O
receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers O
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

Although O
all O
of O
the O
currently O
available O
H2 O
- O
receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium O
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine B
. O

The O
authors O
report O
on O
six O
cases O
of O
famotidine B
- O
associated O
delirium O
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine B
. O

The O
pharmacokinetics O
of O
famotidine B
are O
reviewed O
, O
with O
no O
change O
in O
its O
metabolism O
in O
the O
elderly O
population O
seen O
. O

The O
implications O
of O
using O
famotidine B
in O
elderly O
persons O
are O
discussed O
. O

Chemical O
cystitis O
was O
induced O
by O
cyclophosphamide O
( O
CYP O
) O
which O
is O
metabolized O
to O
acrolein B
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

Effects O
of O
a O
new O
calcium O
antagonist O
, O
CD B
- I
832 I
, O
on O
isoproterenol O
- O
induced O
myocardial O
ischemia O
in O
dogs O
with O
partial O
coronary O
stenosis O
. O

Effects O
of O
CD B
- I
832 I
on O
isoproterenol O
( O
ISO O
) O
- O
induced O
myocardial O
ischemia O
were O
studied O
in O
dogs O
with O
partial O
coronary O
stenosis O
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

After O
the O
control O
ISO O
infusion O
with O
stenosis O
was O
performed O
, O
equihypotensive O
doses O
of O
CD B
- I
832 I
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine O
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem O
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
ISO O
infusion O
. O

Both O
CD B
- I
832 I
and O
diltiazem O
, O
but O
not O
nifedipine O
, O
significantly O
reduced O
the O
increase O
in O
heart O
rate O
induced O
by O
ISO O
infusion O
. O

In O
contrast O
to O
nifedipine O
, O
CD B
- I
832 I
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
01 O
) O
and O
ST O
- O
segment O
elevation O
from O
5 O
. O
6 O
+ O
/ O
- O
1 O
. O
0 O
mV O
to O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
mV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO O
infusion O
with O
stenosis O
. O

These O
data O
show O
that O
CD B
- I
832 I
improves O
myocardial O
ischemia O
during O
ISO O
infusion O
with O
stenosis O
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD B
- I
832 I
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD B
- I
832 I
. O

Nefiracetam B
( O
DM B
- I
9384 I
) O
reverses O
apomorphine O
- O
induced O
amnesia O
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

Nefiracetam B
is O
a O
novel O
pyrrolidone B
derivative O
which O
attenuates O
scopolamine O
- O
induced O
learning O
and O
post O
- O
training O
consolidation O
deficits O
. O

Given O
that O
apomorphine O
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10 O
- O
12h O
post O
- O
training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam B
to O
attenuate O
amnesia O
induced O
by O
dopaminergic O
agonism O
. O

A O
step O
- O
down O
passive O
avoidance O
paradigm O
was O
employed O
and O
nefiracetam B
( O
3 O
mg O
/ O
kg O
) O
and O
apomorphine O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
were O
given O
alone O
or O
in O
combination O
during O
training O
and O
at O
the O
10 O
- O
12h O
post O
- O
training O
period O
of O
consolidation O
. O

Co O
- O
administration O
of O
nefiracetam B
and O
apomorphine O
during O
training O
or O
10h O
thereafter O
produced O
no O
significant O
anti O
- O
amnesic O
effect O
. O

However O
, O
administration O
of O
nefiracetam B
during O
training O
completely O
reversed O
the O
amnesia O
induced O
by O
apomorphine O
at O
the O
10h O
post O
- O
training O
time O
and O
the O
converse O
was O
also O
true O
. O

These O
effects O
were O
not O
mediated O
by O
a O
dopaminergic O
mechanism O
as O
nefiracetam B
, O
at O
millimolar O
concentrations O
, O
failed O
to O
displace O
either O
[ O
3H O
] O
SCH O
23390 O
or O
[ O
3H O
] O
spiperone B
binding O
from O
D1 O
or O
D2 O
dopamine O
receptor O
subtypes O
, O
respectively O
. O

It O
is O
suggested O
that O
nefiracetam B
augments O
molecular O
processes O
in O
the O
early O
stages O
of O
events O
which O
ultimately O
lead O
to O
consolidation O
of O
memory O
. O

Two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone B
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia O
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia O
. O

Human O
corticotropin B
- O
releasing O
hormone O
and O
thyrotropin B
- O
releasing O
hormone O
modulate O
the O
hypercapnic O
ventilatory O
response O
in O
humans O
. O

Human O
corticotropin B
- O
releasing O
hormone O
( O
hCRH O
) O
and O
thyrotropin B
- O
releasing O
hormone O
( O
TRH O
) O
are O
known O
to O
stimulate O
ventilation O
after O
i O
. O
v O
. O
administration O
in O
humans O
. O

Analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
TFL O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia O
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte B
colony I
- I
stimulating I
factor I
due O
to O
neutropenia O
; O
no O
patient O
required O
platelet O
transfusions O
. O

Efficacy O
and O
proarrhythmia O
with O
the O
use O
of O
d B
, I
l I
- I
sotalol I
for O
sustained O
ventricular O
tachyarrhythmias O
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades O
de O
pointes O
, O
and O
the O
presumable O
risk O
factors O
for O
torsades O
de O
pointes O
in O
patients O
treated O
with O
d B
, I
l I
- I
sotalol I
for O
sustained O
ventricular O
tachyarrhythmias O
. O

Eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary O
artery O
disease O
, O
and O
20 O
with O
dilated O
cardiomyopathy O
) O
with O
inducible O
sustained O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
received O
oral O
d B
, I
l I
- I
sotalol I
to O
prevent O
induction O
of O
the O
ventricular O
tachyarrhythmia O
. O

During O
oral O
loading O
with O
d B
, I
l I
- I
sotalol I
, O
continuous O
electrocardiographic O
( O
ECG O
) O
monitoring O
was O
performed O
. O

Those O
patients O
in O
whom O
d B
, I
l I
- I
sotalol I
prevented O
induction O
of O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

Induction O
of O
the O
ventricular O
tachyarrhythmia O
was O
prevented O
by O
oral O
d B
, I
l I
- I
sotalol I
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular O
tachyarrhythmia O
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d B
, I
l I
- I
sotalol I
once O
daily O
. O

Four O
( O
5 O
% O
) O
patients O
had O
from O
torsades O
de O
pointes O
during O
the O
initial O
oral O
treatment O
with O
d B
, I
l I
- I
sotalol I
. O

However O
, O
the O
oral O
dose O
of O
d B
, I
l I
- I
sotalol I
was O
significantly O
lower O
in O
patients O
with O
torsades O
de O
pointes O
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

One O
female O
patient O
with O
stable O
cardiac O
disease O
had O
recurrent O
torsades O
de O
pointes O
after O
2 O
years O
of O
successful O
treatment O
with O
d B
, I
l I
- I
sotalol I
. O

Torsades O
de O
pointes O
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d B
, I
l I
- I
sotalol I
. O

Pronounced O
changes O
in O
the O
surface O
ECG O
( O
cycle O
length O
, O
QT O
, O
and O
QTc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d B
, I
l I
- I
sotalol I
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Other O
ECG O
parameters O
before O
the O
application O
of O
d B
, I
l I
- I
sotalol I
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Therefore O
programmed O
electrical O
stimulation O
in O
the O
case O
of O
d B
, I
l I
- I
sotalol I
seems O
to O
be O
of O
limited O
prognostic O
value O
. O

There O
was O
no O
change O
in O
the O
levels O
of O
DA O
, O
norepinephrine O
( O
NE O
) O
, O
serotonin O
( O
5 O
- O
HT O
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 B
- I
hydroxyindoleacetic I
acid I
( O
5 B
- I
HIAA I
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia O
and O
an O
increase O

Thrombotic O
complications O
in O
acute O
promyelocytic O
leukemia O
during O
all B
- I
trans I
- I
retinoic I
acid I
therapy O
. O

A O
case O
of O
acute O
renal O
failure O
, O
due O
to O
occlusion O
of O
renal O
vessels O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
treated O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

We O
report O
a O
case O
of O
acute O
renal O
failure O
in O
an O
APL O
patient O
treated O
with O
ATRA B
alone O
. O

This O
case O
further O
supports O
the O
concern O
about O
thromboembolic O
complications O
associated O
with O
ATRA B
therapy O
in O
APL O
patients O
. O

The O
patients O
, O
a O
43 O
- O
year O
- O
old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
APL O
and O
was O
included O
in O
a O
treatment O
protocol O
with O
ATRA B
. O

We O
conclude O
that O
ATRA B
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
APL O
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O

A O
30 O
- O
year O
- O
old O
cocaine O
- O
dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion B
( O
DEP B
) O
became O
manic O
during O
his O
second O
week O
on O
the O
study O
drug O
. O

Pupillometric O
changes O
while O
on O
DEP B
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary O
oscillation O
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic O
. O

Oral O
administration O
of O
2 B
, I
5 I
- I
di I
- I
O I
- I
acetyl I
- I
D I
- I
glucaro I
- I
1 I
, I
4 I
- I
6 I
, I
3 I
- I
dilactone I
protected O
rats O
against O
renal O
failure O
induced O
by O
kanamycin O
- O
dextran O
. O

The O
protective O
effect O
was O
prevalent O
among O
D O
- O
glucarates O
, O
and O
also O
to O
other O
saccharic O
acid O
, O
hexauronic B
acids I
and O
hexaaldonic B
acids I
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B
alcohols I
, O
substances O
inthe O
TCA B
cycle O
and O
other O
acidic O
compounds O
. O

Rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal O
lesions O
by O
monosaccharides B
. O

Acute O
severe O
depression O
following O
peri O
- O
operative O
ondansetron B
. O

A O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative O
nausea O
and O
vomiting O
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron B
prophylaxis O
had O
been O
used O
. O

Ascending O
dose O
tolerance O
study O
of O
intramuscular O
carbetocin B
administered O
after O
normal O
vaginal O
birth O
. O

OBJECTIVE O
: O
To O
determine O
the O
maximum O
tolerated O
dose O
( O
MTD O
) O
of O
carbetocin B
( O
a O
long O
- O
acting O
synthetic O
analogue O
of O
oxytocin O
) O
, O
when O
administered O
immediately O
after O
vaginal O
delivery O
at O
term O
. O

MATERIALS O
AND O
METHODS O
: O
Carbetocin B
was O
given O
as O
an O
intramuscular O
injection O
immediately O
after O
the O
birth O
of O
the O
infant O
in O
45 O
healthy O
women O
with O
normal O
singleton O
pregnancies O
who O
delivered O
vaginally O
at O
term O
. O

Dosage O
groups O
of O
15 O
, O
30 O
, O
50 O
, O
75 O
, O
100 O
, O
125 O
, O
150 O
, O
175 O
or O
200 O
microg O
carbetocin B
were O
assigned O
to O
blocks O
of O
three O
women O
according O
to O
the O
continual O
reassessment O
method O
( O
CRM O
) O
. O

CONCLUSION O
: O
The O
MTD O
was O
calculated O
to O
be O
at O
200 O
microg O
carbetocin B
. O

This O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine B
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine O
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement O
of O
pulse O
pressure O
and O
the O
tachycardia O
following O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
. O

Differential O
effects O
of O
17alpha O
- O
ethinylestradiol O
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile B
salt I
synthesis O
in O
the O
rat O
. O

Effects O
of O
17alpha O
- O
ethinylestradiol O
( O
EE O
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile B
salt I
( O
BS B
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long O
- O
term O
bile O
diversion O
to O
induce O
BS B
synthesis O
. O

For O
this O
purpose O
, O
bile B
salt I
pool O
composition O
, O
synthesis O
of O
individual O
BS B
in O
vivo O
, O
hepatic O
activities O
, O
and O
expression O
levels O
of O
cholesterol O
7alpha O
- O
hydroxylase O
( O
CYP7A O
) O
, O
and O
sterol B
27 O
- O
hydroxylase O
( O
CYP27 O
) O
, O
as O
well O
as O
of O
other O
enzymes O
involved O
in O
BS B
synthesis O
, O
were O
analyzed O
in O
rats O
treated O
with O
EE O
( O
5 O
mg O
/ O
kg O
, O
3 O
days O
) O
or O
its O
vehicle O
. O

BS B
pool O
size O
was O
decreased O
by O
27 O
% O
but O
total O
BS B
synthesis O
was O
not O
affected O
by O
EE O
in O
intact O
rats O
. O

Synthesis O
of O
cholate B
was O
reduced O
by O
68 O
% O
in O
EE O
- O
treated O
rats O
, O
while O
that O
of O
chenodeoxycholate B
was O
increased O
by O
60 O
% O
. O

A O
clear O
reduction O
of O
BS B
synthesis O
was O
found O
in O
bile O
- O
diverted O
rats O
treated O
with O
EE O
, O
yet O
biliary O
BS B
composition O
was O
only O
minimally O
affected O
. O

In O
addition O
, O
mRNA O
levels O
of O
sterol B
12alpha O
- O
hydroxylase O
and O
lithocholate O
6beta O
- O
hydroxylase O
were O
increased O
by O
bile O
diversion O
and O
suppressed O
by O
EE O
. O

This O
study O
shows O
that O
17alpha O
- O
ethinylestradiol O
( O
EE O
) O
- O
induced O
intrahepatic O
cholestasis O
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile B
salt I
( O
BS B
) O
synthesis O
. O

Simultaneous O
impairment O
of O
other O
enzymes O
in O
the O
BS B
biosynthetic O
pathways O
may O
contribute O
to O
overall O
effects O
of O
EE O
on O
BS B
synthesis O
. O

Glibenclamide O
- O
sensitive O
hypotension O
produced O
by O
helodermin B
assessed O
in O
the O
rat O
. O

The O
effects O
of O
helodermin B
, O
a O
basic O
35 O
- O
amino O
acid O
peptide O
isolated O
from O
the O
venom O
of O
a O
lizard O
salivary O
gland O
, O
on O
arterial O
blood O
pressure O
and O
heart O
rate O
were O
examined O
in O
the O
rat O
, O
focusing O
on O
the O
possibility O
that O
activation O
of O
ATP O
sensitive O
K O
+ O
( O
K O
( O
ATP O
) O
) O
channels O
is O
involved O
in O
the O
responses O
. O

Helodermin B
produced O
hypotension O
in O
a O
dose O
- O
dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
VIP O
. O

Hypotension O
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide O
, O
which O
abolished O
a O
levcromakalim B
- O
produced O
decrease O
in O
arterial O
blood O
pressure O
. O

Oxyhemoglobin O
did O
not O
affect O
helodermin B
- O
induced O
hypotension O
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine O
( O
ACh O
) O
- O
produced O
hypotension O
. O

These O
findings O
suggest O
that O
helodermin B
- O
produced O
hypotension O
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide O
- O
sensitive O
K O
+ O
channels O
( O
K O
( O
ATP O
) O
channels O
) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

